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Abstract 
This PhD investigated the role of human cytomegalovirus (HCMV) in inflammatory 
disease associated with common variable immunodeficiency (CVID) by examining the 
functional competence of HCMV specific CD8+ T cell responses. The project was based 
on the hypothesis that HCMV is a major factor driving the expansion of CD8+ T cells 
that contribute to the inflammatory pathology.  
HCMV specific CD8+ T cell frequencies were significantly elevated in inflammatory 
patients compared to non-inflammatory patients or healthy subjects. The frequency of 
EBV (GLC) epitope specific CD8+ T cells did not differ between patient groups. 
HCMV CD8+ T cells from inflammatory patients displayed a distinct cytokine 
expression profile with the majority of cells producing IFN-γ only or IFN-γ and TNF-α 
in response to antigen stimulation. These cells did not show evidence of exhaustion, with 
low PD-1 expression; rather, they showed high functionality, high TCR avidity and high 
proliferative potential. CD8+ T cells from inflammatory patients but not non-
inflammatory patients or healthy donors expressed high levels of Ki-67 and proliferated 
in response to antigen stimulation in vitro without co-stimulation. Further phenotypic 
analysis revealed striking correlations between the frequencies of HCMV specific CD8+ 
T cells expressing PD-1 or granzyme B and the overall frequency of CD8+ CD27-
CD28- T cells. Consistent with their hypothesized role in the inflammatory disease, the 
CD8+ T cells from inflammatory patients expressed reduced levels of the anti-
inflammatory marker CD73. Further support for the involvement of HCMV in driving 
the inflammatory pathology came from collaborative work in which viral antigen was 
detected at the sites of inflammation.  
The results support the hypothesis that HCMV and HCMV-specific T cells are key 
factors in CVID associated inflammation. They explain previously reported T cell 
‘abnormalities’ seen in CVID and provide an evidence base for clinical trials of anti-
TNF therapy and/or antiviral therapy in these patients. 
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1.1 History of cytomegalovirus  
It was in 1881 that Ribbert first noted large “protozoan-like” cells in the section of the 
kidney and the parotid glands of children. He published his observation in 1904 although 
he was not able to interpret them until he noticed the report by Jesionek and 
Kiolemenoglou, who described similar cells in the lungs, kidneys and liver of an 8 
month luetic, old name for syphilis, fetus. The eccentrically placed nuclei of these large 
cells contained a “central nuclear body” surrounded by two well defined zones, an inner 
dark and an outer clear halo. Additional instances were reported in 1910 and again in 
1914 by Smith and Weidman, but they concluded that they were dealing with protozoa 
until 1921 when Goodpasture and Talbot reported the similar structures in the lungs, 
liver, and kidneys of a 2 months’ old infant and they concluded that they were dealing 
with a new kind of abnormal cytomorphosis to which they gave the name of 
cytomegalia. These findings appear to be the first description of cytomegalic cells 
containing intranuclear inclusions (Farber and Wolbach, 1932). In 1925, Von Glahn and 
Pappenheimer noted that Lipschuetz had also discovered these intranuclear inclusion 
containing cells four year earlier from a man infected by herpes zoster. Therefore, like 
Goodpasture and Talbot, they doubted that these cells were related to protozoa and they 
believed that these unusual cells might be related to a group of related viruses, now 
known as the Herpesviridae (Ho, 2008). The story of detecting the large cells with 
similar structures (containing typical intranuclear inclusions) from variety of organs 
carried out until the name of “generalized cytomegalic inclusion disease (CID)” had 
been suggested by Wyatt et al, although the virological etiology of CID was not yet 
known (Wyatt and Saxton, 1950). It was 1953 when in a case of CID, Minder first saw 
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by electron microscopy the particles of 199nm size, suggestive of a virus, in the 
pancreatic cells containing intranuclear inclusions (Minder, 1953). 
However, discovery of human embryonic cell cultures provided a breakthrough for the 
field of virology and many virologists who were eager to apply these techniques. Tomas 
Weller, who was a pediatrician and parasitologist, applied the newly discovered cell 
culture techniques to culture the protozoa Toxoplasma and to clinical cases of CID. This 
work together with two other independent studies headed by Smith and Rowe finally let 
to the identification of a virus that later proposed to name as cytomegalovirus by Weller 
(Craig et al., 1957;Weller, 1970).  
Human cytomegalovirus (HCMV) or human herpes virus 5 (HHV5) is the prototype 
member of the Betaherpesvirinae subfamily of the Herpesviridae family. The recent 
availability of extensive nucleotide sequence data has led to the establishment of a new 
order, Herpesvirals, by the Herpesvirus Study Group of the International Committee on 
Taxonomy of Viruses (ICTV) (Pellett and Roizman, 2007).  
In general, species-specificity is one of the main characteristics of the Betaherpesvirinae 
and therefore each species has their own uniquely adapted CMV. The fact that human 
cytomegalovirus does not infect animals is one of the limitation of studying CMV. 
Although beyond the scope of the present study, there are several animal models (Figure 
1-1) for studying various aspects of CMV in addition to in vitro models such as AD169 
(a commonly used laboratory strain of human CMV which is derived from the clinical 
strains as a result of in vitro passage) (Wynn and Khanna, 2006).  
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Figure 1-1: Schematic representation of animal models used for studies of cytomegalovirus.  
The focus of this study is HCMV as shown in coloured boxes. The figure is modified from(Wynn and 
Khanna, 2006). Abbreviations: RhCMV, rhesus CMV; BCMV, baboon CMV; CCMV, chimpanzee CMV; 
PCMV, porcine CMV; GPCMV, guinea pig CMV; MCMV, murine CMV, RCMV, rat CMV.  
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Human  Higher primates Porcine Guinea pig Rodents 
HCMV RhCMV PCMV GPCMV MCMV 
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1.2 Epidemiology of Human Cytomegalovirus  
Naturally, transmission of HCMV infection occurs both vertically and horizontally 
through direct contact with infectious body fluids including blood, saliva, breast milk, 
and cervical secretions, indicating the intimate contact requirement for its spread. 
Contact with children and sexual activity are two of the most common types of 
horizontal modes of transmission (Pereira et al., 1990;Sohn and Oh, 1991;Coonrod et al., 
1998). 
Sero-epidemiological studies carried out in different populations show that human 
cytomegalovirus is ubiquitous among the population with seroprevalance levels ranging 
from 60-100% based on numerous factors including living circumstances, socio-
economic status, and hygiene. Many of HCMV infections are acquired during early 
childhood and the overall prevalence of HCMV infection generally increases with age. 
However, the influence of seasonal variation on the prevalence of HCMV infection has 
not been proven (Gratacap, 1998;Mocarski et al., 2007).  
1.3 Replication cycle of HCMV  
1.3.1 Structure and genome organization  
Similar to other members of Herpesviridae, HCMV morphologically consists of a virion 
structure at 200 to 300nm diameter containing a double-stranded linear DNA core which 
is enclosed in an icosahedral capsid at 100-110nm size. The capsid is composed of 162 
capsomers which is embedded in a tegument containing a number of virus-encoded 
proteins which are mostly phosphorylated. The tegument is surrounded by a host cell 
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derived lipid bilayer containing more than 20 virus encoded surface glycoproteins which 
are incorporated during the maturation process (Figure 1-2) (Emery and Griffiths, 
1990;Mocarski et al., 2007;Crough and Khanna, 2009). 
The terminally redundant genome is composed of two covalently linked segments so-
called long (L) and short (S), each consisting a unique long (UL) and unique short (US) 
domains, which are flanked on one end by terminal repeated sequences (TRL and TRS) 
and on the other end by internal repeats (IRL and IRS) (Figure 1-2) (Davison et al., 
2003;Dolan et al., 2004).  
 
Figure 1-2: Schematic representation of the structural features as well as genome organizations of HCMV 
(not to scale). 
The lettering within the individual segments of the genome indicates the following features: terminal 
repeat long (TRL); unique long (UL); internal repeat long (IRL); internal repeat short (IRL); unique short 
(US); and terminal repeat short (TRS). 
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The life cycle of HCMV initiates with a series of distinct steps including attachment, cell 
penetration, gene transcription and DNA replication which is followed by virion 
assembly and egress (Compton, 2004;Mocarski et al., 2007). 
1.3.2 Attachment and Entry    
To initiate infection, the virus must attach to the cell surface. The cell entry of HCMV 
can be triggered in at least two ways, resulting in different pathways of entry. Fusion of 
virus envelope with the plasma membrane is considered to be the main pathway which is 
dependent on multiple receptor-ligand interaction on the cell surface (Compton and 
Fiere, 2006). The second pathway involves endocytosis of the enveloped capsid with the 
membrane of the endocytic vesicle (Ryckman et al., 2006) (Figure 1-3). Many different 
cell surface molecules can serve as receptors for the virus entry. Initial binding is 
believed to be mediated through engagement of glycoprotein B (gB) which binds to cell 
surface heparan sulphate proteoglycan (HSPG) moieties, a relatively conserved feature 
of herpesvirus entry pathways (Mocarski et al., 2007). Glycoprotein B, encoded by the 
UL55 gene, is the major structural protein of the viral envelope  which is present on the 
surface of infected cells, involving  in all stages of virus entry (Emery and Shannon-
Lowe, 2007). Interaction of gB with heparan sulphate is believed to initiate a signaling 
cascade that involves other cellular receptors and viral entry mediators (Boyle and 
Compton, 1998) such as heterodimeric complexes of glycoproteins H, L, M, and N (gM: 
gN, gH: gL). The role of gB and gH/gL as the main HCMV entry molecules has been 
supported by most studies (Compton et al., 1993;Compton and Fiere, 2006;Mocarski et 
al., 2007). It has recently been shown that HCMV infects cells through interacting with 
epidermal growth factor receptor (EGFR), indicating additional cell receptors for virus. 
Chapter 1: Introduction [2010] 
25 
 
In response to human cytomegalovirus, EGFR is phosphorylated, inducing signaling 
events through activating the phosphatidylinositol 3-kinase (PI-3 kinase), Akt 
(serine/threonine protein kinase), and releasing intracellular calcium stores (Wang et al., 
2003).  
Following attachment, virus penetration occurs at the cell surface via direct fusion such 
as in fibroblasts or via an endocytic route in endothelial cells. Based on cell type, it 
seems the functional requirement involved in attachment and penetration vary, 
suggesting the various minor envelope glycoproteins of HCMV may play a part in entry 
into different cell types. Once the virus nucleocapsid containing the viral genome and 
tegument proteins is deposited into the cytoplasm, the capsid is transported along 
cytoplasmic microtubules and then translocated to the nucleus where viral DNA is 
entered through nuclear pores (Mocarski et al., 2007).   
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Figure 1-3: Schematic representation of working models of human cytomegalovirus entry into the cells.  
Depending on cell type, receptor-dependent endocytosis (shaded box) or receptor-dependent fusion are 
main entry pathways. This figure is modified from (Compton, 2004;Milne et al., 2005) 
Toll like receptors (TLRs) 
Integrins (α and β) 
Epidermal growth factor receptor (EGFR) 
Heparin sulphate proteoglycan (HSPG) 
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1.3.3 Viral gene expression and DNA replication 
Following the deposit of the HCMV nucleocapsid into the cytoplasm, it translocates to 
the nucleus where viral DNA is released. It appears that cytoplasmic microtubules 
facilitate the translocation of viral genome to the nucleus (Mocarski et al., 2007). 
Expression of IE genes starts immediately following the entry of viral genome to the 
nucleus. HCMV gene expression like other members of the Herpesviridae is temporally 
regulated, with three classes of gene products namely immediate-early (IE) (α), delayed-
early (DE) (β) and late (L) (γ) (Figure 1-4) (Emery and Shannon-Lowe, 2007). Initial 
transcription occurs in the absence of protein synthesis and is not affected by the 
expression of other viral genes while the expression of DE genes requires the expression 
of functional products of IE genes. Following the interaction of the viral envelope with 
the cell membrane and entering the viral genome to the nucleus, IE gene expression 
occurs by regulating the activity of HCMV major IE promoter (MIEP). Although the 
regulation of IE gene expression is highly complex, many gene products including 
IE1and IE2, UL36 and UL37, and TRS1/IRS1 have been shown to be important for the 
regulation and the activities of MIEP. These genes give rise to multiple transcripts and 
gene products.  IE1 (UL123/IE72) and IE2 (UL122/IE86) are two major immediate early 
transactivators which play a central role in the activation of DE and L gene expression. 
In addition, ppUL123 and ppUL122 are shown to be essential transactivators for DNA 
replication (Mocarski et al., 2007). UL36 and UL37 are two other gene products that 
influence gene expression during replication. It has also been shown that these two 
genes have anti-apoptotic functions (Mocarski et al., 2007). In addition to being a  
transactivator, the gene products of TRS1 and IRS1 are both shown to counteract with 
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the host cell antiviral response pathways by blocking IFN-inducible protein kinase R 
(PKR) (Child et al., 2004;Mocarski et al., 2007). 
The DE step of HCMV replication initiates following the expression of major immediate 
early (MIE) regulatory proteins when a large proportion of the viral genome becomes 
transcriptionally active. This stage starts by 6 hours post infection (hpi), lasting around 
18 to 24 hpi when synthesis of viral DNA starts (Yu et al., 2003). Several genes such as 
UL112/UL113 and UL54 are involved in regulation of the DE stage which encodes viral 
transcripts or gene products required for DNA replication or stages of capsid maturation. 
The expression of the UL54 gene encoding DNA polymerase catalytic subunit has been 
shown to start early but reaches much higher levels at late (L) times of infection. Despite 
their importance, little information is available regarding late gene expression in HCMV 
infected cells (Mocarski et al., 2007).  
Although HCMV replication is a slow event in vitro and takes 48 to 72 hours before the 
release of progeny virions, in the human host active replication of HCMV is highly 
dynamic (with doubling times around 1 day) although the rate of replication depends on 
several factors such as target cell availability and the functional capacity of the specific 
immune system (Emery et al., 1999). The HCMV genome contains one origin of lytic 
(oriLyt) and DNA synthesis of virus depends on transcriptional activation of oriLyt 
which is a structurally complex region. The core region of orilyt includes repeat 
elements and transcription factor binding sites (Prichard et al., 1998). Viral DNA 
synthesis have been shown to be dependent on a set of HCMV proteins, including 
UL54-UL44 complex with polymerase activity (UL54: the DNA polymerase catalytic 
subunit; UL44: the polymerase accessory protein), single stranded (ss) DNA binding 
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protein (UL57), and the heterotrimeric complex of helicase-primase (HP) which consist 
of HP1 (UL105), HP2 (UL70), and UL102-encoded HP3 (McMahon and Anders, 2002). 
However, HCMV DNA replication ocurrs on the circularized genome and create a 
concatameric DNA structure that needs to be cleaved into unit genome lengths prior to 
encapsidation (Mocarski et al., 2007).  
 
 
Figure 1-4: Schematic representation of virus structure and temporal hierarchy of gene expression by 
HCMV.  
IE, E, and L indicate immediate early, early, and late, respectively. The IE genes are expressed within 2-4 
hours of infection followed by the expression of early genes which starts within 8-24 hours post infection 
before initiation of late gene expression. The image is provided and modified with permission from 
Professor Vincent Emery. 
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1.3.4 Viral Capsid Assembly and Virion Egress 
Capsid maturation, DNA encapsidation, and release from the cells are crucial functions 
which are carried out by late and many delayed-early genes. Following accumulation of 
L proteins, viral DNA is encapsidated in the nucleus and matures by moving to the 
cytoplasm (Penfold and Mocarski, 1997). Studies from most herpesviruses suggest the 
involvement of a complex two-stage process (envelopment/ de-envelopment/ re-
envelopment) in the budding processes of newly formed virions. This process ocurrs in 
different subcellular compartments and finally leads to virion release by exocytosis at 
the plasma membrane. The first step (or envelopment process) starts at the inner nuclear 
membrane and it has been shown that two HCMV-encoded proteins of UL50 and UL53 
genes are crucial (Mettenleiter, 2004). This process delivers viral particles to the 
prenuclear space between the inner and outer nuclear membranes where is likely to be 
followed by a de-envelopment event. A secondary process (or final envelopment) occurs 
in cytoplasm in close proximity to the Golgi apparatus. Whereas some virion tegument 
proteins are associated with the nucleocapsid during the first envelopment process, it 
appears that the bulk of these proteins found in mature virions are added to the 
nucleocapsid during final or secondary envelopment as it travels through the cytoplasm 
(Mocarski et al., 2007). The endpoint of the final envelopment process is an enveloped 
virion within a secretory vesicle which is then transported to the plasma membrane 
where it fuses, resulting in the release of mature virions from the infected cells 
(Mettenleiter, 2004). 
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1.4 Role of different cell types in replication of HCMV 
HCMV has strict host specificity and is limited to humans; however, within the human 
host the virus can target an exceptionally broad range of cell types including endothelial 
cells, connective tissue cells, mucosal epithelial cells and smooth muscle cells, 
macrophages and dendritic cells. In immunocompromised hosts, different cell types 
from various organs including liver, gastrointestinal tract, lung, kidneys, salivary glands, 
retina and brain have been shown to be sites of infection with HCMV, with the 
endothelial and epithelial cells being the primary target for virus infection (Sinzger et al., 
2008;Revello and Gerna, 2010). 
In cell culture, primary cultures of human foreskin or embryonic lung fibroblasts 
(HELF) are the most commonly used cell type for propagation of HCMV which yield 
relatively high titer stocks (Revello and Gerna, 2010). However, having a finite life span 
and not being predominantly infected in vivo are two main disadvantages of primary 
human fibroblasts that limits the study of HCMV replication (Bresnahan et al., 
2000;Emery, 2001). Several other cell types including vascular smooth muscle cells 
(Tumilowicz et al., 1985), placental trophoblast cells (Halwachs-Baumann et al., 1998), 
retinal pigment epithelial cells (Tugizov et al., 1996), hepatocytes (Sinzger et al., 1999), 
macrophages and monocytes (Ibanez et al., 1991), astrocytoma cell line (Kari et al., 
1992), a teratocarcinoma cell line (LaFemina and Hayward, 1986), and endothelial cells 
have been shown to support the replication of the virus in vitro. However, none of these 
cell lines produce high-titer stocks or plaques when infected with HCMV (Bresnahan et 
al., 2000). The entry of HCMV into certain cell types such as epithelial and endothelial 
cells have been shown to be influenced to large extent by the unique long b′ (ULb′) 
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region of the HCMV genome, encoding particularly UL131A, UL130 or UL128 genes 
which form a  complex with gH/gL (Hahn et al., 2004;Wang and Shenk, 2005;Revello 
and Gerna, 2010). 
Since the immediate-early phase of viral gene expression is dependent on transcription 
factors in the host cell, it was thought that cell type-specific differences in IE 
transcription of HCMV might be the reason behind differences in permissiveness to 
infection in most cultured cell types, even those that are not permissive for virus 
infection but high levels of transcription by the major IE promoter have been observed 
(Fritschy et al., 1996). The ability of HCMV to persist in the face of strong T and B cell 
immunity is likely related to its properties such as latency, cell association of virions and 
a large number of virus encoded gene products that allow the virus to escape the host 
immune system through different mechanisms (see later) (Reeves and Sinclair, 
2008;Sinclair, 2010). Persistent virus replication usually occurs in epithelial cells of 
salivary glands as well as kidneys which shed sporadically in body fluids throughout 
life. Reactivation of virus occurs when an endogenous virus reactivates in a seropositive 
individual (Emery et al., 2000;Rubin, 2007).. 
1.4.1 Latency and virus reactivation 
HCMV like other members of herpes family establishes lifelong latency within the host 
and as a result, the ability to reactivate from latency is a common feature of this virus. 
Viral latency can be defined as the ability of the viral genome to maintain itself in the 
absence of production of infectious virions. Under certain conditions, however, the viral 
genome is able to reactivate (Sinclair, 2008). Genomic viral DNA has been detected in 
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various cell types including monocytes and macrophages (Taylor-Wiedeman et al., 
1991;Soderberg et al., 1993), endothelial cells (Sinzger et al., 1995), lymphocytes 
(Schrier et al., 1985), and CD34+ bone marrow cells (Mendelson et al., 1996). Although 
the exact site of virus latency has not yet been determined, cells of myeloid lineage 
appear to be the main site of latency (Soderberg-Naucler et al., 1997b;Sinclair, 2008). 
Active viral replication appears to be directly related to the state of differentiation of the 
permissiveness of cells such as myeloid cells. However, HCMV can enter the 
undifferentiated cells but these cells are not permissive for viral replication (Soderberg-
Naucler et al., 1997b;Sissons et al., 2002).  
Regarding the establishment of virus latency, at least three possible pathways have been 
proposed. The first possibility is the entrance of virus (following attachment) directly 
into a latent state without expressing any de novo viral genes. A second option is that 
following entry the virus initiates productive infection which is interrupted prematurely 
which may finally lead to latency. The third possibility is the expression of a subset of 
viral genes unrelated with productive infection but appear to be necessary for the 
successful establishment of latency (Kondo et al., 1994;Goodrum et al., 2002;Reeves et 
al., 2005a;Cheung et al., 2006;Crough and Khanna, 2009). 
It is becoming increasingly clear that the repression of the major immediate early 
promoter by cellular transcription factors as well as post-transcriptional of histone 
modifications is the key event in latency (Sinclair, 2010;Reeves, 2010). Therefore, 
desilencing of the MIE promoter or enhancer is shown to be crucial for triggering the 
reactivation of virus from latency (Reeves et al., 2005b;Zydek et al., 2010). In addition, 
it has been suggested that cytokines particularly TNF-α can play a role in reactivation of 
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HCMV infection (Docke et al., 1994;Fietze et al., 1994). In this context, it has been 
shown that more than 25 gene products of HCMV play some part in modulation of both 
innate and adaptive immune responses either directly or via a proinflammatory process 
based on cytokines such as TNF-α which binds to TNF-α receptor on latently infected 
cells, stimulating the latently infected cells to differentiate and support virus reactivation 
probably via initiating a signaling process which involves activation of NF-kB (Pleskoff, 
2005;Mocarski et al., 2007;Rubin, 2007). Reactivation of HCMV has also been shown 
in response to inflammation or even stress (Prosch et al., 2000;Crough and Khanna, 
2009), but the precise mechanisms involved are not fully elucidated. It seems that stress 
catocholamines, epinephrine and norepinephrine are, at least in part, responsible for 
HCMV reactivation via inducing cyclic AMP-dependent signaling pathways and finally 
stimulating the reactivation process (Reinke, 1999).  
1.5 Pathogenicity and Clinical Manifestation 
Human cytomegalovirus disease can follow primary infection or reactivation. In 
immunocompetent individuals, primary (and recurrent) infection with HCMV is usually 
asymptomatic, indicating a healthy immune system has the ability to control virus. 
Although rare, severe infection with HCMV even in the immunocompetent host has 
been reported (Eddleston et al., 1997). Additionally, congenital CMV disease, which is 
an important medical and public health problem, occurs in the normal host (Mocarski et 
al., 2007). Clinical symptoms of newborns with congenital HCMV disease are included 
petechiae, microcephaly, purpura, hepatospelenomegaly, prematurity, and jaundice.  
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However, when the host immune system is unable to function properly due to either 
infection such as HIV, immaturity as seen in neonates, or through iatrogenic intervention 
following organ transplantation, HCMV becomes potentially pathogenic. In 
immunocompromised individuals particularly in transplant patients HCMV infection can 
arise from reactivation virus, reinfection, or primary infection (Emery, 2001). Viral 
replication and viral load have been shown to be important factors in pathogenesis in 
neonates, AIDS patients, and transplant populations. It has also been demonstrated that 
there is a direct correlation between peak viral loads and CMV disease (Cope et al., 
1997;Hassan-Walker et al., 1999;Emery et al., 2000;Regoes et al., 2006). Accordingly, 
high levels of virus replication in the T cell immunocompromised patients such as HIV-
infected individuals has been observed to be related with a variety of end-organ diseases 
caused by HCMV (Regoes et al., 2006).  
In the immunocompromised host, HCMV infection can cause a range of clinical 
manifestations (such as gastrointestinal, retinitis, and pneumonitis) which can vary 
between immunocompromised patient groups (Table 1-1). Pneumonitis, for example, is 
the most common clinical manifestation of HCMV in bone marrow recipients, whereas 
hepatitis and retinitis are the most frequent clinical features in liver transplant recipients 
and patients with AIDS, respectively (Emery, 2001). 
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Clinical Manifestations 
Immunocompromised host 
SOT HST AIDS 
Fever * * * 
Hepatitis ** *  
Gastrointestinal * * * 
Retinitis * * ** 
Pneumonitis * **  
Encephalopathy   * 
Polyradiculopathy   * 
Myelosuppression  **  
Immunosuppression *   
Rejection *   
Addisonian  *  
 
Table 1-1: Clinical manifestation of cytomegalovirus in immunocompromised host.  
The table is reproduced from (Emery, 2001). Abbreviations: SOT, solid organ transplantation; HST, 
haematopointic stem cell transplantation; AIDS, Acquired immune definciency synderome. 
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1.6 Immune responses to HCMV 
Our knowledge of the exact mechanisms behind the viral latency is not complete; 
however, there is no doubt that immune responses are crucial in keeping HCMV 
replication, and as a consequence life threatening disease, in check. Although beyond the 
focus of this study, there are several animal models available (described in section 1.1) 
to investigate different functional aspects of immune response against cytomegalovirus 
(Wynn and Khanna, 2006). For example, MCMV is the most commonly used animal 
model to address many fundamental aspects of immunology such as the cellular (Sierro 
et al., 2005) and humoral immune responses to CMV (Wilson et al., 2008). However, for 
several reasons defining the crucial features of protective responses to relevant viruses in 
human can not be directly applied by the findings from the mouse model systems. 
Because deliberate infection of humans is impossible and symptoms of primary infection 
may not be recognized or only develop weeks following infection, it is difficult to 
identify the exact time point of infection in humans which is contrary to what can be 
achieved in mouse models. Additionally, humans encounter a variety of pathogens 
throughout their life some of which (such as herpesviruses) can reach a latent stage in 
the host; as a consequence, different viral-specific T cells can present and be active 
simultaneously whereas in mouse models it is usual to study singular pathogens. 
Another issue that needs to be considered in this context is the fact that, compared to the 
human immune system providing lifelong protection, many studies performed in mice 
usually last for few weeks. Furthermore, in immunocompetent mice the immune system 
has the ability to clear the majority of pathogens whereas even in immunocompetent 
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individuals, many of the persistent viruses are not eliminated and have to be 
continuously kept in check by the immune system (van Leeuwen et al., 2006).  
It appears that innate immunity, such as NK cells, and adaptive immune responses 
including CD8, and CD4 T cells, all play important roles in containing HCMV (Khan, 
2007). In a study carried out by Emery et al, preexisting HCMV immunity has been 
shown to reduce both the replication rate and the peak of virus load during HCMV 
active infection (Emery et al., 2002). According to many studies protective immunity is 
T cell mediated, although in most settings especially in vertical transmission, antibody 
responses play an important role (Plotkin et al., 1989;Gonczol et al., 1989;Mocarski et 
al., 2007).  
1.6.1 Innate immunity 
The innate immune system is essential for the initial detection of invading viruses and 
subsequent activation of adaptive immunity. Recruiting immune cells such as NK cells 
and phagocytes to sites of infection, recognition of foreign pathogens by several innate 
immune receptors expressed either at the host cell surface or within cells, activation of 
the complement cascade as well as the adaptive immune system through antigen 
presentation are major functions of innate immune system. 
Natural Killer Cells: natural killer cells (NK) are an integral part of innate immunity 
that serve as a first line of defense to prevent viral invasion (Redpath et al., 2001). NK 
cells are widespread throughout lymphoid and non-lymphoid tissues and represent a 
minor fraction of total lymphocytes (from 2% to 18% in human peripheral blood). 
Through various activatory (ITAMs:  immunoreceptor tyrosine-based activation motifs) 
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and inhibitory (ITIMs:  immunoreceptor tyrosine-based inhibition motifs) cell surface 
receptors, NK cells recognize a vast array of molecules (Vivier et al., 2008). These cells 
mediate their killing activity via different mechanisms (Lee et al., 2007), including 
release of cytokines (Orange et al., 1995), utilizing cytolytic granules such as perforin 
(Loh et al., 2005), and induction of cell death through TNF-related apoptosis inducing 
ligand (TRAIL) (Mirandola et al., 2004). In addition, NK cells are known to express 
several cell surface activating complexes that are formed by noncovalent association 
between distinct transmembrane ligand-binding and signaling adaptor polypeptides such 
as Fcγ receptor. These receptors enable NK cells to recognize the antibody-coated target 
cells and thereby facilitate antibody-dependent cell cytotoxicity (ADCC) and cytokine 
production (Vivier et al., 2004). 
The role of NK cells in the clearance of experimental MCMV infection has been 
demostrated as the adoptive transfer of NK cells can provide protection against MCMV 
(Bukowski et al., 1985;Poliç et al., 1998b;Crough and Khanna, 2009). Little is known 
about the role of these cells in the immune defense of humans against HCMV. Data 
supporting a key role for these cells in HCMV infection came from the increasing 
numbers of viral gene products blocking NK cell-mediated recognition (see section 1.7). 
In addition, the MHC class I down regulation which the virus uses to escape T cell 
response likely increases the susceptibility of infected-cells to lysis by NK cells (Falk et 
al., 2002;Mocarski, 2004). An increase of NK cell activity has also been shown during 
both primary and recurrent HCMV infection of renal transplant patients (Venema et al., 
1994).  
Chapter 1: Introduction [2010] 
40 
 
Pattern recognition receptors: Another innate immune component which has recently 
received extensive attention is Toll-like receptors (TLRs) and their critical role in host 
defense against infection. It was originally thought that innate immunity recognize 
antigens nonspecifically, however, the discovery of TLRs in the mid-1990s showed that 
pathogen recognition by the innate immune system instead occurs in a specific manner. 
This specific recognition is receptor mediated and relies on germ line-encoded pattern-
recognition receptors (PRRs) that have evolved to detect components of foreign 
pathogens referred to as pathogen-associated molecular patterns (PAMPs). Based on the 
recognition patterns there are several members of the TLR family (10 and 12 functional 
TLRs in human and mice, respectively). Toll-like receptors are type I transmembrane 
proteins with multiple leucine-rich ectodomines that mediate the recognition of PAMPs 
and are related to IL-1 receptors based on the similarity in the cytoplasmic portions. It 
appears that TLRs are essential for protective immunity against infection. However, 
inappropriate TLR responses can contribute to systemic autoimmune diseases as well as 
inflammation (Kawai and Akira, 2010). 
The role of TLRs in sensing innate responses to viral pathogens including HCMV is 
becoming increasingly clear. Following stimulation, TLRs activate signal transduction 
pathways which can induce the secretion of a broad range of inflammatory cytokines 
that are important for the activation of adaptive immune response (Compton et al., 
2003;Boehme and Compton, 2004). It has been documented that  HCMV can trigger 
inflammatory cytokine production through the interaction of certain virus envelope 
glycoproteins (such as gB) and TLR2 (Compton et al., 2003;Boehme et al., 
2006;Juckem et al., 2008). In this regard, the HCMV envelope glycoproteins B and H 
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have been shown to activate TLR2 and both gB and gH physically associate with TLR2 
as shown via co-immunoprecipitation experiments. In response to HCMV, it appears 
that TLR2 exerts its functional activity together with TLR1 as a heteromeric complex. In 
support of this, it has been shown that gB and gH also co-precipitate with TLR1 
(Boehme et al., 2006).  
Complement system: The complement-mediated immune system is another facet of the 
first-line immunological defense which includes inflammatory proteins, proteolytic 
enzymes, cell surface receptors and proteins, causing apoptosis via osmotic lysis after 
insertion into biological membranes such as virus-infected cell surfaces (Hengel et al., 
1998). HCMV is able to escape this system probably by producing some gene products 
which express a surface Fc-receptor that is distinct from endogenously produced Fc-
receptors. Using mutant analysis, it has been identified that HCMV encodes two distinct 
Fcγ receptor (FcγR) homologs, including vFcγR gp68 (encoded by UL119-UL118) and 
vFcγR gp34 encoded by TRL11/IRL11 (Atalay et al., 2002).  
Fc receptors (FcRs) constitute a family of cell-surface receptors expressed on most cells 
of the immune system and play a key role in host defenses against pathogens via linking 
humoral and cellular immune responses. Multiple components of the immune system can 
interact with the Fc domain of immunoglobulins via distinct binding sites such as 
complement (Ravetch and Bolland, 2001).  
Moreover, by inducing FC receptors it has been shown that HCMV infection can 
upregulate the cell surface expression of CD46 and CD55, two complement control 
proteins (CCPs), in some cell types (Spiller et al., 1996). The increased CD55 expression 
enhances the capacity of infected cells to regulate C3 deposition and thus protects 
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infected cells from complement-mediated lysis. Furthermore, the incorporation of CD55, 
CD59 and CD46 into virus particles may also be a potential tool for HCMV to escape 
from host defenses probably via downregulation of HLA molecules at the infected cell 
surface (Spear et al., 1995;Spiller et al., 1997). 
1.6.2 Acquired Immunity: Humoral Responses 
Although the focus of the response to HCMV is typically cell mediated, clinical and 
experimental evidence indicate that humoral immune responses to HCMV may play a 
role in defence against infection (Weber et al., 1993). Initial infection with HCMV 
induces a primary immune response and following establishment of long-term 
immunity, this serves to control the replication of virus following reactivation. Although 
impairment of cellular immunity can enhance the severity of HCMV infection, a 
synergistic role for the humoral response in keeping HCMV loads below critical 
thresholds cannot be discounted. Indeed, it has been shown in clinical studies that the 
humoral response has a beneficial role in preventing the blood borne spread of the virus 
(Schoppel et al., 1998). This is also supported by evidence that the probability of 
transmission of viral infection from mother to fetus significantly increased if the 
antibody response to HCMV is of low avidity and of poor neutralizing activity (Fowler 
et al., 1992;Schleiss et al., 2004). Recent studies have shown that treating pregnant 
women with HCMV-specific hyperimmune globulin not only increased virus-specific 
IgG concentrations and avidity but also considerably lowered the risk of congenital 
HCMV infection and disease (Nigro et al., 2005). In addition, recently published results 
of a phase 2, placebo-control and randomized trial have showed that HCMV 
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glycoprotein B vaccine has the potential to reduce the incidence of maternal and 
congenital infection (Pass et al., 2009).  
Studies in guinea pig models have previously demonstrated the efficacy of gB, either 
purified from CMV virions (Harrison et al., 1995) or produced as a recombinant protein 
(Schleiss et al., 2003), as an effective vaccine (Schleiss et al., 2007). Moreover, passive 
immunization with hyperimmune anti-gB to pregnant guinea pigs has also been shown 
to be protective against congenital infection (Chatterjee et al., 2001).     
HCMV is a structurally complex virus encoding around 168 unique proteins, a large 
number of which can generate antibody responses. Although, in vivo, the tegument and 
capsid proteins are inaccessible to antiviral antibodies because they are enclosed within 
the virion envelope, interestingly, protein components of the tegument and capsid elicit 
the most intense and durable antibody responses, serving often as the basis for 
diagnostic serological assays (Britt, 2007). Figure 1-5 illustrate the virion proteins and 
glycoproteins that have been experimentally defined. Neutralizing antibody responses 
have been detected against many viral surface  glycoproteins such as gB (UL55), gM 
(UL100), gN (UL73), and gH (UL75) (Mocarski et al., 2007;Britt, 2007). Glycoproteins 
B and H (gB and gH) are two main glycoproteins in the virion envelope that have 
significant immunogenicity in humans and to be targeted by antiviral antibodies 
(Rasmussen et al., 1991). In addition to being involved in cell attachment and 
penetration, gB is the major target for neutralizing antibodies to HCMV (Britt et al., 
1990;Marshall et al., 1992). Glycoprotein H is another target which induces potent virus-
neutralizing antibodies as well as being involved in the fusion of the viral envelope with 
the host cell membrane (Rasmussen et al., 1991).  
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In HCMV, gM forms a heterodimeric complex through disulfide bonds with gN. The 
gM/gN complex is the most abundant glycoprotein components of the HCMV virion 
envelope that can elicit a virus-neutralizing antibody response in HCMV infected 
individuals. Antibodies derived from convalescent human serum have been shown to 
react with the gM/gN complex and neutralize virus infectivity (Shimamura et al., 
2006;Britt, 2007). 
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Figure 1-5: Schematic representation of protein components of the HCMV virion.  
The most immunogenic envelope proteins (gB and gH) are located in envelope as coloured in red. This 
figure reproduced from(Emery and Shannon-Lowe, 2007). Abbreviations: gB, glycoprotein B; pp65, 
phosphoprotein 65; MCP, major capsid protein; MnCP, minor capsid protein; SCP, small capsid protein. 
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1.6.3 Acquired Immunity: Cellular Responses  
Antigen-specific T cells are essential components of the immune response against a 
large number of pathogens. It has also been shown that T cell responses have an 
important role in limiting viral replication as well as controlling virus-associated 
diseases (Pantaleo and Harari, 2006).  
1.6.3.1 CD4+ T cell response  
There is increasing data which emphasizes an important role for CD4+ T cell responses 
in the control of infection (Khan, 2007) and these cells  are likely to be important in 
aiding control of HCMV (Nebbia et al., 2008). CD4+ T cell activation is dependent on 
antigen presentation by MHC-II molecules on antigen presenting cells. Unlike CD8+ T 
cells which recognise endogenous antigens (presented directly from cytosol), antigen 
recognition by CD4+ T cells usually occurs when antigen has been taken up by an 
antigen-presenting cell (Landsverk et al., 2009). Therefore, the cytotoxic potential of the 
CD4+ T cell response for viral infections could be limited as it might be impossible for 
virally infected cells to present antigens through MHC class II molecules (Crompton et 
al., 2008). However, recent evidence has indicated that HCMV glycoprotein B (gB) can 
be presented directly from infected cells without the need for cross-presentation (Hegde 
et al., 2005). Cross-presentation, which was first described by Bevan four decades ago, 
is an important factor for the development of CD8+ T cell responses specific to viruses 
that are not able to directly infect antigen-presenting cells (APCs). It appears that 
dendritic cells (DCs) are the main potent APCs for cross-presentation (Ackerman and 
Cresswell, 2004;Singh and Cresswell, 2010).  
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Evidence supporting the importance of CD4+ T cells in controlling of HCMV infection 
is obtained from studies of transplant patients undergoing a primary infection. In patients 
undergoing bone marrow transplantation, although CD8+ T cell infusions are able to 
protect patients from HCMV disease, the maintenance of effective CD8+ T cell response 
was shown to be dependent on the presence of CD4+ T cells specific to HCMV (Walter 
et al., 1995;Einsele et al., 2002;Waller et al., 2008). In addition, an increased incidence 
of recurrent MCMV infection has been reported following selective depletion of CD4+ 
T cells in mice infected with MCMV (Poliç et al., 1998a). 
The effector mechanisms of CD4+ T cells include cytokine secretion, facilitating the 
differentiation and proliferation of antigen (Ag)-specific CD8+ T cells, activation of 
dendritic cells by ligation of CD40, and providing signals for virus-specific B cells. 
Accumulating evidence  proposes that CD4+ T cells can directly act as effectors against 
virus-infected cells or help virus-specific CD8+ T cells to expand and become cytotoxic 
(Gamadia et al., 2004;van Leeuwen et al., 2004;Hegde et al., 2005;Wills and Sissons, 
2007). Moreover, it has also reported that patients who have higher numbers of IFN-  
producing CD4+ T cells specific for HCMV clear the virus faster and exhibit fewer 
clinical symptoms (Sester et al., 2001;Gamadia et al., 2003).  
The analysis of HCMV specific CD4+ T cell responses is not as intensive as for CD8+ T 
cells because of, in part, difficulties in producing MHC class II tetramers, however, 
CD4+ T cells often respond to the same HCMV ORFs as CD8+ T cells (Waller et al., 
2008). Similar to the CD8+ T cell response, a high frequency of HCMV specific CD4+ 
T cells (an average of 10% and in some donors even 40%) has been reported in healthy 
seropositive individuals (Sester et al., 2002;Sylwester et al., 2005).  
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1.6.3.2 Gamma deltaT cells 
The γδ T lymphocytes comprises a small fraction (0.5-6%) of peripheral blood; 
however, it represents a more substantial fraction of lymphoid cells in areas of the body 
exposed to the external milieu, such as the intestinal mucosa (Dechanet et al., 1999b). 
An important role of the γδ T cells in host immunity to viral infections including HSV-1 
and MCMV has been examined using mouse models (Sciammas et al., 1997). 
Additionally, a protective role of circulating γδ T cells has been suggested in renal 
transplant patients as marked expansion of these cells was shown to be co-incident with 
active HCMV infection (Dechanet et al., 1999a). 
1.6.3.3 CD8+ T cell response 
The importance of CD8+ T cell responses in the elimination of pathogens and tumors is 
well known. Several studies support the importance of CD8+ T cell in control of HCMV 
infection (Gandhi and Khanna, 2004). This notion initially came from the observation 
that HCMV disease is a typical problem in patients with normal levels of antibody but 
who have impaired T cell immunity such as solid organ transplant recipients, stem cell 
transplant recipients and since 1983 patients with HIV infection (Mocarski et al., 2007). 
Accordingly, it has been shown that adaptive transfer of virus-specific CD8+ T cells into 
allogenic bone marrow transplant recipients is effective in controlling HCMV 
replication (Riddell et al., 1992;Walter et al., 1995).  
Virus-specific CD8+ T cells recognize and respond to the short viral-encoded peptides 
(with 8-10 amino acid residues in length) presented by MHC class I molecules on either 
infected cells or antigen presenting cells (Daniels et al., 2001;Haring et al., 2006) as 
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shown in Figure 1-6. Endogenously synthesized proteins are cleaved in the proteasome 
and transported into the lumen of the endoplasmic reticulum (ER) via heterodimeric 
transporter associated with antigen processing (TAP) proteins which is composed of 
TAP1 and TAP2 subunits. The newly formed MHC class I molecules are transported to 
the lumen of the ER where they associate with calnexin (a chaperon protein). Once the 
β2- microglobulin associates with the MHC-I, calnexin is displaced by a set of different 
chaperone proteins including calreticulin (a lectin-like chaperone that binds to the heavy 
chain of the MHC class I), Erp57, and tapasin to form the peptide loading complex 
(Purcell and Elliott, 2008). ERp57 is a thiol oxido-reductase that associates with 
calreticulin noncovalently and in disulfide-linked to tapasin, which is necessary for 
optimization of the MHC class I peptide cargo (Williams et al., 2002;Radcliffe et al., 
2002). The peptide/MHC-I complex is finally transported via the Golgi apparatus to the 
surface of infected cells where they can be targeted by the T cell receptor (TCR) of 
CD8+ T cells (Purcell and Elliott, 2008).    
In addition to the interaction between the TCR and the peptide-MHC complex, 
subsequent co-stimulatory signals provided by molecules such as CD28 are required for 
optimal activation of naïve T cells. It has been shown that the engagement of CD28 as a 
co-stimulatory molecule with its ligand B7, which is present on the surface of antigen 
presenting cells, provides an important co-stimulatory signal for optimal T cell 
activation (Shahinian et al., 1993). 
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Figure 1-6: Schematic representation of MHC-I antigen presentation to CD8+ T cells.  
Degradation of proteins by proteasome results in generation of eight to ten amino acid peptides that (1) 
translocate via TAP to the endoplasmic reticulum (2). Nascent MHC-I molecules form the peptide loading 
complex in association with tapasin, calreticulin, and ERp57 to facilitate the peptide loading into the 
peptide binding groove (3). Peptide-MHCI complex then transports via Golgi apparatus to the cell 
membrane (4) where interacts with TCR (5). Zoomed circle shows the structure of CD8 involving in 
MHC-TCR interaction. Abbreviations: TCR, T cell receptor; β2m, β2-microglobolin; TAP, transported 
associated with antigen processing, APC, antigen presenting cell; TK, tyrosine kinase; MHC-I, major 
histocompatibility complex class I. 
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In response to viral antigens, naive CD8+ T cells become activated and virus specific T 
cells undergo an extensive clonal expansion, differentiating into a heterogeneous 
effector CD8+ T cell pool, acquiring effector functions and the capability of tissue-
trafficking which together with many other mediators can control viral infection. After 
antigen clearance or neutralization of the pathogen, the expanded T cells specific to 
antigen contracts substantially and fewer than 10% of the remaining antigen stimulated 
T cells differentiate into memory T cells conferring enhanced protection following 
reinfection (Klenerman and Hill, 2005;Harty and Badovinac, 2008;Cui and Kaech, 
2010). 
Recognition of specific epitopes on the surface of infected cells allows the activated 
CD8+ T cells to lyse them via different mechanisms such as exocytosis of granules 
containing granzymes and perforin. Granzyme B is a 32 KDa serine protease which has 
been shown to induce rapid cell death of a virus infected target cell through the cleavage 
of downstream substrates as well as the activating cleavage of caspases (Poe et al., 
1991;Sutton et al., 1997;Bird et al., 1998;Waugh et al., 2000). Following recognition and 
binding to virus infected or other target cells, cytotoxic lymphocytes (or NK cells) 
release perforin (a Ca2+-dependent pore-forming protein which multimerizes in the 
plasma membrane of the target cells) and granzyme B which can provide protease access 
to the cytosol of target cells (Kagi et al., 1994;Liu et al., 1995;Boivin et al., 2009). Upon 
target cell recognition and release into the cytoplasm, granzyme B can target substrates 
in the cytosol as well as the nucleus, inducing cell death (Boivin et al., 2009). 
Engagement of death receptors is another complementary mechanism by which 
cytotoxic T cells induce apoptosis in infected cells. The engagement of cell receptors 
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occurs via a group of cell surface molecules of the tumor necrosis factor (TNF) receptor 
superfamily such as Fas (CD95) which bind to the relevant ligand (FasL) expressed on 
the cell surface of activated CTLs predominantly CD8+ T cells (Lowin et al., 1994). 
However, it is becoming clear that cytotoxic CD8+ T cells can control viral infections 
through noncytolytic mechanism by secretion of antiviral cytokines such as IFN-γ and 
TNF-α, thereby limiting the extent of the infection (Guidotti and Chisari, 2001). IFN-γ 
and TNF-α  are the main cytokines produced by differentiated CD8+ effector T cells and 
have a critical role in CD8+ T cell mediated immunity and control of viral infection by 
inducing intracellular pathways that activate an anti-viral state or apoptosis (Kaech et al., 
2002b;Glimcher et al., 2004). In addition, these cytokines, which have often been 
considered as a signature of a proinflammatory environment, play an important role in 
cellular proliferation and differentiation, inflammation, and cytotoxic activity 
(MacEwan, 2002;Kelchtermans et al., 2008).  
1.6.3.3.1 CD8+ T cell response to HCMV 
The proportion of CD8+ T cell responses against HCMV antigens can be quite large 
particularly in elderly individuals. Unlike the response to many viruses such as influenza 
virus and varicella-zoster virus, which reduces with progressing age (Asanuma et al., 
2000;Deng et al., 2004), there is an accumulation of HCMV-specific CD8+ T cells with 
age, eventually representing up to 40% of the CD8+ T cell pool (Khan, 2004;Crough 
and Khanna, 2009). This rise in virus-specific CTLs, so called ‘memory inflation’, has 
also been described in the CD8+ T-cell immune response to MCMV (Karrer et al., 
2003). During persistent infection, memory CD8+ T cell responses specific to HCMV 
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have been shown to be highly dynamic in terms of both function and absolute number 
(Crough et al., 2007).  
Recent data using peptides (of 15 amino acids in length) which represent the entire 
HCMV proteome reveal that many proteins are targeted by the host CD8+ or CD4+ T 
cell responses. In the study carried out by Sylwester et al, the majority (70.9%) of 
HCMV proteins (151 out of 213 HCMV ORFs) were shown to elicit CD8+ and CD4+ T 
cell response in at least one donor (as illustrated in Figure 1-7) and UL48, UL83 (pp65), 
and UL123 (IE-1) were three ORFs that recognized by more than half of the cohort   
(Sylwester et al., 2005).  
Regardless of targeting many HCMV proteins by CD8+ T cell responses; however, pp65 
and IE-1 are two HCMV proteins that have been extensively studied in terms of the 
immunology of CD8 T cell response (Jackson et al., 2010). It has been well documented 
by several studies that the pp65 phosphoprotein is the dominant target antigen of 
cytotoxic T lymphocytes as well as being a target of both the humoral and cellular 
immune system (Grefte et al., 1992;Laughlin-Taylor et al., 1994;Beninga et al., 
1995;Wills et al., 1996). The UL83-encoded pp65 phosphoprotein is the major 
constituent of HCMV particles (Kalejta, 2008) and is dispensable for growth in cell 
culture (Schmolke et al., 1995). In addition, it has been shown that pp65 is able to 
mediate the phosphorylation of viral IE proteins, thereby preventing their proteasomal 
processing and subsequent presentation by MHC class I molecules (Gilbert et al., 1996). 
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Figure 1-7: Identification of CD8+ and CD4+ T cell responses specific to HCMV ORFs in HCMV-
seropositive adults. 
The image is modified from(Sylwester et al., 2005).     
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44 HCMV ORFs recognized only by CD4+ T cells 
62 HCMV ORFs recognized neither by CD4+ nor CD8+ T cells 
  
26 HCMV ORFs recognized only by CD8+ T cells  
81 HCMV ORFs recognized with both CD8+ and CD4+ T cells  
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The expansion of CD8+ T cells specific to HCMV is usually oligoclonal although in 
some instances can be monoclonal (Price et al., 2005;Day et al., 2007;Wynn et al., 
2008). Moreover, it has been shown that the immune response to a given HCMV peptide 
is characteristically highly focused as up to 23% of oligoclonal expansions of CD8+ 
memory cells in elderly individuals are shown to be directed against a single HCMV 
epitope (Khan et al., 2002;Waller et al., 2008). The clonal repertoire of HCMV-specific 
CD8+ T cell memory response is known to be distinct in latent HCMV infection from 
that observed during acute infection (Karrer et al., 2003). Although primary HCMV 
infection generates a diverse virus-specific TCR repertoire which comprises clones with 
a range of affinities, analysis of the clonal composition of the memory CD8+ T cells 
repertoire specific to pp65 epitopes shows a high degree of clonal focusing on a few or 
even a single TCR (Day et al., 2007;Jackson et al., 2010). 
Furthermore, data from longitudinal-ageing studies indicate the association of HCMV 
seropositivity with a cluster of immune parameters (a so-called “immune risk 
phenotype”) such as an inverted CD4+/CD8+ T cell ratio due to increased levels of 
CD8+ T cells and the presence of CD8+ T cell clonal expansions. In very elderly 
individuals over 80 years of age, immune risk phenotype (IRP) is considered as 
predictive of increased mortality (Olsson et al., 2000;Khan et al., 2002;Akbar and 
Fletcher, 2005;Crough and Khanna, 2009).  
1.6.3.3.2 Dynamics of HCMV specific CD8+ T cells  
Transition from naive to effector and effector to memory CD8+ T cell populations are 
associated with distinct changes in gene expression which results in the expression of 
signature genes central to CD8+ effector T cell function, including genes that encode 
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cytokines and genes associated with cytolysis (Kaech et al., 2002a). Human memory T 
cells were originally assigned into two broad classes named effector memory T cells 
(TEM) and central memory T cells (TCM) based on the differential expression of the 
lymph-node homing receptors CC-chemokines receptor 7 (CCR7) and CD62 ligand 
(CD62L), immediate effector capability, and ability to proliferate after subsequent 
encounter with antigen (Sallusto et al., 1999). Human TCM cells are CD45RO+ memory 
cells that express CCR7 and CD62L and proliferate strongly in response to antigen. 
Human TEM cells are memory cells that lack CCR7 and CD62L, and enriched in 
peripheral tissues such as lung, liver, and gut. TEM cells have immediate effector 
functions but proliferate less strongly in response to antigen (Wherry et al., 
2003b;Sallusto et al., 2004).  
The leukocyte common antigen, CD45, is a transmembrane tyrosine phosphatase that 
regulates signaling through the T-cell receptor (TCR)-CD3 complex (Thomas, 
1989;Trowbridge, I, 1994;van Lier et al., 2003). It is expressed as distinct isoforms with 
different molecular weights as a result of differential splicing of three exons (A, B and 
C) (Streuli et al., 1987). High molecular weight isoform CD45 which contains exons A, 
B and C (or A and B) are referred to as CD45RA, whereas the low molecular weight 
form, CD45RO, lacks any of the variable exons (Wills and Sissons, 2007).    
It has previously been suggested that naïve CD8+ T cells express CD45RA (the long 
isoform of CD45) and the expression of CD45RO (the short isoform of CD45) marks 
memory and effector T cells. However, it has been shown that following resolution of 
HCMV viremia, a subset of these effector memory CD8+ T cells specific to HCMV re-
express CD45RA being therefore known as “revertant” memory cells (T effector 
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memory CD45RA cells, TEMRA). Most of these cells (TEMRA) lack the chemokine 
receptor CCR7 and do not express the costimulatory receptors CD27 and CD28 (Wills 
and Sissons, 2007;Waller et al., 2008;Cantisan et al., 2010). Although antigen specific T 
cells display some degree of heterogeneity; they exhibit unique profiles based on their 
viral specificity. For example, it has been shown that HIV- specific T cells preferentially 
exhibit an so called intermediate phenotype (CCR7-CD27+CD28-CD45RA-), whereas 
HCMV and EBV are shown to be frequently CCR7-CD27-CD28-CD45RA+ and CCR7-
CD27+CD28+CD45RA-, respectively (Appay et al., 2002). The presence of HCMV 
specific T cells with a CCR7-CD27-CD28-CD45RA+ phenotype has been shown to be 
directly correlated with HCMV infection but not with previous exposure to other viruses 
such as EBV or VZV (Kuijpers et al., 2003;Waller et al., 2008). CD45RA expression on 
HCMV-specific effector memory CD8+ T cells was also associated with the kinetics of 
HCMV replication after transplantation (Cantisan et al., 2010). 
It is well known that the frequency of memory CD8+ T cells specific to HCMV is very 
large and in elderly HCMV seropositive individuals this frequency is often striking. 
These cells do not express CD27 or CD28 however many of them express CD57 (Waller 
et al., 2008). Moreover, it has been previously shown that there is an association 
between the presence of CCR7-CD27-CD28-CD57+T cells and HCMV infection 
(Gillespie et al., 2000;van Lier et al., 2003;Brenchley et al., 2003). CD57+ cells, which 
have also been called leu-7, are principally defined by reactivity to the antibody HNK-1 
(Abo and Balch, 1981c). The name HNK-1 is originally derived from the ability of the 
antibody to recognize human NK cells. HNK-1’s epitope, CD57 is a carbohydrate 
epitope that is observed in many glycoproteins and glycolipids in various tissues 
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(Uusitalo and Kivela, 2001). It is also found on NK cells and CD8+ T lymphocytes (Abo 
and Balch, 1981b). While the exact function of CD57 on immune cells has not yet been 
elucidated, experiments have begun to produce some ideas about the function of these 
cells. Lymphocytes that express CD57 are clonally expanded (Wood et al., 2009) and 
large oligoclonal expansions have been described in the CD8+CD57+ population 
(Morley et al., 1995). In healthy individuals, 5-20% of  total CD8+ lymphocytes express 
CD57 (Abo and Balch, 1981a;Morley et al., 1995;Wood et al., 2009). Although the 
exact mechanism or the nature of the stimulus behind this expansion is not yet clear, 
some viral or tumor antigens may play an important role as it is well documented that 
expansion of CD8+ T cells can occur in response to chronic viral infections (Wood et 
al., 2009). To support this, expansions of the CD8+CD57+ cell subset has been shown to 
be associated with both infections with HCMV (Wang et al., 1993;Rossi et al., 2007) 
and HIV (Wood et al., 2005). 
Unlike acute viral infections where the combination of antigen-independent responses 
and generation of memory CD8+ T cell responses confer long-term protective immunity 
and control replication, virus specific CD8+ T cells during many persistent virus 
infections often fail to differentiate into fully functional memory CD8+ T cells. 
Substantial alterations in the phenotype and functionality of memory CD8+ T cells are 
often observed following persistent infections compared with acute infection 
(Klenerman and Hill, 2005;Harty and Badovinac, 2008). These phenotypic and 
functional changes may result in the exhaustion of their effector functions or even the 
deletion of CD8+ T cells of certain specificities (Wherry and Ahmed, 2004). The 
exhaustion of CD8+ T cells during persisting infection, which is likely to have an 
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important impact on viral control, was first described by Barber et al in persistently 
infected mice with LCMV. Using LCMV specific T cells from both acute and chronic 
LCMV infection models, they performed a genome-wide gene profiling and showed a 
significant upregulation of PD-1 in a subset of exhausted cells. Additionally in vivo 
blockade of PD-1 and PD-L1 interactions was shown to enhance the clearance of 
infection and improve the functionality of the memory CD8+ T cells (Barber et al., 
2006). The finding that exhausted T cells exhibit high expression of the programmed 
cell death 1 (PD-1)  has been a centre of several studies analyzing the expression of PD-
1 on CD8+ T cells specific to HIV (Trautmann et al., 2006;Day et al., 2006;Petrovas et 
al., 2006) and HCV (Urbani et al., 2006;Penna et al., 2007). These studies have 
demonstrated that the expression of PD-1 is higher on CD8+ T cells specific to HIV and 
HCV. However, looking at T cells specific to, for example, nonpersisting viruses such as 
vaccinia and influenza has showed that this phenomenon is not uniform as low PD-1 
expression was also found on these virus-specific T cells (Urbani et al., 2006;Day et al., 
2006;Sharpe et al., 2007).   
The immunoreceptor PD1, also called CD279, is a negative regulator of T cell activation 
and is expressed by many cells including T cells, B cells, NK cells, and myeloid derived 
cells (Greenwald et al., 2005;Sharpe et al., 2007). The PD-1 receptor, which was 
originally isolated as a transcript up-regulated in apoptotic cells, is a 288 amino acid cell 
surface monomer. Although this receptor shares structural properties with the members 
of CD28 family, it is located on a different region of the same chromosome (2q37). Two 
ligands with different expression patterns have been described for PD-1, PD-L1 and PD-
L2. PD-L1 (also known B7-H1 and CD274) is broadly distributed on various cell types 
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such as B cells, DCs, macrophages, mesenchymal stem cells as well as a wide variety of 
nonhematopoietic cell types. PD-L2 (also known B7-DC and CD273), by contrast, is 
limited to professional antigen presenting cells including macrophages, DCs, and 
cultured bone marrow-derived mast cells (Augello et al., 2005;Okazaki and Honjo, 
2006;Keir et al., 2007;Sharpe et al., 2007). 
1.7 Manipulation of immune system by HCMV 
Because of selective pressures imposed by the host immune response, viruses have 
developed numerous strategies in order to subvert and also down regulate the host 
immune surveillance and defense by both the innate and adaptive facets of the immune 
system, thereby allowing the virus to survive (Galluzzi et al., 2010).  
As described previously, T cells play a key role in eliminating virus infected cells by 
recognition of viral antigens in the context of MHC class I. In the endoplasmic reticulum 
(ER), MHC class I molecules as well as viral peptides undergo several maturation stages 
in order to be presented on the cell surface. Particular specialized proteins including 
calreticulin, tapasin, ERp57, and the transporter associated with antigen processing 
(TAP) play a critical role in this scenario (Hansen and Bouvier, 2009). Therefore, it is 
not surprising that viruses target key stages of the antigen presentation pathways by 
MHC class I. The immunomodulatory roles of gene products encoded by HCMV have 
been largely characterized and because of the multitude of immune-modulatory 
strategies, HCMV is considered as a prototype for viral immune evasion with the 
capability of modulating both the innate and adaptive immune response. Figure 1-8 
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illustrates the HCMV-encoded immune evasion genes as well as targeting of the MHC-I 
pathway by particular gene products of HCMV (gpUS2, gpUS3, gpUS6, and gpUS11).  
It is well documented that numerous proteins of HCMV are involved in manipulating of 
immune system; however, US2, US3, US6, and US11 are the four most extensively 
studied proteins that target the key stages of the MHC class I antigen presentation 
pathways (Gewurz et al., 2001;Mocarski, Jr., 2002;Hansen and Bouvier, 2009;Mueller, 
2010).  
US3 is a type I transmembrane glycoprotein that is preferentially expressed during the 
immediate early phase of virus infection. By directly binding to tapasin, it is able to 
block the expression of MHC class I presenting HCMV peptides on cell surface via 
inhibiting the optimization of the peptide cargo and thereby preventing the translocation 
of MHC-I from the endoplasmic reticulum to the Golgi apparatus (Lee et al., 2000;Park 
et al., 2004). In the peptide loaded complex (PLC), tapasin stabilizes the groove of MHC 
class I against irreversible denaturation and plays a crucial role for the optimal 
expression of MHC class I molecules on cell surface (Ortmann et al., 1997;Chen and 
Bouvier, 2007).  
US6 (21-KDa) is another type I transmembrane glycoprotein expressed during both 
early and late phases of HCMV infection. US6 can interact directly with the ER lumen 
side of TAP (Ahn et al., 1997;Lehner et al., 1997). By stimulation of ATP hydrolysis, it 
has been suggested that TAP provides required energy for peptide translocation (Hansen 
and Bouvier, 2009). By inhibiting ATP binding and thereby depriving the energy source 
from TAP, US6 inhibits the peptide translocation into ER (Ahn et al., 1997;Kyritsis et 
al., 2001). 
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US2 and US11 are two small gene products of HCMV that have been shown to play a 
role in the destruction of MHC class I heavy chains (Jones et al., 1995).The human 
cytomegalovirus proteins US11 and US2  are both ER-resident membrane glycoproteins, 
and induce the dislocation of MHC class I heavy chains from the ER into the cytosol for 
degradation by ubiquitin-dependent proteasome. It seems that ubiquitin plays an 
important role in this case (Wiertz et al., 1996;Story et al., 1999;Rehm et al., 2002). 
Using trophoblast cells, it has also been shown that these proteins can mediate 
degradation of Human histocompatibility leukocyte antigens (HLA)-A and B locus 
products but not HLA-C and G (Schust et al., 1998). Moreover, it was shown that 
gpUS2 and gpUS11 downregulate the MHC class I presentation of HCMV infected 
fibroblast cells in an antigen dependent manner (Besold et al., 2009).  
In addition to MHC class I down regulation, it has also been demonstrated that HCMV 
can down regulate the expression of MHC-II. In this context, inhibition of the MHC 
class II transactivator (CIITA) early in infection and cytokine-mediated mechanisms 
probably through viral IL-10 are two proposed strategies by which virus can down 
regulate MHC-II expression (Silacci et al., 1994;Zhou and Glimcher, 1995;Mocarski, 
Jr., 2002).  
Considering the important role of NK cells during innate phase of the immune response 
against HCMV, it is not surprising that the virus has evolved strategies to modulate NK 
cell activities(Lodoen and Lanier, 2005). It has been shown that HCMV encodes at least 
six gene products including UL18, UL16, UL40, UL83, UL141, UL142, and a micro 
RNA that are capable of interfering with NK cell function using different mechanisms 
(Wilkinson et al., 2008;Loewendorf and Benedict, 2010). 
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UL18 is one of genes encoded by HCMV that is involved in NK cell immune evasion.  
Similar to classical host MHC class I molecules gpUL18 can express as trimeric 
complex associated with β2-microglobolin and peptide (Browne et al., 1990). It has been 
shown that gpUL18 binds specifically to the NK cell inhibitory receptor, leukocyte 
immunoglobulin-like receptor 1 (LIR1/ILT2), expressed predominantly on monocytes, 
B cells, and NK cells. Binding affinity of LIR1 for gpUL18 was shown to be much 
higher than (>1000 fold) for endogenous MHC class I (Chapman et al., 1999;Cosman et 
al., 1999). 
UL16 glycoprotein is another virus gene product that has a potent NK cell immune 
evasion function by impeding the expression of NKG2D ligands. NKG2D is an 
activating receptor that is expressed on almost all NK cells and CD8+ T cells (Wilkinson 
et al., 2008). In addition to MHC-I chain related A and B proteins (MICA and MICB), 
human NK cells express at least six other ligands from another family of UL16-binding 
proteins (ULBP1-6) which recognize NKG2D receptor. The UL16 protein of HCMV 
has been shown to bind MICB, ULBP1, 2, and 6 (Cosman et al., 2001;Kubin et al., 
2001;Welte et al., 2003).   
UL40, an early HCMV protein, induces protection against NK cell activation via 
upregulating the cell surface expression of HLA-E independent of TAP as constructed 
adenovirus encoding US6, an efficient inhibitor of the TAP, was shown to downregulate 
the surface expression of MHC-I however it did not affect the capacity of gpUL40 to 
upregulate the surface expression of HLA-E (Tomasec et al., 2000). HLA-E that is a 
non-classical MHC class I molecule that is recognized by the NK cell inhibitory receptor 
complex CD94/NKG2A (Braud and McMichael, 1999;Wilkinson et al., 2008). 
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UL83 is another HCMV gene that encodes an abundant tegument protein (pp65). 
Regardless of it being major target for T cell responses it has also been  shown that pp65 
can bind directly to the NK cell activating receptor NKp30 (Arnon et al., 2005). 
 UL141 is a highly conserved gene between HCMV isolates and it can be readily 
detected from 24 h post-infection and it accumulates into the late phase of the virus 
replicative cycle. UL141 has the ability to evade the NK cell lysis by sequestering 
CD155 in the endoplasmic reticulum. CD155 is a cell surface ligand interacting with 
activating receptors of the NK cells, CD226 and CD96. Multiple cellular functions have 
been attributed to CD155 including transendothelial migration, adhesion, and 
endocytosis (Tomasec et al., 2005). 
UL142 is an MHC-I like molecule that has been shown to inhibit the NK cell lysis of 
virus infected cells (Wills et al., 2005) via interfering with cell surface expression of 
ULBP3, a ligand for the NKG2D receptor (Bennett et al., 2010).   
There is also accumulating evidence that HCMV encodes additional membrane proteins 
that interact with host proteins such as chemokine receptors (Streblow et al., 1999), a 
viral TNF receptor (UL144, is a type I transmembrane glycoprotein that is expressed 
early after infection of fibroblasts) (Benedict et al., 1999;Rahman and McFadden, 2006), 
a viral CXC-1 inducing the chemotaxis of human peripheral blood neutrophils (UL146) 
(Penfold et al., 1999), and UL111A encoded interleukin 10 (IL10) homologue that likely 
reduces cell-surface expression of MHC class I and II proteins (Kotenko et al., 2000).  
The role of small, non-coding microRNAs (miRNAs) in both gene silencing and stress 
responses has been recently recognized (Leung and Sharp, 2007). In addition to proteins 
it has been shown that HCMV can express an array of mirRNAs (Grey et al., 2005;Dunn 
Chapter 1: Introduction [2010] 
65 
 
et al., 2005). Mir-UL112 is one of the microRNAs encoded by HCMV that has been 
shown to specifically suppress cell surface expression of  MICB, therefore reducing the 
sensitivity of NK cell recognition (Stern-Ginossar et al., 2007;Wilkinson et al., 2008).  
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Figure 1-8: Schematic representation of HCMV-encoded immune evasion genes targeting MHC-I 
pathway with HCMV proteins (gpUS2, gpUS3, gpUS6, and gpUS11).  
Cleaved endogenously derived cytosolic proteins via proteasome translocate into the ER through TAP. 
HCMV gene products US2 and US11 redirect nascent MHC-I molecules to the cytosol where it is 
degraded. By binding to tapasin, US3 retain MHC-I complexes in the ER, and US6 blocks TAP via 
directly interacting with the ER lumen side of TAP. Abbreviations: ER, endoplasmic cytoplasm; TAP, the 
transporter of antigen processing; IRL, internal repeat long; TRS, terminal repeat short; UL, unique long; 
US, unique short; gp, glycoprotein. 
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The focus of this thesis has been on human cytomegalovirus, however, Epstein-Bar virus 
(EBV) was used as control in my studies. EBV is another member of herpes family that 
is characterized by latency and reactivation. The biology of virus is described in next 
section. 
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1.8 Epstein-Barr virus  
EBV is a member of herpes virus family which was the first in the family to be 
completely sequenced. Like other herpesviruses, EBV has a linear double-stranded 
184kb DNA enclosed in a nucleocapsid, an outer envelope, and a tegument between 
envelope and nucleocapsid. The genome encodes around 85 genes (Baer et al., 
1984;Kieff and Rickinson, 2007). 
Primary infections occur mostly during the first years of life and are usually subclinical 
(Amon and Farrell, 2005). However, in some individuals (particularly in adolescence) 
acute primary infection can manifest as a self-limiting lymphoproliferative disease 
known as infectious mononucleosis (IM) (Kutok and Wang, 2006).  
Several malignancies including endemic Burkitt lymphoma (BL), nasopharyngeal 
carcinoma (NC), post-transplant lymphoproliferative disease (PTLD) and subsets of 
Hodgkin lymphoma (HL) have been shown to be associated with persistent EBV 
infection. EBV-related lymphoproliferative disorders have been shown to arise 
frequently in the setting of iatrogenic suppression in organ transplantation or in AIDS 
(Kutok and Wang, 2006). Additionally, EBV infection in the immunocompromised host 
may result in uncontrolled virus-driven activation and proliferation of B cells with the 
development of lymphomatous diseases ranging from polyclonal B cell 
lymphoproliferation to monoclonal B cell lymphomas. The tumors are an increasing 
problem, affecting both the transplant population and those with HIV infection (Rowe 
and Zuo, 2010). EBV is also implicated in T-cell lymphoma, adult T-cell leukemia, 
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Natural Killer cell leukemia, and various other lymphoid and epithelial malignancies 
(Kutok and Wang, 2006). 
1.8.1 EBV infection and persistence  
EBV preferentially infects B lymphocytes (Kuppers, 2003). However, in some 
circumstances virus can also infects other cell types including T cells and thymocytes 
(Watry et al., 1991;Kelleher et al., 1996;Dreyfus et al., 1996), epithelial cells(Shannon-
Lowe et al., 2009), NK cells (Kanegane et al., 1996), and monocytes (Revoltella et al., 
1989;Savard et al., 2000).  
B cell infection is preferentially mediated through the binding of the EBV glycoprotein 
gp350/220 to the C3d complement receptor CD21 (Fingeroth et al., 1984) as virus entry 
can be blocked using purified CD21 (Nemerow et al., 1990). However, successful 
immortalization of cells with recombinant virus lacking gp 350/220 indicates other 
alternative viral entry pathways (Janz et al., 2000). It appears that a complex of three 
additional envelope glycoproteins including gH, gL and gp42 is necessary for virus entry 
into B cells whereas entry of EBV into epithelial cells is shown to be mediated by the 
gH/gL complex but not gp42. It has been shown that gp42 interacts with HLA class II, 
which functions as a co-receptor. B cells express high levels of HLA class II whereas 
epithelial cells do not express significant levels of HLA class II (Wang et al., 
1998;Borza and Hutt-Fletcher, 2002). 
EBV is potent in transforming infected B cells in vitro (resulting in B-lymphoblastoid 
cell lines (B-LCLs)) and autonomously proliferating lymphoblasts in vivo. This ability 
has been shown to be associated with a set of latent genes encoding six nuclear antigens, 
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EBNAs 1, 2, 3A, 3B, 3C, LP, and three latent membrane proteins, LMPs 1, LMP2A, and 
LMP2B (Hislop et al., 2007b;Rowe et al., 2009). Therefore, keeping the virus under 
control relies on efficient immune control in vivo. 
Based on the location and differentiation state of the infected cells in vivo, EBV 
establishes a complex set of latency programs as well as lytic infection (Kutok and 
Wang, 2006). Table 1-2 shows the patterns of latent infection gene expression in EBV 
infected cells. Latency type 0 is associated with no detectable latent gene expression 
whereas in latency type I, gene expression is restricted to only Epstein-Barr virus 
nuclear antigen 1 (EBNA1) expression and is seen in Burkitt lymphoma (Niller et al., 
2008;Halder et al., 2009). EBNA1 is a DNA binding protein that mediates genome 
maintenance (Lee et al., 1999) and plays a central role in latency by binding to 
sequences in viral origin of replication termed OriP, therefore promoting initiation of 
episomal DNA replication. Moreover, EBNA1 has been shown to play an important role 
in plasmid segregation of dividing cells through its ability to bind both the viral genome 
and metaphase host chromosomes (Yates et al., 1985;Sears et al., 2004;Speck and 
Ganem, 2010).  
 Latency type II is another viral gene expression pattern that is frequently detected in 
both Hodgkin's lymphoma and nasopharyngeal carcinomas. Type II latency is associated 
with the expression of EBNA1, latent membrane protein 1 (LMP-1), LMP-2A, and 
LMP-2B (Niller et al., 2008;Halder et al., 2009). LMP-1 is a member of TNF 
superfamily that is capable of activating NF-kB to promote cell survival (Mosialos et al., 
1995).   
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Latency type III is mostly seen in immunocompromised individuals developing 
lymphoproliferative diseases and lymphoblastoid cell lines transformed by EBV. It is 
characterized by the expression of EBV-encoded nuclear antigens (EBNA1, 2, 3A, 3B, 
3C), latent membrane proteins (LMP-1 and LMP-2), and  Epstein-Barr virus nuclear 
antigen leader protein (EBNA-LP) (Niller et al., 2008;Halder et al., 2009). EBNA-LP 
has been shown to play a key role in upregulating B cell gene expression (Mannick et 
al., 1991). 
Although the viral genes expressed during latency are not clustered in a single region of 
the genome, the promoters and cis-elements that control these genes are shown to be 
clustered in a relatively small region spanning the fused terminal repeats (TRs) of the 
viral genome (Speck and Ganem, 2010). 
 
Latency program Disease association Genes expressed 
Latency 0 - Un detectable genes 
Latency I BL EBNA1 
Latency II HL, NC EBNA1, LMP1, LMP2A, LMP2B 
Latency III IM, PTLD EBNA1, EBNA2, EBNA3 (A, B, and C), 
EBNA-LP, LMP1, LMP2A 
Table 1-2: Patterns of latency and genes expressed during EBV infection.  
Abbreviations: EBNA, Epstein-Barr virus nuclear antigen; LMP, Latent membrane protein; NC, 
Nasopharyngeal carcinoms; BL, Burkitt’s lymphoma; HL, Hodgkin lymphoma; IM, infectious 
mononucleosis; PTLD, Post-transplantation lymphoproliferative disorders. 
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1.8.2 The immune response to EBV 
 Like other members of herpes family, EBV establishes a life-long infection and more 
than 90% adult human population worldwide are infected with the virus (Rowe and Zuo, 
2010). Both cellular and humoral immune systems are important to keep the infection 
under control (Thorley-Lawson and Gross, 2004). Most of the information available on 
the primary antibody response to EBV is provided through patients with infectious 
mononucleosis which is an acute but self-limiting illness observed in approximately 
25% of adolescent seroconversions. The early phase of acute IM is associated with 
generally increased levels of total serum IgM, IgG, and IgA in addition to antibody 
responses specific to EBV (Crawford et al., 2006;Kieff and Rickinson, 2007). The role 
of NK cells (as a main component of innate immune responses) in the case of EBV is 
controversial. It has been shown that the inhibition of EBV-induced transformation of 
resting B cells can occur in vitro when NK cells added within few days of infection, 
however the clinical evidence suggest a less important role for these cells as in recipient 
of T-depleted stem cell transplantation, the most commonly seen symptom is EBV-
driven lymphoproliferative disease (LPD) (Hislop et al., 2007b). 
Studies following individual IM patients showed large numbers of CD8+ T cells during 
acute infection probably through either a polyclonal response to a virus encoded or virus 
induced superantigen or a nonspecific bystander phenomenon (Sutkowski, 
2001;McNally and Welsh, 2002;Hislop et al., 2007b). It has also been shown that these 
CD8+ T cells from acute IM individuals are functional in terms of cytokine expression 
as well as cytotoxic activity (Steven et al., 1997;Catalina et al., 2001;Catalina et al., 
2002). In healthy individuals, a significant proportion of the circulating CD8+ T cell 
Chapter 1: Introduction [2010] 
73 
 
pool is devoted to control virus infection. In the case of EBV lytic and latent epitopes, it 
has been shown that individual epitope-specific populations usually account for 0.2%-
2% and 0.05%-1% of CD8+ T cells, respectively (Benninger-Doring et al., 
1999;Saulquin et al., 2000;Bihl, 2006;Hislop et al., 2007b). Although the proportion of 
EBV-specific CD8+ T cells appears to be stable over time (Crough et al., 2005), there is 
evidence indicating the presence of an age-related inflation over a longer time frame. 
This inflation of EBV-specific CD8+ T cells occurs in elderly people infected with EBV 
alone and can reach levels of ~14% of total CD8+ T cells (Ouyang et al., 2003;Hislop et 
al., 2007b). However, in older people caring both EBV and HCMV it appears there is no 
inflation of CD8+ T cells specific to EBV unlike massive expansion of HCMV specific 
CD8+ T cells. It seems that HCMV may overtake EBV in terms of CD8+ T cell inflation 
although it is not fully clear how this phenomenon occurs (Khan, 2004). 
During acute IM, the majority of EBV specific CD8+ T cells express the activation 
markers HLA-DR and CD38 and the memory marker CD45RO. The expression of 
CD28 and CD57 on CD8+ T cells specific to EBV varies depending on the donor and 
ranges from 9% to 86% for CD28 and 2% to 37% for CD57 (Appay et al., 
2002;Radziewicz et al., 2007). However, in the latency or memory stage, EBV-specific 
memory T cells have been found to have an early phenotype (CCR7-
CD27+CD28+CD45RA-) (van Lier et al., 2003). 
Until recently, EBV was not considered as a major virus in manipulating the immune 
system in contrast to the multiple immune evasion strategies described for HCMV. 
However, many EBV genes have been recently characterized that manipulate the 
immune response (Hansen and Bouvier, 2009). EBV nuclear antigen 1(EBNA1) is the 
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best known example that can specifically interfere with the proteasomal processing 
which plays a central role in generation of peptides for antigen presentation pathways 
through MHC class I (Levitskaya et al., 1995;Ressing et al., 2008). In addition, BARF1, 
BZLF2, BILF1, and BNLF2a are at least four other genes of EBV that are known to 
have immune-modulatory functions (Rowe and Zuo, 2010). By encoding a secreted 
protein with the capability of binding to colony stimulating growth factor-1, BARF1 has 
been shown to inhibit macrophage activation (Strockbine et al., 1998).  
BZLF2 encodes gp42 which mediates immune evasion through MHC class II molecules. 
Mechanistically, it has been shown that gp42 associates with MHC-II molecules in the 
endoplasmic reticulum and accompanies the MHC-II complexes to the cell surface, 
blocking the proper interaction with T cell receptors of CD4+ T cells (Ressing et al., 
2003;Ressing et al., 2005).  
BILF1 is a seven transmembrane segment G-protein receptor (GPCR) that shares 
structural and functional characteristics with chemokine receptors. Although the precise 
mechanisms have yet to be defined, BILF1 targets and downregulates MHC class I 
expression (Beisser et al., 2005;Ressing et al., 2008). BNLF2a is one of the EBV-
encoded lytic phase proteins that contributes to the MHC class I downregulation via 
inhibiting TAP-mediated peptide transport, resulting in a diminished peptide supply into 
the ER lumen. BNLF2a is a small membrane-associated protein that interferes with both 
ATP and peptide binding to TAP (Hislop et al., 2007a;Horst et al., 2009). 
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1.9 Common Variable Immunodeficiency 
Common variable immunodeficiency (CVID), first described by Janeway in 1953 
(Janeway et al., 1953), is a heterogeneous disease characterized by defective antibody 
production, resulting in recurrent bacterial infections of the respiratory and 
gastrointestinal tract (Park et al., 2008;Chapel and Cunningham-Rundles, 2009). After 
selective IgA deficiency, CVID is the second most frequent primary immunodeficiency 
disease and, worldwide, has an incidence between one in 50000 and one in 200000 
(Bayry et al., 2005;Lopes-da-Silva and Rizzo, 2008;Park et al., 2008).  
The number of circulating B lymphocytes can be reduced or normal; however , these 
cells fail to terminally differentiate into plasma cells secreting antibody (Cunningham-
Rundles and Ponda, 2005). It has also been documented that 50-75% of CVID patients 
have low numbers of class-switched memory B cells (CD27+IgM-IgD-) (Tangye et al., 
1998;Piqueras et al., 2003;Alachkar et al., 2006;Park et al., 2008). Phenotypic 
heterogeneity of CVID disease makes the proper classification difficult. In the last few 
years three different classifications including Freiburg (Warnatz et al., 2002), Paris 
(Piqueras et al., 2003), and EUROclass (Wehr et al., 2008) have been suggested for 
CVID patients based on the assessment of Ig synthesis in vitro and immunophenotyping 
of B-cell subsets. 
 CVID has a broad and heterogeneous phenotype including sinopulmonary and 
gastrointestinal complications, inflammatory lesions, autoimmune disease, and 
malignancies, mainly non-Hodgkin’s lymphoma (Park et al., 2008;Chapel and 
Cunningham-Rundles, 2009). Although monogenic defects including mutations in 
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inducible T cell co-stimulator (ICOS) (Grimbacher et al., 2003;Salzer et al., 2004), 
TACI (transmembrane activator and calcium-modulating cyclophilin ligand interactor) 
(Castigli et al., 2005;Salzer et al., 2005;Pan-Hammarstrom et al., 2007), CD19 (van 
Zelm et al., 2006), and BAFFR (B-cell activating factor of the TNF family receptor) 
have been described in 5-10% of CVID patients, the vast majority of these patients have 
no identifiable genetic defect.  
While CVID is categorized as a B-lymphocyte-related disease, reports have described 
alterations in both the phenotype and function of T cells (Webster, 2001) such as the 
impaired function of dendritic cells, Th1 skewing and decreased production of IL-2 
(Bayry et al., 2004b;Isgro et al., 2005a). In addition, the reduced expression of surface 
molecules (for example: CD40L, L-selectin and attractin) (Farrington et al., 1994), 
defective Vav expression, and impaired F-actin organization (Paccani et al., 2005) have 
also been described. Beside the reduction in the absolute numbers of T cells as well as 
inversion of the CD4:CD8 ratio due to reduced CD4+ T cell numbers (Isgro et al., 
2005b), in some studies disturbed function of monocytes or monocyte-derived dendritic 
cells have also been reported in a subset of CVID patients (Cambronero et al., 
2000;Bayry et al., 2004a;Cunningham-Rundles and Ponda, 2005).   
CVID patients are known to be susceptible to recurrent infections such as multisystem 
inflammatory granuloma although the exact mechanisms are unknown (Chapel and 
Cunningham-Rundles, 2009). Although CVID patients have not been historically 
considered at risk of serious viral infections, patients with diminished specific antibody 
production and concurrent disturbances in T lymphocytes, infection with particular 
viruses have been reported such as entroviral infection (Halliday et al., 2003), HCV 
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(Yap et al., 1994), HSV-1 (Dray et al., 2006), HHV-8 (Wheat et al., 2005), EBV (Le et 
al., 2003), and HCMV (Tahan et al., 2000;Witte et al., 2000;Stack et al., 2004). The role 
of persistent viral infections in CVID patients is still not clear. However using CD4 
responses to HCMV lysate as a marker of HCMV infection, 60% of CVID patients have 
been found to be HCMV-infected (Raeiszadeh et al., 2006). Little is known about T cell-
mediated immunity to viral antigens in these patients and understanding the viral and 
host immuno-regulatory mechanisms that are involved in the development of disease is 
critical for developing new and improved treatments. 
A significant proportion of CVID patients suffer from inflammatory lesions within a 
variety of organs. The role of HCMV infection in inflammatory diseases and long term 
complications such as atherosclerosis after solid organ transplantation is supported by 
data from epidemiological, interventional and mechanistic studies (Soderberg-Naucler, 
2006). Table 1-3 shows the most common clinical manifestation of inflammatory 
disease in CVID patients with inflammation. 
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Clinical Manifestations Organs Involved 
Granulomatous disease Lungs, liver, spleen, skin, and gastrointestinal tract  
Pulmonary complications  Lung and airways 
Gastrointestinal disease Gut and intestine 
Infections  Lung, liver, intestine, sinuses, middle ear, and spleen 
Autoimmune diseases Red blood cells and platelets  
Neoplasias  Breast, prostate, ovary, skin, and colon 
Table 1-3: Clinical phenotypes and organs involved in CVID patients. 
 
1.10 HCMV and Inflammation 
Human cytomegalovirus infection has, historically, been an important clinical problem 
after organ transplantation, leading to a broad range of direct and indirect clinical 
symptoms such as hepatitis, pneumonitis, enteritis, acute and chronic organ rejection. 
Morbidity and mortality attributed to HCMV has been reduced significantly in recent 
years due to the development of prophylactic and pre-emptive therapeutic strategies. 
High level viral replication is a dominant and well documented risk factor in HCMV 
disease (Emery, 2001). In addition, studies have shown a direct association between the 
functional impairment of CD8+ T cells specific to HCMV in interferon gamma 
production and increased virus replication and disease (Crough et al., 2007;Mattes et al., 
2008). Regardless of the direct immunosuppressive effects of HCMV in transplant 
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patients for instance, increasing in vitro evidence is accumulating that suggests HCMV 
infection has many other effects on the host’s immune response (Soderberg-Naucler, 
2006;Freeman, Jr., 2009). There is substantial anecdotal evidence suggesting the role of 
infectious agents such as HCMV as potential contributors in the pathogenesis of 
vascular disease (Freeman, Jr., 2009). For example, the role of HCMV in atherogenesis 
through specific effects on matrix metalloproteinase 9 (MMP-9) activities has been 
suggested. To support this, it was found that MMP-9 can prevent the development of 
atherosclerotic plaques in mice (Straat et al., 2009). Moreover, the potential role of 
HCMV and p53 interaction in coronary restenosis has been examined (Speir et al., 
1995). More recently, HCMV has been found in atherosclerotic plaques of patients with 
peripheral vascular disease and it appears that endothelial cells infected with virus play a 
central role in this scenario (Bentz and Yurochko, 2008). 
Active HCMV replication has been frequently found in the site of chronic inflammation 
in rheumatoid arthritis and inflammatory bowel disease (IBD), in the vascular lesions of 
coronary artery transplant vasculopathy, systemic lupus erythematosus (SLE), several 
autoimmune diseases such as Sjögren's Syndrome and Hashimoto's Thyroiditis 
(Soderberg-Naucler, 2008). HCMV has also been implicated in contributing to the net 
state of immunosuppression seen in cancer patients (Harkins et al., 2002;Miller, 
2009;Michaelis et al., 2009). HCMV-induced proinflammatory state could play the 
formation or progression of these diseases. 
In the light of these studies linking HCMV with inflammatory conditions the potential 
role of HCMV infection and the CD8+ T cell responses in CVID patients with 
inflammatory disease provided the major focus for my PhD studies. 
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1.11 Project Aims 
The aim of this PhD project was to investigate several aspects of functional competence 
of CD8+ T cell responses induced against HCMV compared to EBV in CVID patients 
(with and without inflammation) and to compare them with healthy HCMV and EBV 
seropositive individuals. The whole project was based on the hypothesis that HCMV 
may be a major factor driving CD8+ T cell expansion and inducing an aberrant HCMV 
specific CD8+ T cell response in CVID patients with inflammation. 
Determining the sero-status against previously encountered viral pathogens in these 
patients is not possible because they do not produce immunoglobulins. Previous work in 
the laboratory used analysis of T cell response to determine the exposure of CVID 
patients to HCMV and EBV and this project builds upon these data to provide a 
comprehensive phenotype of these cells and to investigate their association with the 
pathology observed in CVID patients. 
The aims of the thesis were as follows: 
1. To assess the total CD8+ T cell response against epitopes specific to HCMV and 
EBV using virus-specific peptide stimulation in inflammatory CVID patients 
compared to both non-inflammatory patients as well as healthy age-matched 
controls. 
2. To investigate the polyfunctional signature of CD8+ T cells specific to both 
HCMV and EBV in CVID patients with or without concurrent inflammatory 
disease as well as healthy controls to probe in more detail whether HCMV-
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specific CD8+ T cells in CVID patients with inflammation are characterized by 
unique features.  
3. To evaluate the phenotypic analysis of HCMV and EBV specific-CD8+ T cells 
and pentamer stained T cells in CVID patients and healthy individuals with 
regard to phenotypic maturation, cytotoxicity, and cell exhaustion. 
4. To assess functional aspects of CD8+ T cells, with respect to proliferative 
capacity following single virus-specific peptide stimulation. 
5. To assess the avidity of CD8 binding and anti-inflammatory potential of CD8+ T 
cells in CVID patients (with and without inflammation). 
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Chapter 2   
2 Materials and Methods 
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2.1 Study population 
A cohort of thirty two CVID patients who had an HLA type for which a ppUL83 class I 
HLA pentamer was available, and 14 HLA- and age matched healthy controls were 
recruited to the study. Because HLA-A2 is relatively common in the UK population and 
class I HLA pentamers for HCMV and EBV was available the study focused on this 
group of patients. CVID was defined according to the International Union of 
Immunological Societies (IUIS) criteria (Chapel et al., 2003;Chapel and Cunningham-
Rundles, 2009). There was no significant differences in either age or gender between 
patients (40-69 years (median: 55years); 13 female and 12 male) and the healthy group 
(34-60 years (median: 49 years); 8 female and 6 male). Seven of the CVID patients were 
excluded because of either being HCMV negative (as judged by CD4+ T cell responses 
against HCMV lysates or not having an HLA type for which an HLA multimer was 
available. The CVID group (n = 25) were all HCMV positive using previous criteria 
(Raeiszadeh et al., 2006). Prior exposure to HCMV was determined based upon CD4+ T 
cell responses to a cytomegalovirus cell infected lysate (Autogen Bioclear, UK). For 
EBV, prior exposure was determined using pentamer staining as described in section 
2.4. 
All HCMV positive CVID patients were further sub-divided by the treating clinicians 
into patients with inflammatory disease (n = 9) and those with no inflammation (n =16). 
Inclusion in the inflammatory disease group was based on fulfillment of one or more of 
the following criteria: i) hepatitis without evidence of hepatitis B or hepatitis C virus 
infection; (ii) splenomegaly; (iii) clinical evidence and a biopsy indicative of chronic 
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enteropathy involving small and/or large bowel not explained by infection or gluten 
sensitivity; (iv) interstitial lung disease not explained by bacterial infection. All CVID 
patients regularly received standard immunoglobulin therapy.  
The study was approved by the local research ethics committee of the Royal Free 
Hospital. 
2.2 Cell culture 
2.2.1 Isolation of PBMC from peripheral blood 
Fresh whole blood (20-25mL) was collected from CVID patients and healthy volunteers 
using the monovette system, containing heparin. The blood was then carefully overlaid 
onto Ficoll-Paque (GE Healthcare, UK) at a 1:1 volume ratio in 50 ml sterile Falcon 
universal tubes (Fisher, UK). Peripheral blood mononuclear cells (PBMCs) were 
separated by centrifugation (778g, 22 min at room temperature) with slow acceleration 
and without braking.  Following centrifugation, the interphase containing mononuclear 
cells, created between the plasma and the lymphocyte separation medium, was carefully 
removed and placed into a fresh 25ml universal tube and the volume made up to 25ml 
with unsupplemented RPMI-1640 (Gibco, UK) and centrifuged at 600g (1800 rpm) for 
10 minutes (with fast acceleration and brake) to remove any residual Ficoll. After 
centrifugation, the supernatant was discarded and the resultant PBMC pellet was 
resuspended in an additional 10ml of RPMI-1640 and centrifuged extra time at 500g 
(1500rpm) for 5 min.  Following the final wash, the PBMC pellet was resuspended in 
5ml RPMI-1640 supplemented with 2-mM glutamine and 10% fetal calf serum (FCS). 
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Viable cells were stained with trypan-blue (Sigma) and counted using a haemocytometer 
and either used immediately or stored in liquid nitrogen.  
2.2.2 Freezing/thawing PBMC 
Isolated PBMCs were centrifuged at 500g for 5 minutes and the pellets were 
resuspended at concentration of 3×106 to 5×106 per ml in pre-coold 90% FCS and 10% 
dimethyl sulphoxide (DMSO) (Sigma, UK). Resuspended cells were then transferred in 
1ml aliquots into labeled 1.5ml cryovials (Starlab, UK) and placed in an isopropanol 
freezing container (previously equilibrated to 40C) prior to transfer into liquid nitrogen 
storage for long term storage. For thawing PBMC, frozen cells were taken from liquid 
nitrogen storage and immediately placed the cryovials in a water bath (370C). When the 
cells had almost completely thawed they were then transferred to a 15ml Falcon tube 
and resuspended gently in 9ml RPMI-1640 containing 10% FCS. Cells were then 
centrifugated at 500g for 5 minutes to remove residual DMSO. Following additional 
washing, cells were assessed for both number and viability using the Trypan Blue (TB) 
(Sigma, UK) exclusion method (to stain dead cells) and counted via a haemocytometer.  
2.3 Intracellular cytokine staining 
Following PBMCs separation, cells were resuspended in RPMI-1640 supplemented with 
10% FCS at a density of 1 × 106 cells/0.5ml in sterile capped 12×75mm polypropylene 
tubes (Marathon Lab Sup, UK). Cells were stimulated with 5µg/ml of viral peptides 
(shown in table 2-1) or left unstimulated as a negative control in the presence of 5µg/ml 
co-stimulatory monoclonal antibody, anti-CD28 (Becton Dickinson, UK). Tubes 
containing cells were vortexed gently to mix and then incubated for two hours in a 
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humidified incubator at 370C with 5% CO2. Following 2 hours stimulation, suspensions 
were mixed by adding 0.5ml supplemented RPMI-1640 (total volume 1ml per tube) 
containing freshly thawed Brefeldin A (Sigma St Louis, MO, US) at a concentration of 
10µg/ml and incubated for an extra 14 hours at 370C 5% CO2. 
Viral peptides Virus Proteins  Stock Preparation 
NLVPMVATV HCMV  Derived from pp65 (UL83) protein 
1mg lyophilized peptide 
dissolved in 50µl DMSO + 
950µl sterile dH2O, and frozen 
in aliquots at -200C. 
GLCTLVAML EBV  Derived from lytic protein of BMLF1 
Pp65 pool peptide HCMV  Tegument protein (UL83) 
Lyophilized powder dissolved 
in 50µl of DMSO + 200µl 
sterile dH2O and stock frozen in 
aliquots at -200C. 
IE-1 HCMV  Non-structural protein 
Table 2-1: Viral peptides used for intracellular cytokine stimulation assay.  
All purchased antibodies and antigens used in this study are listed with catalogue number and shown in 
appendix 1. Matched peptides including NLV and GLC peptides were purchased from Proimmune and 
pp65/IE-1 pool peptides were purchased from JPT technologies PepMix.  
  
Following 16 h stimulation, tubes were vortexed to mix, centrifuged at 500g (1500rpm) 
for 5 minutes and the supernatant discarded. The resuspended cells in residual media 
were subjected to surface staining by adding 10µg/ml anti-CD8 (or anti-CD4) 
conjugated with Peridinin-chlorophyll proteins (PerCp cy5.5) to each tube, and 
incubated for 15 minutes at room temperature (RT) followed by washing in 2ml 
phosphate buffered saline (PBS) containing 0.1% sodium azide (NaN3) and 
centrifugation at 500g for 5 minutes. The cells were then fixed/permeabilised for 15 
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minutes at RT by adding 100µl Caltag medium A (Invitrogen) whilst vortexing. For 
intracellular staining, cells were washed again in 2ml PBS containing 0.1% NaN3, 
permeabilised with 100ml Caltag medium B (Invitrogen) while vortexing and stained 
with fluorochrome antibodies against IFN-γ (10µg/ml), TNF-α (10µg/ml), and IL-2 
(2µg/ml) conjugated with Allophycocyanin (APC), Phycoerythrin (PE), and Fluorescein 
(FITC) (BD Biosciences, UK), respectively. Stained cells were then incubated in the 
dark at RT for 15 minutes followed by a final wash as described above. Following the 
final wash, cells were resuspended in 100µl of 4% paraformaldehyde in PBS (Sigma, 
UK) to fix and either directly acquired using Fluorescence Activated Cell Sorter (FACS) 
Calibur (BD Biosciences, UK) or stored at 40C in the dark until acquisition. 50,000 CD8 
cells were acquired using Cell Quest software and four-colour FACSCalibur. All further 
data analysis was done using the FlowJo software (Tree Star, Inc, US). Background 
subtraction was used in all cases. For this purpose, number of cytokine producing cells 
measured in unstimulated PBMC was subtracted from the cells producing the same 
cytokines following peptide stimulation to yield the final frequencies. Figure 2-1 
illustrates an example of representative FACS density plots of cytkokine producing 
CD4+ T cells in response to CMV lysate stimulation and background level of 
unstimulated cells.  
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Figure 2-1: Representative FACS plots of cytokine expressing CD4+ T cells in response to no stimulation 
as background staining (A) or CMV lysate (B). 
 
B) A) 
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For polyfunctional analysis, cytokine co-expression subsets were further determined 
using the Boolean gating function in the FlowJo software. Figure 2-2 illustrates a 
schematic of the polyfunctional analysis and combination analysis of the seven potential 
subsets. For this purpose as shown in Figure 2-2, lymphocytes (A) were gated based on 
forward scattering (FSC) and side scattering (SSC) and CD8+ T cells (B) were then 
analyzed for individual cytokine production including IFN-γ (C), TNF-α (D), and IL-2 
(E). Polyfunctional analysis for cytokine co-expression profiles were determined using 
the Boolean gating function available in the FlowJo software to measure the frequencies 
of different expression profiles corresponding to triple producers (F), double producers 
(G, H, and I), and single producers (J, K, and L).  
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Figure 2-2: Schematic representation for the analysis of cytokine co-expression profiles of CD8+ T cells 
in response to HCMV peptide stimulation.  
*ILT: IFN-γ, IL-2, and TNF-α; *LT: IL-2 and TNF-α; *IT: IFN-γ and TNF-α; *IL: IFN-γ and IL-2; *I:  
IFN- α; *L: IL-2; *T: TNF- α. 
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2.4 Ex vivo staining 
Both fresh and frozen PBMCs were counted and placed in FACS tubes (12×75mm 
polypropylene tubes) at a concentration of 1 × 106 cells/0.5ml (supplemented RPMI-
1640 in 10% FCS) and centrifuged at 500g for 5 minutes. Following centrifugation, the 
supernatant was discarded and cells resuspended in residual fluid and then stained for 15 
minutes at RT (protected from light) with PE conjugated pentamers (A*0201: 
NLVPMVATV derived from pp65 (ppUL83) of HCMV and for EBV A*0201: 
GLCTLVAML derived from lytic protein of BMLF1) (Proimmune, UK). After 
incubation, cells were washed for 5 minutes at 500g with 2ml PBS containing 0.1% 
NaN3. Following discarding the supernatant, cell pellets were resuspended and stained 
for 15 minutes in RT with 10µg/ml of conjugated surface markers including, CD8 PerCP 
Cy5.5, CD57FITC, CD45RO FITC, CD45RA APC, PD-1 FITC, IgG1k isotype control 
FITC (all from BD Biosciences, UK), and CD73 APC (eBiosciences, UK). Following 15 
minutes incubation, cells were washed (all washes consisted of adding 2ml PBS/0.1%  
NaN3 and centrifuging at 500g for 5 minutes) and then resuspended in 100µl of 4% 
paraformaldehyde in PBS and stored at 40C until acquisition. Surface staining was 
carried out at room temperature for 15 minutes. The cells were washed with PBS/ 0.1% 
azide as above, and. For some markers such as granzyme B (Invitrogen, UK) and Ki-67 
(BD Biosciences, UK), after surface staining with pentamer and CD8, cells were fixed 
by adding 100µl Caltag medium A fixative reagent and further incubated for 15 minutes 
at room temperature. Cells were washed again, permeabilised using 100µl Caltag 
medium B and co-incubated for 15 minutes with 5µg/ml and 10µg/ml of granzyme B-
APC or Ki67-FITC, respectively. Cells were washed a final time and resuspended in 
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100µl of 4% paraformaldehyde and were stored at 40C until FACS acquisition. 50,000 
CD8+ T cells were acquired on a FACS Calibur. 
2.5 Carboxyfluorescein diacetate succinimidyl ester (CFSE) 
labelling assay 
CFSE is a fluorescent dye with the ability of permanently labeling the cells, providing a 
valuable tool for monitoring the cell proliferation. CFSE powder (Molecular Probes, 
UK) was dissolved in DMSO to a final concentration of 5mM and stored in suitably 
sized aliquots (6µl) at -20°C. CFSE labeling was performed according to a standard 
protocol (Quah et al., 2007). For this purpose, freshly isolated PBMCs were re-
suspended in PBS containing 5% FCS at a concentration of 5-10 × 106 cells/ml, and 
CFSE labeled by adding 2.5µM of CFSE into cell suspension for 5 minutes in the dark 
at room temperature. Cells were then washed three times with 5% FCS in PBS and 
subsequently re-suspended in RPMI 1640 supplemented with 10% FCS. CFSE-labeled 
cells were then cultured in 96-well plates at a concentration of 5-10 × 105cells/200 µl per 
well for 5 days in 370C 5% CO2. In each set of experiments, CFSE-treated cells were 
stimulated with 10 µg/ml of HCMV pp65-derived peptide (A2: NLVPMVATV), EBV 
BMLF1-derived peptide (A2: GLCTLVAML), or Phytohemagglutinin (PHA) (Sigma, 
UK) at a final concentration of 10 µg/ml. As a negative control, labeled cells were left 
unstimulated. On day 5, cells were harvested, centrifuged and surface stained with 
5µg/ml of PE conjugated pentamers as described in section 2.4. Following 15 minutes 
incubation at room temperature and washing with PBS/0.1% sodium azide, cells were 
subsequently stained for the surface marker CD8 using anti-CD8 PerCP Cy5.5. Finally 
cells were washed and fixed by suspending in 100µl of 4% paraformaldehyde in PBS. 
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2.6 Supernatant transfer assay 
Freshly isolated PBMCs from inflammatory CVID patients were CFSE labeled, as 
mentioned in section 2.5, with 2.5µM of CFSE. 5×105 CFSE labeled cells in 200µl 
RPMI-1640 medium supplemented with 10% FCS were added per well of a 96 well 
plate following stimulation with a final concentration of 10µg/ml HCMV pp65-derived 
peptide (A2: NLVPMVATV), EBV BMLF1-derived peptide (A2: GLCTLVAML), or 
no peptide stimulation as a negative control for 5 days. In addition, a HCMV pp65 
peptide pool covering the whole ORF (JPT Peptide Technologies GmbH, Germany) was 
included in this setting to check that any response to HCMV was specific. On day two, 
cell cultures were collected and centrifuged for 5 minutes at 500g. Supernatants were 
then collected in pre-labeled tubes and filtered using 0.2µm filters.   
For supernatant transfer experiments, PBMCs were taken from both healthy donors and 
non-inflammatory patients and the same procedure was followed; cells were CFSE 
labeled and treated with the same panel of antigens. Stimulated cells at a concentration 
of 5×105 labeled cells/100µl were cultured in 96 well plates in the absence and presence 
of 100µl supernatants collected (and filtered using 0.2µm filter) from the inflammatory 
CVID samples. Plates were incubated at 370C 5% CO2 for 5 days before surface 
staining with PE-labeled pentamers and anti-CD8-PerCP Cy5.5. Figure 2-3 shows a 
schematic of the supernatant transfer assay. 
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Figure 2-3: Schematic representation of supernatant transfer assay.  
PBMCs taken from inflammatory CVID patients (light red box) were CFSE labeled and stimulated with 
(GLC, NLV, pp65 pool) and without antigens. On day 2 (D2), supernatants were collected from cell 
cultures, centrifuged, filtered, and transferred into sterile tubes (shown as different colors) for supernatant 
transfer assay (SNT). Before SNT, PBMCs were taken from healthy or non-inflammatory CVID patients 
(light green) and cells were CFSE labeled and stimulated as above. Cell cultures were then incubated for 5 
days in the absence (dashed circles) and presence of supernatants. After 5 days, cell cultures were 
collected, washed, and stained for FACS analysis. 
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2.7 Cytokine blocking assay 
Freshly isolated PBMCs from CVID patients with inflammation were CFSE labeled as 
described in the previous section. CFSE labeled cells were stimulated with 10μg/ml of 
GLC, NLV, or pp65 peptide pool peptides or left unstimulated as a control. Cells were 
then seeded in a 96 well plate at a concentration of 5×105 cells in 200µl medium (RPMI-
1640) supplemented with 10% FCS. Different concentrations of anti-human TNF-α (0-
0.2μg/ml) and anti-IFN-γ (0-0.26μg/ml) purified polyclonal antibodies (Peprotech, UK) 
were used for cytokine inhibition to determine their effect on proliferation. Prior to 
transfer into the cell cultures, polyclonal antibodies were reconstituted in sterile water to 
a concentration 0.1-1.0mg/ml. On day five, cell cultures were collected, washed and 
surface stained at room temperature with PE-conjugated pentamers and CD8 PerCP 
Cy5.5 as described in sections 2.4 and 2.5. 
2.8 Production and use of differential avidity class I HLA 
tetramers 
Monomers of CMV pp65 NLV epitope specific tetramers with differential avidity were 
synthesized in E-coli, purified and refolded in the presence of ß2m by the Klenerman 
laboratory at Oxford. For tetramerisation, monomers (25µg) were diluted to 0.5µg/µl in 
PBS and kept on ice or at 40C. Using a 1:20 molar ratio of streptavidin: monomer, PE-
conjugated extravidin at a final concentration of 25µg/ml (Sigma) was added 10 times to 
the vial containing monomer with 15 minute intervals between additions. The CD8 null 
tetramer has reduced avidity for peptide bearing targets because of a mutated CD8 
binding domain (Wooldridge et al., 2007) as shown in Figure 2-4. Once prepared, 
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tetramers were stored in the dark at 40C for a maximum of one month. For staining, 1 × 
106 cells were stained by adding 4μg of PE-labeled tetramers (null and normal) for 20 
min at 40C. Cells were washed in PBS  and then surface stained with 10µg/ml of  anti-
CD8 PerCP Cy5.5 for further 20 minutes at 40C. Finally cells were washed in PBS, fixed 
with 100ml of 4% paraformaldehyde in PBS and acquired using FACSCalibur as 
described in section 2.4.  
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Figure 2-4: Schematic representation of HLA class I tetramers with differential avidity 
For simplicity tetramers is drawn as monomers. Unmutated CD8 tetramer does allow CD8 co-receptor 
ligation and thereby both high (light red balls) and low (light green balls) sensitivity cells CD8+ T cells 
can interact with pMHC-TCR complex. Because of a mutation in CD8 binding site, null tetramers only 
detect high avidity CD8+ T cells. 
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2.9 Telomere length measurement  
Telomere length of PBMCs in the cohort of CVID patients with and without 
inflammation was measured using flow-fluorescence in situ hybridization (FISH) 
method (Plunkett et al., 2001;van de Berg et al., 2010b). Frozen PBMCs were thawed in 
RPMI-1640 supplemented with 10% FCS (as described in section 2.2.2) and washed in 
phosphate-buffered PBSA (PBS plus bovine serum albumin, BSA, 0.5%) (Lonza, UK). 
Cells were then surface stained with 15µl of CD8-biotin (BD Biosciences) for 15 min at 
RT followed by washing with PBSA for 5 minutes. Surface staining was carried out by 
adding 0.2µg (per 1×106 cells) streptavidin-Cy3 (Cedarlane Laboratories, Burlington, 
Canada) for 15 min at RT before washing cells in PBS (not PBSA) for 5 min at 688g 
(1800rpm). Following cell surface staining, cells were fixed using 2mM BS3 solution 
(BS3, Bis [sulfosuccinimidyl] suberate, is a water-soluble, non-cleavable and membrane 
impermeable crosslinker that crosslinks cell-surface proteins prior to cell lysis and 
immunoprecipitation. As it is unstable, 2mM BS3 solution was prepared immediately 
before use by adding 200µl of PBS into one BS3 ‘no-weigh’ powder aliquot from 40C). 
Cell pellets were resuspended in 100µl of PBS and 100µl BS3 solution then incubated 
for 30 minutes at 40C. The fixation process was followed by quenching the BS3 by 
adding 1ml of 50mM Tris-HCL pH 7.2 in PBS and incubating for 20 min at RT in the 
dark before washing with PBS. For hybridisation, while vortexing, 1ml of hybridisation 
buffer was added to the cell pellet, centrifuged at 778×g for 7 min and cells were 
resuspended in 300ml hybridisation solution (refer to the tables in this section). After 
washing in hybridisation buffer, cells were subjected to telomere-Cy5 (3µl human 
telomere PNA (peptide nucleic acid) probe + 97µl hybridisation solution per tube) and 
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were heated for 10 min at 820C in a water bath, rapidly cooled on ice, and hybridized for 
1 h at room temperature in the dark. Samples were washed twice with 1ml of post-
hybridisation solution (refer to the tables 2.1 and 2.2) for 7 min at 778×g. Following the 
final wash in PBSA (5 minutes at 478×g) cells were analyzed immediately by flow 
cytometry. Two cryopreserved PBMC samples with known telomere fluorescence were 
used as standards to ensure consistency of the results. Results were obtained as median 
fluorescence intensity values. The following tables indicate the reagents used and 
solutions for the telomere length studies. 
Hybridisation Buffer: 
Formamide 7ml 10.5ml 14ml 
Tris. HCL 0.2ml of 1M stock 0.3ml of 1M stock 0.4ml of 1M stock 
BSA 2.5ml of 4% stock 3.75ml of 4% stock 5ml of 4% stock 
NaCl 0.3ml of 5M stock 0.45ml of 5M stock 0.6ml of 5M stock 
Total Volume 10ml 15ml 20ml 
Table 2-2: Hybridisation buffer ingredients. 
 
2g BSA dissolved in 50ml sterile distillated water (SDW) (store at 40C) 
4% BSA:  
29.22g in 100ml SDW (steriled by autoclaving) 
5M NaCl:  
5ml 1M Tris + 10 ml 10x PBS + 85ml SDW 
50mM Tris in PBS: 
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Post – Hybridisation Buffer: 
Formamide 7ml 14ml 28ml 
Tris. HCL 0.1ml of 1M stock 0.2ml of 1M stock 0.4ml of 1M stock 
BSA 0.25ml of 4% stock 0.5ml of 4% stock 1ml of 4% stock 
Tween20 0.1ml of 10% stock 0.2ml of 10% stock 0.4ml of 10% stock 
NaCl 0.3ml of 5M stock 0.6ml of 5M stock 1.2ml of 5M stock 
H2O 2.25ml 4.5ml 9ml 
Total Volume 10ml 20ml 40ml 
Table 2-3: Post-Hybridisation buffer ingredients. 
 
1ml Tween20 in 10ml SDW (stored at 40C) 
10% Tween20:  
2mM BS3 solution was prepared immediately before by reconstituting BS3 powder in 
200µl of PBS and transferring to a tube containing 1550µl of PBS (1750µl total 
volume). This gave enough 2mM solution for 17 samples. BS3 was purchased from 
Pierce (Thermo Fisher Scientific Inc, US). 
2mM BS3 solution: 
2.10 Statistical analysis 
GraphPad Prism was used for plotting graphs and for statistical analysis, Student’s t 
test,2 way ANOVA, and paired t-test were used as appropriate. P-values ≤ 0.05 were 
regarded as significant.  
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Chapter 3 
3 CD8+ T cell responses to HCMV and EBV in 
CVID patients 
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3.1 Introduction 
T cell responses and antibodies comprise a key part in the natural history of the host 
response to self-antigens and various pathogens such as viruses. As a result, both T cells 
and antibodies could potentially be useful as markers of disease for clinical as well as 
diagnostic purposes. Most importantly, of course, they play an essential role in 
protection against a variety of infections. The role of CD8+ T cells, as the second wave 
of the cellular immune counterattack, has been extensively studied in mouse model 
systems (Pantaleo and Harari, 2006). Although the direct role of CD8+ T cells in human 
antiviral immunity is difficult to establish, adoptive transfer of virus-specific CD8+ T 
cells has been shown to be effective against HCMV, EBV, and HIV-1(Walter et al., 
1995;Brodie et al., 1999;Khanna et al., 1999;Yewdell and Hill, 2002). 
Viral antigens are initially presented to CD8+ T cells as peptide-MHC Class I complexes 
on the surface of infected cells, particularly by professional antigen presenting cells 
(pAPC) (Tewalt et al., 2009). CD8+ T cells exert their principal antiviral effects via the 
localized secretion of lytic molecules in close vicinity to the virus-infected APCs. The 
killing process is mediated by releasing perforin and granzymes. In addition, nearly all 
CD8+ T cells secrete IFN-γ and TNF-α, which induce a potent antiviral state in cells 
(Yewdell and Hill, 2002). 
The focus of this chapter is on the CD8+ T cell responses to HCMV and EBV in a 
population of CVID patients. Defective antibody production and therefore failure to 
control microbial infections are the main characteristic features of these patients (Park et 
al., 2008). The inability to produce immunoglobulin against invading pathogens 
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provides an important clinical model for the study of various aspects of the adaptive 
immune response. This study aimed to focus on T cells because of their projected role in 
the control of established chronic viral infections (Ahmed and Gray, 1996;Klenerman 
and Hill, 2005). Because CVID patients are unable to mount a humoral immune 
response, determining whether they have been previously exposed to virus has been 
problematic. The recent development of standardized T cell stimulation assays has 
allowed consistent and reproducible measurement and characterization of antigen-
specific memory T cells in human whole blood, indicative of previous infection (Breinig 
et al., 2006;Pantaleo and Harari, 2006).  
Data available from studies of HCMV and tuberculosis have demonstrated the 
importance of CD8+ and CD4+ T cell responses in the control of these infections and 
verified that quantitative measures of T-cell function (for instance IFN-γ- secretion) are 
clinically applicable and can be an important tool in monitoring of disease activity 
(Fishman and Rubin, 1998;Lalvani et al., 2001;Bunde et al., 2005;Lazarevic et al., 
2005;Pantaleo and Harari, 2006). Much of this work has been made possible by the 
advancement of virus specific tetramer and peptide technology.   
Fluorescence labeled, peptide-MHC multimers (which is usually known in the field of T 
cell immunology as MHC ‘tetramers’ or ‘pentamers’) was first described by Altman et 
al in 1996. Unlike functional assays involving ex vivo re-stimulation, MHC tetramers 
allow direct and specific staining of the T cell without further in vitro manipulation. 
They also allow for simultaneous characterization of multiple functions through co-
staining for various cell surface markers, enabling a broad assessment of the magnitude, 
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phenotype and therefore functional capacity of T-cell effector functions (Perfetto et al., 
2004;Leisner et al., 2008).  
Taken together, the fact that CVID patients have dysfunctional humoral immunity and 
the growing body of evidence supporting the development of T cell phenotyping as a 
marker of disease, characterizing T cells in these patients may provide new insights into 
disease progression and the role of viral infections. This could ultimately lead to 
improved monitoring and patient management (Pantaleo and Harari, 2006).   
Until fairly recently it was not clear how common HCMV infection was in CVID 
patients. However, using HCMV lysate and measuring CD4+ T cell response in CVID 
patients the incidence of HCMV among these population was previously shown to be 
around 60%. Additionally, no significant difference was found when CD4+ T cell 
response against HCMV was compared between CVID patients and healthy controls 
(Raeiszadeh et al., 2006). 
The work discussed in this chapter, aimed to investigate the role of CD8+ T cell 
responses to HCMV and EBV in CVID patients, with the focus on a subset of patients 
who experienced inflammatory diseases compared to non-inflammatory patients. The 
first aim of this chapter was to determine whether these patients mount CD8+ T cell 
responses to HCMV and EBV. If they do, is there any difference between inflammatory 
CVID patients and those without inflammation. The second aim was to check whether 
any elevation in CD8+ T cell responses was a generalized phenomenon to the virus.  
Although a variety of different cytokines can be used to measure the CD8+ T cell 
immune response to viral peptide stimulations, three well studied cytokines; IFN-γ, 
TNF-α, and IL-2, were chosen because measures of T cell function cannot be based the 
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quantification of an individual cytokine. In terms of assessing effector functions, the role 
of IFN-γ and TNF-α in the clearance of various microbial infections and the induction of 
cellular antiviral proteins has been well documented (Bogdan et al., 1990;Liew et al., 
1990). However, to define a relatively good antigen-elicited response against specific 
infections that require T cells for protection, IL-2 was included in the cytokine panel. IL-
2 has little direct effector function, but it is important in promoting the expansion of T 
cells to amplify effector T cell responses (Seder et al., 2008). 
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3.2 Comparison and analysis of antigen-specific pentamer 
populations in HCMV/EBV infected CVID patients and 
healthy controls 
Ex vivo staining using pentamers specific for HCMV and EBV (A2: NLVPMVATV, 
A2: GLCTLVAML, respectively) was used to determine the frequency of HCMV and 
EBV specific CD8+ T cells in CVID and healthy individuals.  
HCMV ppUL83 NLV specific CD8+ T cell frequencies were significantly increased in 
CVID patients compared to healthy age matched controls (Mean ± SD; CVID: 2.6% ± 
0.49%, n = 25; Healthy: 0.6% ± 0.2%, n = 14; P= 0.005). No such difference was 
observed in the frequency of EBV BMLF1 GLC-specific CD8+ T cells between the two 
groups (CVID: mean frequency 0.18% ± 0.04%, n = 25; Healthy: mean frequency 
0.32% ± 0.19%, n = 14; P> 0.05) (Figure 3-1).  
Within the CVID patient group, the frequency of HCMV-specific CD8+ T cells was 
significantly higher than the frequency of EBV-specific cells with an average difference 
of 14.4-fold (HCMV: mean frequency 2.6% ± 0.49%; EBV: mean frequency 0.18% ± 
0.04%;  P< 0.0001). This was much greater than the difference observed between the 
responses to these epitopes in healthy individuals (2.1-fold) (HCMV: mean frequency 
0.66% ± 0.2%; EBV: mean frequency 0.32% ± 0.19%; P> 0.05) (Figure 3-1). 
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Figure 3-1: Mean percentage frequency of antigen-specific CD8+ T cells.  
HCMV-specific CD8+ T cell population was significantly higher in CVID patients compare to healthy 
controls. Bars indicated mean values. Each point represents a single subject. 
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3.3 Cytokine production of HCMV-specific CD8+ T cells in 
CVID patients and healthy controls 
The magnitude of the CD8+ T cell response is a basic characteristic used to describe T 
cell responses. However, measuring a single parameter for the magnitude of the 
response, for example IFN-γ production, does not reflect the full functional potential of 
T cells. Determining which functions to measure is important and can broaden our 
understanding of T cell function (Seder et al., 2008). 
To gain a preliminary insight into the functional capacity of CD8+ T cells, the 
production of IFN-γ, TNF-α, and IL-2 was measured. To determine the frequency of 
cytokine producing CD8+ T cells, PBMCs isolated from the CVID patients and healthy 
controls were stimulated with the A2/NLV peptide (for HCMV). The proportion of 
cytokine producing CD8+ T cells were enumerated by intracellular cytokine staining and 
FACS analysis and background levels of cytokine production measured in unstimulated 
PBMC which were then subtracted from the stimulated cells to yield the final 
frequencies. Figure 3-2 shows an example of representative FCAS plots of CD8+ T cells 
producing cytokines (IFN-γ, TNF-α, and IL-2). CD8+ T cells from CVID patients were 
characterized by a significant increase in the frequency of cells releasing IFN-γ (Mean ± 
SD; CVID: mean frequency 1.6% ± 0.29%, n = 25; healthy: mean frequency 0.49% ± 
0.14%, n = 14; P = 0.0006) and TNF-α  (CVID: mean frequency 0.86% ± 0.13%, n = 
25; healthy: mean frequency 0.26% ± 0.07%, n = 14; P = 0.002) as compared to healthy 
controls (Figure 3-3)  However, IL-2 production by CD8+ T cells showed no significant 
difference between the two groups (CVID: mean frequency 0.24% ± 0.05%, n = 25; 
healthy: mean frequency 0.11% ± 0.03%, n = 14; P> 0.05) (Figure 3-3).  
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Figure 3-2: Representative FACS density plots of cytokines producing CD8+ T cells.  
IFN-γ, TNF-α and IL-2 productions after overnight incubation are shown for unstimulated cells (A) and 
after Ag stimulation (B). 
 
A) B) 
Chapter 3: CD8+ T cell responses to HCMV and EBV [2010] 
110 
 
IFN-γ TNF-α IL-2 IFN-γ TNF-α IL-2
0
2
4
6
CVID Healthy
P= 0.0006
P= 0.002
P> 0.05
F
re
qu
en
cy
 o
f c
yt
ok
in
e 
pr
od
uc
in
g 
C
D
8+
 T
 c
el
ls
 (
%
 o
f 
to
ta
l C
D
8+
)
 
Figure 3-3: Cytokine production of CD8+ T cells in response to HCMV (NLV) peptide.  
In CVID patients, CD8+ T cells produced significantly higher IFN-γ and TNF-α, but not IL-2, compared 
to healthy controls. Bars indicated mean values. Each point represents a single subject. 
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3.4 Cytokine production of EBV-specific CD8+ T cells in CVID 
patients and healthy controls 
To determine whether the data obtained with HCMV CD8+ T cells was unique or 
reflected a more general phenomenon, the response to another herpesvirus, EBV, was 
investigated as an internal control. Although CVID manifests as an antibody deficiency, 
CD20+ EBV-associated lymphoma has been described in the context of CVID (Le et al., 
2003) and patients still have B cells although they are compromised in antibody 
production, so validating the use of this virus as a control.  
Intracellular cytokine staining to enumerate the frequency of CD8+ T cells producing 
IFN-γ, TNF-α, and IL-2 after stimulation with the EBV GLC peptide, showed a marked 
contrast to the results seen with HCMV NLV peptide stimulation. For EBV, no 
significant differences were observed between the frequencies of CD8+ T cells 
producing  any of the three cytokines in CVID patients  and healthy individuals (Mean ± 
SD; CVID; IFN-γ: 0.31% ± 0.08%; TNF-α: 0.29% ± 0.08%; IL-2: 0.18% ± 0.05%) 
(Healthy; IFN-γ: 0.44% ± 0.17%; TNF-α: 0.41% ± 0.1%; IL-2: 0.23% ± 0.06%) (P> 
0.05) (Figure 3-4). In CVID patients, there was significant differences in the percentage 
of cells producing IFN-γ and TNF-α on stimulation with HCMV peptide compared to 
EBV peptide stimulation (IFN-γ: mean frequency 1.6% ± 0.29% vs. 0.31% ± 0.08%; P< 
0.0001) (TNF-α: 0.86% ± 0.13% vs. 0.29% ± 0.08%; P= 0.0007). However, no such 
difference was found in the frequency of IL-2 production in these patients (HCMV: 
0.24% ± 0.05%; EBV: 0.18% ± 0.05%; P> 0.05) (Figure 3-5). 
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Figure 3-4: Cytokine production of CD8+ T cells in response to EBV (GLC) peptide.  
Statistically there was no significant difference between CVID patients and healthy controls. Bars 
indicated mean values. Each point represents a single subject. 
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Figure 3-5: Cytokine production of CD8+ T cells of CVID patients in response to HCMV and EBV viral 
peptides.  
CD8+ T cells produced significantly higher IFN-γ and TNF-α in response to HCMV pp65 derived epitope 
(NLV) compared to corresponding cells specific to EBV (GLC). Bars indicated mean values. Each point 
represents a single subject. 
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3.5 Differences in HCMV CD8+ T cell responses in CVID 
patients with and without inflammation 
As a subset of the CVID patients was suffering from inflammatory lesions in different 
organs, they were subdivided into two groups: patients with (n = 9) and without (n = 16) 
inflammatory disease. Inclusion in the inflammatory disease group was determined by 
the treating clinicians, based on fulfillment of one or more of the following criteria: (i) 
hepatitis without evidence of hepatitis B or hepatitis C virus infection; (ii) 
splenomegaly; (iii) clinical evidence and a biopsy indicative of chronic enteropathy 
involving small and/or large bowel not explained by infection or gluten sensitivity; (iv) 
interstitial lung disease not explained by bacterial infection; (v) granulomatous disease.  
 The data described in 3.2-3.4 were then analyzed in the context of inflammatory 
diseases. CVID patients with inflammatory disease had a significantly higher frequency 
of HCMV NLV-specific CD8+ T cells compared to CVID patients without 
inflammation and healthy controls (Mean ± SD; inflammatory: 4.81% ± 0.77%, n = 9; 
non-inflammatory: 1.44% ± 0.39%, n = 16; P= 0.0002) (4.81% ± 0.77% inflammatory 
vs. 0.66% ± 0.2% healthy, n = 14; P<0.0001) (Figure 3-6; panel A). Furthermore, 
comparison of the frequency of HCMV (NLV)-specific CD8+ T cells between the non-
inflammatory CVID patients and healthy individuals showed no significant difference 
(non-inflammatory patients: 1.44% ± 0.39%, n = 16; Healthy: 0.66% ± 0.2%, n = 14; P> 
0.05) (Figure 3-6; Panel A).  
As shown in figure 3-6 panel B, the frequencies of EBV GLC-specific CD8+ T cells 
were similar in all groups (inflammatory: 0.2% ± 0.07%; non-inflammatory: 0.17% ± 
0.06%; healthy: 0.32% ± 0.1; P> 0.05). 
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 Based on the striking difference observed in the frequency of HCMV NLV-specific 
CD8+ T cells in CVID patients with inflammatory diseases, the inflammatory disease 
profile was then superimposed on the cytokine expression data in 3.3. After NLV 
peptide stimulation, CVID patients with inflammatory disease had significantly higher 
frequencies of IFN-γ and TNF-α producing CD8+ T cells than the non inflammatory 
group and healthy controls (IFN-γ: 3.04% ± 0.4% inflammatory vs. 0.79% ± 0.2% non-
inflammatory and 0.49% ± 0.1% healthy; P< 0.0001) (TNF-α: 1.46% ± 0.17% 
inflammatory vs. 0.52% ± 0.11% non-inflammatory and 0.26% ± 0.07% healthy; P< 
0.0001) (Figures 3-7 and 3-8; panel A). Frequencies of IFN-γ and TNF-α producing 
CD8+ T cells in the CVID patients without inflammatory disease were similar to those 
observed in healthy controls (IFN-γ: 0.79% ± 0.2% non-inflammatory vs. 0.49% ± 
0.14% healthy; TNF-α: 0.52% ± 0.11% non-inflammatory vs. 0.26% ± 0.07% healthy; 
P> 0.05) (Figures 3-7A and 3-8A).  
IL-2 producing CD8+ T cells showed no significant difference between the two groups 
of CVID patients (P> 0.05). Similarly, the difference between non-inflammatory patients 
and healthy controls was not statistically significant (P> 0.05). However, the difference 
in IL-2 production was significantly elevated in inflammatory patients compared to 
healthy controls (P= 0.03) (Figure 3-9A).  
Figures 3-7B, 3-8B, and 3-9B illustrate the frequencies of cytokine - producing CD8+ T 
cells after EBV peptide stimulation in both CVID patients (with and without 
inflammation) and healthy controls. No significant differences were observed in the 
frequencies of IFN-γ (inflammatory: 0.37% ± 0.15%; non-inflammatory: 0.29% ± 
0.09%; healthy: 0.44% ± 0.17%) or TNF-α (inflammatory: 0.32% ± 0.14%; non-
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inflammatory: 0.28% ± 0.09%; healthy: 0.41% ± 0.1%) producing CD8+ T cells 
between any of the patient groups (P> 0.05) (Figures 3-7B and 3-8B, respectively) and 
frequencies of cells producing these cytokines were similar to healthy controls. IL-2 
production also showed no significant difference between the two subgroups of CVID 
patients or the healthy control group (P> 0.05) (Figure 3-9B). 
An obvious concern was that this elevated CD8+ T cell response observed in CVID 
patients with inflammation is specific to HCMV NLV peptide rather than a generalized 
phenomenon of CD8+ T cell response to HCMV. To address this, PBMCs from 6 
inflammatory CVID and 8 non-inflammatory CVID patients were stimulated with a pool 
of peptides encompassing the entire pp65 ORF. Consistent with NLV peptide specific 
CD8+ T cell response, the frequency of both IFN-γ and TNF-α production, but not IL-2, 
was significantly elevated in inflammatory CVID patients compared to non-
inflammatory patients in response to pp65 peptide pool stimulation (IFN-γ: 1.9% ± 0.3% 
inflammatory vs. 0.7% ± 0.1% non-inflammatory, P= 0.005; TNF-α: 1.34% ± 0.3% 
inflammatory vs. 0.6% ± 0.1% non-inflammatory, P= 0.05) (Figure 3-10), that indicates 
this enhanced response was not a feature of NLV peptide stimulation. It was still 
possible that this result was restricted to responses to pp65 peptide stimulation because 
NLV is part of pp65 pool peptide.   
However, stimulation with another peptide pool encompassing the IE-1 ORF, (a non-
structural protein of HCMV), still showed the same pattern indicating the generalized 
elevated CD8+ T cell response against HCMV in CVID patients with inflammation 
(IFN-γ: 2.2% ± 0.3% inflammatory vs. 0.7% ± 0.2% non-inflammatory, P= 0.004; TNF-
α: 1.5% ± 0.4% inflammatory vs. 0.6% ± 0.2% non-inflammatory, P= 0.05) (Figure 3-
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11). Consistent with previous data, the frequency of IL-2 production, no significant 
difference was found between two subsets of patients as shown in Figure 3-12. 
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Figure 3-6: Frequency of CD8+ T cells specific to HCMV (NLV) and EBV (GLC).  
HCMV-specific CD8+ T cell population elevated significantly in inflammatory CVID patients compared 
to non-inflammatory patients as well as healthy controls (A) whereas there was no difference for EBV-
specific CD8+ T cells. Bars indicated mean values. Each point represents a single subject. 
A) 
B) 
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Figure 3-7: Frequency of IFN-γ producing CD8+ T cells in response to HCMV and EBV specific 
peptides.  
In response to NLV peptide, inflammatory CVID patients produced significantly higher IFN-γ compared 
to non-inflammatory patients as well as healthy controls (A). No difference was found between groups in 
response to EBV (B). Bars indicated mean values. Each point represents a single subject. 
B) 
A) 
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Figure 3-8: Frequency of TNF-α producing CD8+ T cells in response to HCMV (NLV) and EBV (GLC) 
peptides.  
In response to NLV peptide, inflammatory CVID patients produced significantly higher TNF-α compared 
to non-inflammatory patients as well as healthy controls (A). No difference was found between groups in 
response to EBV (B). Bars indicated mean values. Each point represents a single subject. 
A) 
B) 
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Figure 3-9: Frequency of IL-2 producing CD8+ T cells in response to HCMV (NLV) and EBV (GLC) 
peptides.  
No significant difference was found between patient groups as well as healthy controls in response to (A) 
NLV or (B) GLC peptides. Bars indicated mean values. Each point represents a single subject. 
A) 
B) 
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Figure 3-10: Frequency of cytokine-producing CD8+ T cells in response to pp65 pool peptide of HCMV. 
 Frequency of (A) IFN-γ and (B) TNF-α producing CD8+ T cells in patients with and without 
inflammation. CVID patients with inflammation produced significantly higher IFN-γ and TNF-
α compared to non-inflammatory patients. Bars indicated mean values. Each point represents a single 
subject. 
A) B) 
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Figure 3-11: Frequency of cytokine-producing CD8+ T cells in response to IE-1 pool peptide of HCMV. 
 Frequency of (A) IFN-γ and (B) TNF-α producing CD8+ T cells in patients with and without 
inflammation. CVID patients with inflammation produced significantly higher IFN-γ and TNF-
α compared to non-inflammatory patients. Bars indicated mean values. Each point represents a single 
subject. 
A) B) 
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Figure 3-12: Frequency of IL-2 producing CD8+ T cells in response to pp65 and IE-1 pool peptides of 
HCMV. 
No significant difference was found between CVID patients with and without inflammation in the 
frequency of IL-2 producing CD8+ T cells in response to (A) pp65 and (B) IE-1 pool peptides. Bars 
indicated mean values. Each point represents a single subject. 
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3.6 Discussion   
In this chapter, a distinct functional immune signature of HCMV NLV-specific CD8+ T 
cells was found in the context of CVID patients with inflammation. HCMV-specific 
CD8+ T cells were highly elevated in CVID patients compared to healthy controls. 
However, when CVID patients were sub-divided according to the presence of 
inflammatory diseases, the elevated HCMV-specific CD8+ T cells predominantly 
segregated with the patients with inflammatory disease whereas the frequency of these 
cells in non-inflammatory CVID patients was comparable to healthy controls. This 
elevation was specific to HCMV because EBV GLC-specific CD8+ T cell frequencies 
were similar in these two groups of patients and healthy controls. 
HCMV-specific CD8+ T cells were found to be functionally competent as measured by 
the pentamer reagent and by secretion of three cytokines after peptide stimulation. 
Interestingly, CD8+ T cells of inflammatory CVID patients were produced significantly 
higher pro-inflammatory cytokines (IFN-γ and TNF-α), but not IL-2, in response to 
HCMV peptide stimulation. This elevation was not seen in either non-inflammatory 
CVID patients or healthy controls. Similarly, no differences were observed in the 
cytokine expression profiles for EBV-specific CD8+ T cells after peptide stimulation 
between CVID patients with and without inflammatory disease or when compared to 
healthy controls.  
HCMV immune responses in CVID patients are aberrant compared to normal 
individuals, but this is not universal and may implicate HCMV as an important 
pathogenic factor. However, these data contrast with what has been shown  in renal 
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transplant recipients where risk of high level HCMV replication and disease after 
transplantation is associated with a HCMV pentamer+ CD8+ T cell population with a 
reduced ability to produce IFN-γ after peptide stimulation (Crough et al., 2007;Mattes 
et al., 2008). 
In elderly persons, a high type 1 cytokine production such as IFN-γ coupled with low 
levels of type 2 cytokine production such as IL-2 can change the cytokine 
microenvironment in lymphatic tissues and trigger ubiquitous inflammatory processes 
(Almanzar et al., 2005). Moreover, it appears pro-inflammatory cytokines play an 
important role in facilitating the functional pathology and disease course of some age-
related disorders such as atherosclerosis (Almanzar et al., 2005). Therefore, it is 
tempting to speculate that in a subset of CVID patients destined to suffer inflammatory 
disease the unknown underlying genetic lesions result in an aberrant HCMV-specific T 
cell phenotype that is much more pro-inflammatory than those normally produced 
leading to either the formation of the inflammation or exacerbation of an existing 
inflammatory condition. Consistent with this observation, recent data suggests a role for 
pro-inflammatory cytokines including IFN-γ and TNF-α in the pathogenesis of 
inflammatory bowel diseases as well as autoimmune arthritis (Neurath and Finotto, 
2006a;Kim and Moudgil, 2008a). Additionally, treatment of CVID patients with the 
anti-TNF antibody Infliximab has been shown to reduce the inflammatory symptoms 
(Chua et al., 2007b).  
Taken together, the work in this chapter suggest that the pronounced response to HCMV 
could be a homeostatic T cell expansion that attempts to compensate for the failure or 
lack of endogenous specific antibodies in these patients. Data from mouse models have 
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shown that in the absence of the T cell subsets (either CD4+ or CD8+), cell loss can be 
compensated by the remaining cellular subset (Freitas and Rocha, 2000). Indeed, mice 
which lack CD4 T cells, and therefore have a marked decrease in helper cell activity for 
antibody response, have been shown to develop normal functional CD8+ T cells with 
cytotoxic activity against viruses (Rahemtulla et al., 1991). 
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Chapter 4 
4 Polyfunctional analysis of antigen-specific CD8+ 
T cell responses in patients with CVID 
Chapter 4: Polyfunctional analysis of antigen-specific CD8+ T cell responses  [2010] 
129 
 
4.1 Introduction 
Antiviral CD8+ T cell responses play a critical role in the control of many viral 
infections. Production of cytokines such as IFN-γ, TNF-α, and IL-2 are important 
markers of anti-viral T cell function. The magnitude of a T-cell response is generally 
represented as the expression of a specific effector function, such as cytokine production 
or the frequency of antigen-specific T cells. Nevertheless, the magnitude of a T-cell 
response as expressed by a single parameter such as IFN-γ production probably 
underestimates the full functional potential of the response. In this regard, multiple 
functions can be expressed in complex combinations that collectively defined as the 
quality of the T-cell response. This can be expressed on an individual T cell basis or for 
a population of antigen-specific T cells (Perfetto et al., 2004;Seder et al., 2008).  
There are several lines of evidence indicating that multi-cytokine producer T cells are 
important in control of viral infections (Bogdan et al., 1990;Lichterfeld et al., 
2004;Nebbia et al., 2008). For example, Betts et al have shown a strong association 
between the maintenance of polyfunctional HIV-specific CD8+ T cells and virus control 
(Betts et al., 2006), indicating that the quality of antigen-specific CD8+ T cells is a 
clinical correlate of protection from disease progression.  
This chapter aimed to evaluate the cytokine co-expression profiles of HCMV and EBV-
specific CD8+ T cells from CVID patients (with and without inflammation) and healthy 
controls for the expression of the three cytokines (IFN-γ, TNF-α, and IL-2) to better 
understand the functional quality of antigen-specific CD8+ T cells in different settings 
particularly in the context of inflammatory disease. For these purpose, lymphocytes were 
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gated based on forward scattering (FSC) and side scattering (SSC), and CD8+ T cells 
were gated and analyzed for expression of IFN-γ, TNF-α, and IL-2 cytokines. Cytokine 
co-expression profiles were then determined using the Boolean gating function of Flow 
Jo software to quantify the magnitude of expression profiles corresponding to the seven 
different subsets consisting of triple producers (TP), double producers (DP), and single 
producers (SP) based on their expression of IFN-γ, TNF-α , and IL-2 (see Chapter 2, 
section 2.3).  
Boolean gating is a flow cytometric data analysis technique and based on this technique 
cells are divided into all possible combinations of the functions. These functions are 
measured via the Boolean operations 'and' and 'not' on analysis gates which is applied to 
those measurements (Seder et al., 2008). 
After subtracting the background values (from unstimulated cells), the proportion of 
each of the seven subsets was expressed as a percentage of total cytokine-positive cells. 
These included: single producer state (only producing one cytokine such as IFN-γ or IL-
2), double producer state (expression of two cytokines), and triple producer state which 
measures expression of three cytokine including IFN-γ, IL-2, and TNF-α leading seven 
functional states or subsets.  
Additionally, in order to get a better reflection of the total functional response for a 
population of cytokine producing cells, all single cytokine expression profiles were also 
analyzed using integrated median fluorescent intensities (iMFI), a metric term 
incorporating both the magnitude and quality of a response that can be derived by 
multiplying the frequency by the MFI (Darrah et al., 2007). Moreover, by assessing all 
combination of three cytokines at the single cell level it should be possible to define the 
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quality of T cell cytokine response. The relative amount of an individual cytokine 
produced per cell can be measured for each functional population using the MFI which 
is related to the quantitative expression of each functional parameter on a per cell basis 
(Precopio et al., 2007).  
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4.2 Frequencies of cytokine positive cells specific for HCMV and 
EBV in CVID patients 
The pie charts in Figure 4-1show that the proportions of CD8+ T cells producing triple, 
double, or single cytokines were different for CVID patients compared to healthy 
individuals. In the healthy group, 65% of CD8+ T cells specific for HCMV produced 
more than one cytokine. Of the total response, 2% consisted of triple producers, 63% of 
double producers, and 35% of single producers. In this healthy group, a similar cytokine 
expression pattern was found for EBV-specific CD8+ T cells (3% TP, 56% DP, and 
41% SP). 
However, the patterns of cytokine expression and the relative proportion of Ag-specific 
CD8+ T cells positive for the three cytokines were different between the inflammatory 
(n = 9) and non-inflammatory CVID patients (n = 16) and with the healthy group (n = 
14). The proportion of HCMV specific CD8+ T cells producing three cytokines in CVID 
patients were in the same range (2% for inflammatory and 4% for non-inflammatory) of 
healthy controls (2%). The proportion of triple cytokine producers in response to EBV 
peptide stimulation was found to be slightly higher in CVID patients with (5%) and 
without inflammation (9%) compared to healthy controls (3%) although these 
differences did not reach statistical significance (P> 0.05). In CVID patients the 
proportion of CD8+ T cells producing three cytokines in response to EBV was slightly 
higher compared to those detected after HCMV peptide stimulation, but again this did 
not reach statistical significance (P> 0.05). 
Of the total CD8+ T cell response specific to HCMV, the proportion of double cytokine 
producers decreased in CVID patients with and without inflammation compared to 
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healthy group (DP: 63% healthy vs. 48% non-inflammatory vs. 34% inflammatory). 
Interestingly, when the proportion of single cytokine producers in response to HCMV 
was compared between different clinical settings, the CD8+ T cells producing only one 
cytokine constituted a large proportion of the specific response in inflammatory CVID 
patients (64%) compared to non-inflammatory CVID patients (48%) and the healthy 
group (35%).  
In the context of EBV responses, although the proportion of single cytokine producers 
was higher in CVID patients with (55%) and without inflammation (63%) compared to 
the healthy group (41%), the pattern of this individual cytokines was different in CVID 
patients when compared in response to HCMV.  
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Figure 4-1: The quality of CD8+ T cell response specific to HCMV and EBV. 
Pie charts represent the fraction of total responses in each group (Healthy, non-inflammatory, and 
inflammatory CVID patients). The responses comprise of cells expressing all three cytokines (IFN-γ, 
TNF-α, and IL-2), any two cytokines, or any one cytokine. TP: Triple cytokine producer (shown as 
black); DP: Double cytokine producer (shown as green); SP: Single cytokine producer (shown as red). 
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4.3 Cytokine co-expression pattern of CD8+ T cell responses 
specific to HCMV and EBV 
The co-expression of IFN-γ, TNF-α, and IL-2 production by HCMV and EBV specific 
CD8+ T cells was then investigated to produce a polyfunctional CD8+ T cell signature 
in these patients. 
In CVID patients with inflammatory disease, the CD8+ T cell responses to HCMV 
(NLV) peptide stimulation was dominated by IFN-γ producing cells, either as single 
producers (I) or as IFN-γ/TNF-α double producers (IT) as shown in Figure 4-2. These 
two subsets comprise 79.8 percent of the total population of HCMV-specific CD8+ T 
cells. In contrast, the frequency distribution in the non-inflammatory CVID patients was 
essentially the same as that seen after HCMV stimulation in healthy controls.  
In healthy individuals, no significant differences were seen in the distribution of the 
seven subsets after HCMV stimulation compared to EBV stimulation (Figure 4-3). In 
contrast to the HCMV data, the response to the EBV peptide stimulation also showed no 
significant differences between the two CVID patient groups (inflammatory vs. non-
inflammatory) (Figure 4-4). However, when compared to healthy individuals, both 
CVID patient groups showed significantly lower frequencies of IFN-γ single producers 
after EBV peptide stimulation.  All other subsets were similar following stimulation with 
the EBV peptide.  
For a more refined assessment of the differences in cytokine expression an integrated 
median fluorescent intensity (iMFI) analysis was performed which incorporates the 
frequency and MFI providing an estimate of the total amount of cytokine in the system. 
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Figures 4-5 and 4-6 show a worked example of iMFI calculation. Only single cytokine 
producing CD8+ T cell subsets were included for the porpuse of iMFI analysis (Figure 
4-7). The predominance of single-producing IFN-γ HCMV NLV specific CD8+ T cells 
in CVID patients with inflammatory disease was reflected in the iMFI analysis, 
emphasizing the prominence of IFN-γ in this response (Figure 4-7; panel A). 
Interestingly, in the case of EBV the iMFI profile of IFN-γ producing CD8+ T cells was 
much lower than the same responding cells in both non-inflammatory CVID patients and 
healthy controls (Figures 4-7; panel B).  
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Figure 4-2: Cytokine co-expression profile of HCMV (NLV) specific CD8+ T cells.  
The quality of response and cytokine subsets (as a percentage of total cytokine positive CD8+ T cells) in 
inflammatory CVID patients (red; n = 9) compared to non-inflammatory patients (yellow; n = 16) and 
healthy controls (green; n = 14). In response to HCMV (GLC) peptide stimulation, CD8+ T cells of 
inflammatory CVID patients produced significantly higher IFN-γ (as a single producers or co-producer 
with TNF-α) compared to non-inflammatory CVID patients and healthy controls. Data were analyzed 
using 2way ANOVA. Asterisks (***) indicate P< 0.0001. ILT: IFN-γ, TNF-α, and IL-2; IL: IFN-γ and 
IL-2; IT: IFN-γ and TNF-α; I: IFN-γ; LT: IL-2 and TNF-α; L: IL-2; T: TNF-α.  
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Figure 4-3: Cytokine co-expression profile of antigen-specific CD8+ T cells in healthy controls (n = 14).  
The quality of response (as a percentage of total cytokine positive CD8+ T cells) and cytokine subsets of 
CD8+ T cells in response to HCMV (NLV) and EBV (GLC) peptide stimulation. Data were analyzed 
using 2way ANOVA. ILT: IFN-γ, TNF-α, and IL-2; IL: IFN-γ and IL-2; IT: IFN-γ and TNF-α; I: IFN-γ; 
LT: IL-2 and TNF-α; L: IL-2; T: TNF-α.   
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Figure 4-4: Cytokine co-expression profile of EBV-specific CD8+ T cells.  
The quality of response (as a percentage of total cytokine positive CD8+ T cells) and cytokine subsets of 
CD8+ T cells in inflammatory CVID patients (red; n = 9) compared to non-inflammatory patients (yellow; 
n = 16) and healthy controls (green; n = 14). In response to EBV (GLC) peptide stimulation, CD8+ T cells 
of healthy controls produced significantly higher IFN-γ (as a single producers or I subset) compared to 
CVID patients (with and without inflammation). Data were analyzed using 2way ANOVA. Asterisks 
(***) indicate P< 0.0001. ILT: IFN-γ, TNF-α, and IL-2; IL: IFN-γ and IL-2; IT: IFN-γ and TNF-α; I: 
IFN-γ; LT: IL-2 and TNF-α; L: IL-2; T: TNF-α. 
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Figure 4-5: A worked example of integrated median florescent intensities (iMFI), which is the product of 
the frequency of a subset and its MFI.  
Bar charts are showing the total frequency (left panel), MFI (middle panel) and iMFI (rigal panel) of 
single cytokine producing CD8+ T cells, respectively. iMFI values were calculated by multiplying the 
frequency by MFI as shown in tables.     
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Figure 4-6: Representative FACS plots showing an example of the frequency of single cytokine 
producing CD8+ T cell subsets in response to HCMV (NLV) peptide stimulation. 
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Figure 4-7: integrated median florescent intensities (iMFI) of single cytokine expression profile of 
HCMV and EBV-specific CD8+ T cells (A and B panels, respectively). 
The quality of response and single cytokine subsets of CD8+ T cells in CVID patients with inflammation 
(+I; red bars; n = 9) compared to non-inflammatory patients (-I; yellow bars; n = 16) and healthy controls 
(H; green bars; n = 14). In response to HCMV, CD8+ T cells of inflammatory patients produced 
significantly higher IFN-γ (as a single producer) compared to non-inflammatory or healthy controls. Data 
were analyzed using unpaired t test. Asterisks (***) and (*) indicate P< 0.0001 and P< 0.05, respectively. 
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4.4 Level of cytokine production per cell in different CD8+ T cell 
subsets 
The seven functional subsets of CD8+ T cells from CVID patients (with and without 
inflammation) and healthy controls were analyzed to investigate whether the amount of 
cytokine expressed per cell differed after HCMV or EBV stimulation. This was 
determined based on the median fluorescence intensity for each cytokine per subset.  
In most cases, the triple producers expressed higher amounts of cytokine per cell than 
the corresponding double and single producers after stimulation with HCMV (P< 0.05). 
Although no significant differences were seen between double and single producers in 
any of the groups (inflammatory, non-inflammatory or healthy), there was a trend 
toward higher MFIs amongst the double producers (Figure 4-8).  
In contrast to HCMV peptide stimulation, the MFI of IFN-γ production by triple 
cytokine producers of EBV-specific CD8+ T cells found to be much lower in both 
inflammatory CVID patients and healthy individuals compared to non-inflammatory 
CVID patients. In addition, these triple cytokine producers also had a lower MFI for 
IFN-γ production compared to the MFI of the double producers. With this exception, 
MFI patterns after EBV stimulation are similar to those observed after HCMV 
stimulation (Figure 4-9).  
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Figure 4-8: Median fluorescent Intensities (MFI) of HCMV (NLV)-specific CD8+ T cells. 
MFI of HCMV-specific CD8+ T cell triple producers (TP), double producers (DP), and single producers 
(SP) in inflammatory CVID patients (n = 9), non-inflammatory patients (n = 16) and healthy controls (n = 
14). A paired t test was used for comparing cytokine MFI of triple producers and single producers. 
Asterisks (***) and (*) represents P< 0.0001 and P< 0.05, respectively. ILT: IFN-γ, TNF-α, and IL-2; IL: 
IFN-γ and IL-2; IT: IFN-γ and TNF-α; I: IFN-γ; LT: IL-2 and TNF-α; L: IL-2; T: TNF-α. 
Inflammatory CVID patients Non-inflammatory patients Healthy individuals  
M
FI
 o
f I
L-
2 
pr
od
uc
tio
n 
M
FI
 o
f T
N
F-
α
 p
ro
du
ct
io
n 
M
FI
 o
f I
FN
-γ
 p
ro
du
ct
io
n 
Chapter 4: Polyfunctional analysis of antigen-specific CD8+ T cell responses  [2010] 
145 
 
                  
ILT IL IT I
0
100
200
300
400
500
TP DP SP
ILT IL IT I
0
100
200
300
400
500
TP DP SP
ILT IL IT I
0
100
200
300
400
500
TP DP SP
ILT LT IT T
0
10
20
30
40
*
ILT LT IT T
0
10
20
30
40
ILT LT IT T
0
10
20
30
40
**
ILT IL LT L
0
10
20
30
*
ILT IL LT L
0
10
20
30
***
ILT IL LT L
0
10
20
30
***
 
Figure 4-9: Median fluorescent Intensities of EBV (GLC)-specific CD8+ T cells. 
 MFI of EBV-specific CD8+ T cell triple producers (TP), double producers (DP), and single producers 
(SP) in inflammatory CVID patients (n = 9), non-inflammatory patients (n = 16) and healthy controls (n = 
14). A paired t test was used for comparing cytokine MFI of triple producers and single producers. 
Asterisks (***), (**) and (*) represents P< 0.0001, P< 0.001, and P< 0.05, respectively. ILT: IFN-γ, TNF-
α, and IL-2; IL: IFN-γ and IL-2; IT: IFN-γ and TNF-α; I: IFN-γ; LT: IL-2 and TNF-α; L: IL-2; T: TNF-
α. 
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4.5 Discussion  
In Chapter 3, the frequencies of antiviral CD8+ T cells were evaluated by measuring 
IFN-γ, TNF-α, and IL-2 separately. Following stimulation with HCMV antigens (but not 
EBV) a significant elevation of proinflammatory cytokines (IFN-γ and TNF-α) was 
found only in CVID patients with inflammation compared to non-inflammatory patients 
and healthy individuals. However, as both the magnitude and the quality of CD8+ T cell 
are crucial for the control of viral infection, this chapter further evaluated the quality of 
CD8+ T cells specific to HCMV and EBV in CVID patients. For this purpose, the 
cytokine co-expression profiles of antigen-specific CD8+ T cells as well as the 
magnitude of cytokine production per cell were assessed using polyfunctional cytokine 
analysis in CVID patients (with and without inflammation) compared to healthy 
individuals. This was the first study in which the simultaneous analysis of three 
cytokines at the single-cell level for CD8+ T cells specific to HCMV and EBV in CVID 
patients has been performed in the context of inflammatory disease.   
Analysis of data from this chapter showed cytokine co-expression profiles are not only 
diverse in response to different antigens but they are also different in the various settings 
such as inflammatory disease. Interestingly, a distinct functional signature of virus 
specific CD8+ T cells producing single, double or triple cytokines was found in CVID 
patients with inflammation compared to both non-inflammatory and healthy subjects. 
These differences were also observed when the cytokine co-expression profiles were 
analyzed for HCMV-specific CD8+ T cells compared to the same responding cells 
specific to EBV.  
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However, in healthy individuals and non-inflammatory CVID patients, cytokine co-
expression profiles induced by HCMV-specific CD8+ T cells overlapped with EBV-
induced cytokine co-expression profiles. In contrast, the particular cytokine profiles 
observed in response to HCMV peptide stimulation were found to be distinctively 
skewed in inflammatory CVID patients. HCMV-specific CD8+ T cell responses in these 
patients consisted predominantly of IFN-γ producing cells (single producers, ‘I’ subset) 
and IFN-γ- and TNF-α-coproducing cells (‘IT’ subset) (Figure 4-2). This profile was 
different from responding CD8+ T cells responding to EBV where polyfunctional 
analysis showed no differences between the two CVID patient groups. Importantly, 
when iMFI analysis was applied to all single cytokine expression profiling of Ag-
specific CD8+ T cells in both CVID patients (with and without inflammation) and 
healthy controls, the results of iMFI confirmed the patterns observed following data 
analysis measuring the magnitude by frequency.  
Although the majority of cytokine-positive CD8+ T cells in CVID patients were single 
and double cytokine producers, triple-cytokine producers (IFN-γ, TNF-α, and IL-2) 
expressed more cytokine per cell than single producers of the same cytokine. It appears 
that the quality of T cells specific for persistent viral infections to be different from non-
persistent viral infections. To support this, although analyzing antigen-specific CD4+ T 
cells, it has been shown that higher proportion of the total cytokine response to vaccinia 
and flu viruses (representing non-persistent viruses) consisted of triple cytokine 
producers (IFN-γ, TNF-α, and IL-2) compared to the same responding cells to HCMV 
(Kannanganat et al., 2007).  
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It is not yet clear what contributes to these differences and also why HCMV-specific 
CD8+ T cell responses in inflammatory CVID patients are skewed predominantly 
toward single IFN-γ producing cells and IFN-γ- and TNF-α-coproducing cells. It is 
tempting to speculate that antigen exposure and the distinct interaction of this virus in 
response to the adaptive or innate immune system may play an important role in this 
scenario. It has been shown that antigen exposure can influence the cytotoxic-granule 
profiles as well as cytotoxic activity of CD8+ T cells (Harari et al., 2009). Moreover, a 
rapid elimination of intracellular parasites (such as Lieshmania major) was shown to be 
mediated by TNF-α in the presence of IFN-γ which was highly significant compared to 
IFN-γ alone, indicating the crucial role of IFN-γ in TNF-α-mediated killing of 
Lieshmania major parasites (Bogdan et al., 1990). In addition, in response to HIV-1 
peptide stimulation a strong cytotoxic activity has been found by HIV-1 specific CD8+ T 
cells producing both IFN-γ and TNF-α (Lichterfeld et al., 2004). 
Collectively, and consistent with the results in Chapter 3, data from this Chapter suggest 
a distinctive functional signature of HCMV-specific CD8+ T cells in inflammatory 
CVID patients. Although T cell responses to viral antigens or immunizations are broad 
and complex, the results presented in this chapter indicate that a single response by 
looking at individual cytokines is probably inadequate to fully characterize the CD8+ T 
cell immune responses; Therefore, optimal measurements of functional competence of 
immune responses to pathogens require the coordinated measurement of more multiple 
cytokines (De Rosa et al., 2004). 
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5.1 Introduction 
Results from Chapters 3 and 4 showed a clear functional immune signature of HCMV-
specific CD8+ T cells only in CVID patients with inflammatory disease but not in non-
inflammatory patients or healthy controls. The aim of the work discribed in this chapter 
was to perform a phenotypic analysis of HCMV and EBV-specific CD8+ T cells and 
pentamer stained T cells in CVID patients (with and without inflammation) and healthy 
individuals with regard to markers of maturation, cytotoxicity, and T cell exhaustion. 
Monitoring fluctuations in T cell responses over time together with quantitative 
measurement of phenotypic markers (serving as surrogate markers of virus replication) 
can produce a reliable method to measure aspects of the clinical cause of virus-
associated diseases (Pantaleo and Harari, 2006). Over the last two decades, a large 
number of phenotypic markers have been described to both define different populations 
of antigen-specific CD8+ T cells and identify functionally different stages of T cell 
differentiation (Pantaleo and Harari, 2006).  
In this chapter a panel of different cell surface markers (as explained later) were used to 
asses the phenotype of CD8+ T cell responses in CVID patients and healthy controls 
using ex vivo staining as described in Chapter 2 (section 2.4). The panel of cell surface 
markers used included CD57, granzyme B, PD-1, CD45RO, CD45RA, CD27, and 
CD28.  
1) CD57 
As previously mentioned in chapter 1 (section 1.63.3.2), CD57 can be expressed mainly 
by T cells and CD16+ NK cells. In healthy individuals 5-20% of CD8+ T cells express 
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CD57 (Morley et al., 1995). Although CD57 has been extensively studied in different 
contexts, its exact function on an immune cell is unknown (Wood et al., 2009). Initially, 
an increase in CD8+ T cells expressing CD57 was described in elderly individuals 
(Ligthart et al., 1986;McNerlan et al., 1998). Although expansion is seen with aging, the 
stimulus behind the expansion is unclear. It is possible that viral or tumor antigens are 
responsible for this expansion. It is well acknowledged that chronic viral infections and 
persistent antigen stimulation can lead to expansion of CD8+ lymphocytes. Both, 
HCMV and human immunodeficiency virus (HIV) infections have been shown to be 
associated with expansions of the CD8+CD57+ lymphocyte subset (Wang et al., 
1993;Rossi et al., 2007;Wood et al., 2009).  
However, clonal expansion of CD57 expressing lymphocytes can also occur in some 
rheumatologic or autoimmune conditions such as rheumatoid arthritis (Wang et al., 
1993). Moreover, clonal expansion of CD8+CD57+ lymphocytes has been reported in 
HCMV positive transplant recipients such as renal transplant patients, cardiac transplant 
patients, and bone marrow transplant recipients (BMT) (Sabnani et al., 2006;Wood et 
al., 2009).  
2) Granzyme B 
Granzyme B is a 32 kDa serine protease, which has been shown to induce rapid cell 
death of a virus infected target cell through the cleavage of downstream substrates as 
well as activating cleavage of caspases (Poe et al., 1991;Sutton et al., 1997;Bird et al., 
1998;Waugh et al., 2000). Following recognition and binding to virus infected or other 
target cells, cytotoxic lymphocytes (or NK cells) release perforin, a Ca2+-dependent 
pore-forming protein which multimerizes in the plasma membrane of the target cells, 
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forming a pore allowing granzyme B access to the cytosol of target cells (Kagi et al., 
1994;Liu et al., 1995;Boivin et al., 2009). Upon target cell recognition and releasing into 
the cytoplasm, granzyme B can target substrates such as autoantigens in the cytosol or in 
the nucleus, inducing apoptosis via several pathways (Boivin et al., 2009). 
The importance of granzyme B in infection, chronic diseases, and cancer has recently 
emerged with the discovery of new immune and non-immune cell sources of the 
protease. During chronic inflammation, the levels of granzyme B have been found to be 
elevated due to infiltrating activated cytotoxic immune cells such as lymphocytes to 
damaged and inflamed areas. An elevation of extracellular concentrations of granzyme 
B has also been shown in bodily fluids (such as synovial fluid and serum) of various 
diseases including Rheumatoid arthritis (Trapani and Sutton, 2003;Goldbach-Mansky et 
al., 2005;Chowdhury and Lieberman, 2008;Boivin et al., 2009;Darrah and Rosen, 2010).  
3) PD-1 
The immunoreceptor, programmed death (PD)-1(also called CD279) is a negative 
regulator of T cell activation.  PD-1 can be expressed by many cells including T cells, B 
cells, NK cells, and myeloid derived cells. The PD-1 receptor, which was originally 
isolated as a transcript up-regulated in apoptotic cells (Ishida et al., 1992), is a 288 
amino acid cell surface monomer. Although it shares structural properties with the 
members of CD28 family, the PD-1 gene is located on a different region of the same 
chromosome (2q37). Two ligands with different expression patterns have been described 
for PD-1, PD-L1 and PD-L2. PD-L1 (also known B7-H1 and CD274) is broadly 
distributed on various cell types such as B cells, DCs, macrophages, mesenchymal stem 
cells as well as a wide variety of nonhematopoietic cell types. PD-L2 (also known B7-
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DC and CD273), by contrast, is limited to professional antigen presenting cells including 
macrophages, DCs, and cultured bone marrow-derived mast cells (Augello et al., 
2005;Okazaki and Honjo, 2006;Keir et al., 2007;Sharpe et al., 2007).    
In general, resting T cells from healthy individuals express barely detectable levels of 
PD-1. However, TCR engagement on these cells induces PD-1 expression via 
transducing an inhibitory signal through recruiting Src homology phosphatase (SHP)-1 
and SHP-2, blocking PI3K activation, and interfering with glucose uptake (Riley and 
June, 2007;Sharpe et al., 2007). In mouse models, it has been shown that the interaction 
of PD-1 and its ligands contributes directly to T cell dysfunction and lack of viral control 
in established chronic infection. For example, during the first week of infection with 
lymphocytic choriomeningitis virus (LCMV), the level of PD-1 expression on virus-
specific CD8+ T cells increases, consistent with the upregulation of PD-1 on activated T 
cells. In the case of clearance of infection, functional memory T cells are generated 
following the rapid reduction of PD-1 expression. In contrast, PD-1 expression in 
infection with the LCMV clone 13 strain (that causes chronic infection) remains high 
and T cell function decreases (Barber et al., 2006;Sharpe et al., 2007). Applying these 
observations to humans, PD-1 expression has been shown to be elevated on HIV-
specific T cells (Trautmann et al., 2006), T cells specific to hepatitis B virus (HBV) 
(Boettler et al., 2006) and hepatitis C virus (HCV) (Urbani et al., 2006). Indeed, in the 
case of viremic HIV patients, not only was PD-1 expression found to be higher on CD8+ 
T cells specific to HIV, but also its expression on T cells correlated with viral load. It 
seems that high PD-1 expression is not a general phenomenon as T cells specific for 
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non-persisting viruses such as influenza or vaccinia express very low levels of PD-1 
(Sharpe et al., 2007). 
However, it is possible that similar regulatory mechanisms may also apply for other 
persistent viral infections in humans (Klenerman and Hill, 2005;Sester et al., 2008). 
Investigating the functional exhaustion of CD4+ T cells specific to HCMV, Sester et al 
found a significantly higher proportion of PD-1 expression in HCMV-specific CD4+ T 
cells when they compared viremic renal transplant recipients with nonviremic transplant 
patients, dialysis patients or controls (Sester et al., 2008). Additionally, significantly 
higher PD-1 expression has been found on both total and HCMV specific CD8+ T cells 
in transplant recipients who developed HCMV disease compared to the HCMV positive 
healthy controls (La Rosa et al., 2008). 
4) CD45RO, CD45RA, CD27, and CD28 
To investigate the differentiation state of antigen-specific CD8+ T cells in CVID 
patients with and without inflammation, PBMCs were surface stained for the expression 
of CD45RO, CD45RA, CD27, and CD28. As previously described in Chapter1 (section 
1.6.3.3.2), CD45RA, CD45RO, CCR7, CD27, and CD28 are the most-commonly used 
cell surface markers (among various cell surface markers) for defining the memory stage 
of antigen-specific T cells as differential expression of these molecules allows the 
distinction between different subsets of antigen-experienced T cells (Appay et al., 2008).  
Although antigen specific T cells display some degree of heterogeneity; they exhibit 
distinct profiles based on their viral specificity. For example, during latent infection with 
HCV, HIV, HCMV, or EBV cells are predominantly CCR7+CD27+CD28+, CCR7-
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CD27+CD28-, CCR7-CD27-CD28-, or CCR7-CD27+CD28+, respectively (Appay et 
al., 2002). Nevertheless, it is important to note that many of these observations do not 
hold in a setting of T cell activation or inflammation. Many T cell attributes can change 
rapidly upon activation, such that activated T cells will behave differently from their 
resting state. In the circulating pool, for instance, activated CD8+ T cells can be found 
during the acute response to HCMV, EBV, and HIV with a relatively early memory 
phenotype (i.e., CCR7-CD28+CD27+) that still display high cytolytic potential 
(Gamadia et al., 2003;Appay et al., 2008;Waller et al., 2008). It has been shown that 
persistent infections often cause substantial alterations in the phenotype and 
functionality of memory CD8+ T cells (Wherry et al., 2003a;Klenerman and Hill, 
2005;Harty and Badovinac, 2008). 
As explained above, the importance of these functional markers is well documented 
either in the context of antigen or disease. However, there is limited data available 
regarding these functional markers in the context of CVID patients and antigen-specific 
CD8+ T cells. Although a plethora of T cell abnormalities, including increased 
expression of CD57, CD45RO, HLA-DR and perforin or reduced expression of 
CD45RA, have been previously reported in CVID patients (Wright et al., 1990;Baumert 
et al., 1992;Piqueras et al., 2003;Raeiszadeh et al., 2006;Viallard et al., 2006), none of 
these studies looked at these T cell abnormalities in the context of inflammatory disease 
experienced by a subset of CVID patients.  
To get a more complete picture of the phenotypic characteristic of antigen-specific 
CD8+ T cells of CVID patients with and without inflammation this chapter finally aimed 
to analyze data obtained from functional markers such as PD-1 in the context of the total 
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cell population phenotyping analysis which was performed by staff in the diagnostic 
clinical laboratory. Samples from CVID patients were routinely subjected to extensive 
immunological phenotyping (markers listed in table 5-1) as part of standard clinical 
management.  
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T cell phenotyping panel 
(Frequency) 
B cell phenotyping panel 
(Frequency) 
Immunodeficiency panel 
(Count & Frequency) 
CD3+  
CD3+ CD4+ 
CD3+ CD8+ 
CD4+ CD45RO+ 
CD4+ CD45RO+ CXCR5+ 
CD8+ CD27- CD28- 
CD8+ CD27+ CD28- 
CD4- CD8- 
CD4+ CD45RA+ 
CD4+ CDRA+ CD31+ 
CD127low CD25+ 
CD19+ B cells 
CD27- IgD+ (naïve) 
CD27+ IgD+ (IgM memory) 
CD27+ IgD- (Sw. memory) 
CD21- CD38- 
Transitional B cells 
Plasmablasts 
CD3 count & % 
CD4 count & % 
CD8 count & % 
CD19 count & % 
CD16+ CD56 count & % 
CD4/CD8 ratio 
 
Table 5-1: The panel of markers used for regular immunophenotyping of CVID patients.   
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5.2 Frequency of antigen-specific CD8+ T cells expressing CD57 
in CVID patients 
Total CD8+ T cell populations as well as antigen-specific CD8+ T cells expressing 
CD57 were surface stained with pentamers restricted to HCMV and EBV as previously 
described in Chapter 2 (section 2-4). Figure 5-1 illustrates an example of representative 
FACS plots showing the CD57 expression on both total CD8+ T cells and Ag-specific 
CD8+ T cells. 
As shown in Figure 5-2, a significant increase was found in the frequency of CD8+ T 
cells expressing surface marker CD57 in inflammatory CVID patients compared to  non-
inflammatory CVID patients and healthy controls (Mean ± SD; 65.08% ± 3.7% 
inflammatory vs. 40.03% ± 6.01% non-inflammatory; P= 0.007) (65.08% ± 3.7% 
inflammatory vs. 37.37% ± 6.2% healthy; P= 0.003).  
Consistent with CD8+ T cell responses specific to EBV (described in Chapters 3 and 4), 
analyzing the frequency of EBV-specific CD8+ T cells expressing CD57 showed no 
significant difference between inflammatory CVID patients compared to non-
inflammatory patients and healthy controls (28.25% ± 8.1% inflammatory vs. 21.14% ± 
4.7% non-inflammatory; P> 0.05) (28.25% ± 8.1% inflammatory vs. 23.07% ± 5.1% 
healthy; P> 0.05) (Figure 5-3).  
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Figure 5-1: A representative FACS plots of CD57 expressing CD8+ T cells from an inflammatory CVID 
patient. 
CD57 expression was gated on both total CD8+ T cells (gated as quadrant) and NLV-specific CD8+ T 
cells (gated as box). Gates were adjusted according to the appropriate isotype controls. 
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Figure 5-2: Frequency of CD57 expressing HCMV (NLV)-specific CD8+ T cells. 
HCMV-specific CD8+ T cells expressed significantly higher CD57 in inflammatory CVID patients 
compared to non-inflammatory patients as well as healthy individuals. Bars indicated mean values. Each 
point represents a single subject. 
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Figure 5-3: Frequency of CD57 expressing EBV (GLC)-specific CD8+ T cells. 
 No significant difference was found in the frequency of CD57 expression between CVID patients (with 
and without inflammation) and healthy control group. Bars indicated mean values. Each point represents a 
single subject. 
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5.3 Frequency of antigen-specific CD8+ T cells expressing 
granzyme B in CVID patients 
The expression of Granzyme B was examined as a marker of cytotoxicity. Figure 5-4 
shows an example of representative FACS plots of the expression of granzyme B on 
both total- and Ag-specific CD8+ T cells in CVID patients (with and without 
inflammation) and healthy individuals.  
Although there was no significant difference between inflammatory CVID patients and 
non-inflammatory ones, a statistically significant difference was found in the frequency 
of granzyme B expressing CD8+ T cells specific to HCMV in CVID patients (with and 
without inflammation) compared to healthy controls (Mean ± SD: 31.9% ± 4.6% 
inflammatory vs. 13.13% ± 3.1% healthy; P= 0.002) (33.06% ± 4.7% non-inflammatory 
vs.13.13% ± 3.1% healthy; P= 0.002) (Figure 5-5).  
EBV-specific CD8+ T cells in CVID patients with and without inflammation expressed 
nearly same levels of granzyme B (18.2% ± 4.6% inflammatory vs. 15.7% ± 3.7% non-
inflammatory; P> 0.05). Although the frequency of granzyme B expression by EBV-
specific CD8+ T cells were slightly higher in CVID patients compared to healthy 
controls, the difference was not statistically significant (18.2% ± 4.6% inflammatory vs. 
8.4% ± 2.4% healthy; P= 0.05) (15.7% ± 3.7% non-inflammatory vs. 8.4% ± 2.4% 
inflammatory; P> 0.05) (Figure 5-6).  
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Figure 5-4: Representative FACS plots of granzyme B expressing CD8+ T cells from an inflammatory 
CVID patient. 
CD57 expression was gated on both total CD8+ T cells (gated as quadrant) and HCMV (NLV)-specific 
CD8+ T cells (gated as box). Gates were adjusted according to appropriate isotype controls. 
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Figure 5-5: Frequency of granzyme B expressing HCMV (NLV)-specific CD8+ T cells. 
HCMV-specific CD8+ T cells in CVID patients (with and without inflammation) expressed significantly 
higher granzyme B compared to healthy controls. Bars indicated mean values. Each point represents a 
single subject. 
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Figure 5-6: Frequency of granzyme B expressing EBV (GLC)-specific CD8+ T cells. 
EBV-specific CD8+ T cells in CVID patients (with and without inflammation) expressed significantly 
higher granzyme B compared to healthy controls. Bars indicated mean values. Each point represents a 
single subject. 
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5.4 Frequency of PD-1 expression by antigen-specific CD8+ T 
cells in CVID patients 
The analysis of PD-1 in the context of Ag-specific CD8+ T cells has not been carried out 
in CVID patients. Therefore, PD-1 expression was analyzed, on both total CD8+ T cells 
and Ag-specific T cells from CVID patients with and without inflammation and 
compared to healthy HCMV-seropositive individuals. Figure 5-7 shows an example of 
FACS plot analysis of a CVID patient and the gating strategy which was applied to all 
data sets. 
Unlike CD57 and Granzyme B in which expression in inflammatory CVID patients was 
significantly higher than healthy controls, the levels of PD-1 expression in these 
patients, although marginally higher than healthy controls, was generally very low. As 
shown in Figure 5-8, the percentage of PD-1 expressing HCMV-specific CD8+ T cells 
was higher in non-inflammatory patients compared to both inflammatory patients and 
healthy controls. This difference was statistically significant for the comparison with 
healthy controls (Mean ± SD; 34.1% ± 7.4% non-inflammatory vs. 11.1% ± 3.7% 
healthy; P= 0.01) but not for inflammatory patients (34.1% ± 7.4% non-inflammatory 
vs. 19.6% ± 9.5% inflammatory; P> 0.05). Similarly, the MFI of PD-1 expression on 
HCMV-specific CD8+ T cells was higher in non-inflammatory CVID patients; however, 
there was no significant difference between different groups (60.5 units ± 19.6 non-
inflammatory vs. 32.4 units ± 10.03 inflammatory and 32.8 units ± 5.6 healthy) (P> 
0.05) (Figure 5-9). No difference was seen when comparing PD-1 expression on total 
CD8+ T cells.  
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Additionally, the same set of PD-1 analyses was performed on EBV-specific CD8+ T 
cells in the CVID patients as well as healthy individuals (Figures 5-10 and 5-11). No 
significant difference was found in the levels of PD-1 expression on CD8+ T cells 
specific to EBV between non-inflammatory and inflammatory CVID patients. The mean 
percentage of PD-1 expression levels on EBV-specific CD8+ T cells was slightly higher 
in non-inflammatory patients compared to inflammatory patients but not significantly so 
(32.6% ± 5.1% non-inflammatory vs. 22.08% ± 7.2% inflammatory; P> 0.05). 
Nevertheless, these levels were significantly higher compared to healthy subjects (32.6% 
± 5.1% non-inflammatory vs.14.6% ± 5.2% healthy; P= 0.03) (Figure 5-10). In this 
regard, analysis of PD-1 expression based on MFI revealed no significant difference 
between different groups (70.4 units ± 20.7 non-inflammatory vs. 49.7 units ± 24.3 
inflammatory and 49.8 units ± 11.5 healthy) (P> 0.05) (Figure 5-11).     
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Figure 5-7: Representative FACS plots of PD-1 expression on total CD8+ T cells and HCMV-specific 
CD8+ T cells.  
The lower panels (Histogram) show the isotype control (IgG1 κ; dash line) and anti-PD1 FITC antibody 
(blue line). For PD-1 analysis, positive populations were gated on total CD8+ T cells and HCMV-specific 
CD8+ T cells.  
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Figure 5-8: Frequency of PD-1 expressing HCMV (NLV)-specific CD8+ T cells. 
HCMV-specific CD8+ T cells of non-inflammatory CVID patients expressed higher PD1 compared to 
inflammatory patients and healthy controls although this difference was significant for healthy group. Bars 
indicated mean values. Each point represents a single subject. 
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Figure 5-9: Median fluorescent intensity (MFI) of PD-1 expression on HCMV (NLV)-specific CD8+ T 
cells. 
Comparing the MFI of PD1 expression on CD8+ T cells specific to HCMV showed no significant 
difference between any of three groups (non-inflammatory CVID patients, inflammatory patients, and 
healthy controls). The blue dashed line shows the MFI of isotype controls. Each point represents a single 
subject. 
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Figure 5-10: Frequency of PD-1 expressing EBV (GLC)-specific CD8+ T cells. 
EBV-specific CD8+ T cells of non-inflammatory CVID patients expressed higher PD1 compared to 
inflammatory patients and healthy controls although this difference was significant for healthy group. Bars 
indicated mean values. Each point represents a single subject. 
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Figure 5-11: Median fluorescent intensity (MFI) of PD-1 expression on EBV (GLC)-specific CD8+ T 
cells. 
No significant difference was found in the comparisons made for the MFI of PD1 expression on CD8+ T 
cells specific to EBV between any of three groups (non-inflammatory CVID patients, inflammatory 
patients, and healthy controls). The blue dashed line shows the MFI of isotype controls. Each point 
represents a single subject. 
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5.5 Phenotypic characteristics of CD8+ T cells in CVID patients 
CD45RO, CD45RA, CD27, and CD28 can be used to distinguish naïve cells from Ag-
experienced CD8+ T cells. Expression of these markers was analyzed on both total 
CD8+ T cells and Ag-(HCMV and EBV) specific CD8+ T cells of inflammatory CVID 
patients compared to non-inflammatory patients using ex vivo staining. Only samples 
CVID patients with and without inflammation were analysed for the purpose of this part 
of chapter since the phenotypic characterization of HCMV and EBV specific CD8+ T 
cells has already been described for healthy controls in a same range of age (Colonna-
Romano et al., 2007).  
Figure 5-12 illustrates an example of representative FACS plots of CD45RO and 
CD45RA expression on both total CD8 and NLV+ CD8+ T cells from an inflammatory 
CVID patient. As shown in Figure 5-13, the levels of CD45 (RO and RA) expression 
were heterogeneous and no significant difference was found comparing the mean 
percentage frequency of CD45RO expressing total CD8+ cells or NLV-specific CD8+ T 
cells in inflammatory CVID patients compared to non-inflammatory patients (Total 
CD8: 17.2% ± 3.8% inflammatory vs. 7.8% ± 3.1% non-inflammatory; NLV+ CD8+ T 
cells: 12.5% ± 7.7% inflammatory vs.26.8% ± 5.5% non-inflammatory; P> 0.05). CD8+ 
T cells of inflammatory patients possessed significantly higher frequency of CD45RA 
cells compared to non-inflammatory patients (15.8% ± 4.7% inflammatory vs. 4.3% ± 
2.4% non-inflammatory; P= 0.03) although this elevation was not statistically significant 
when the CD45RA expressing CD8+ NLV+ T cells were analyzed (32.5% ± 10.2% 
inflammatory vs.11.7% ± 5.05% non-inflammatory; P> 0.05).  
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Additionally, in order to appropriately define the memory state of Ag-specific CD8+ T 
cells in CVID patients with and without inflammation, samples were also analyzed for 
the surface expression of CD27 and CD28. As an example, a representative FACS plot 
for CD27 and CD28 expression on both total CD8+ cells and NLV+ CD8+ T cells is 
shown in Figure 5-14. With the exception of one individual, CD8+ T cells of CVID 
patients (with and without inflammation) expressed low or negligible levels of CD28 
(Mean ± SD; 5.7% ± 1.8% inflammatory vs. 5.2% ± 2.5% non-inflammatory; P> 0.05). 
However, CD8+ T cells, although heterogeneous, expressed high levels of CD27 and 
this elevation was statistically significant in CVID patients with inflammation compared 
to non-inflammatory patients (23.4% ± 2.3% inflammatory vs. 15.3% ± 1.8% non-
inflammatory; P= 0.01) (Figure 5-15; Panel A). However, this difference was not found 
when CD8+ T cells specific to HCMV (NLV+) were analyzed for CD27 expression 
(43.4% ± 8.3% inflammatory vs. 47.2% ± 6.5% non-inflammatory; P> 0.05). In the 
same cell population, although not significant, CD28 expression was higher in non-
inflammatory patients than other patients with inflammation. Indeed, in latter group, 
NLV+CD8+ T cells were mostly negative for CD28 expression (14.2% ± 5.5% vs. 3.4% 
± 1.7%; P> 0.05) (Figure 5-15; Panel B). 
In order to examine whether the phenotypic patterns of Ag-specific CD8+ T cells in 
CVID patients are influenced by viral infection, HCMV and EBV specific CD8+ T cells 
were further analyzed for the expression of CD45RO, CD45RA, CD27, and CD28. 
Table 5-2 shows the results of this analysis on CD8+ T cells specific to both HCMV and 
EBV. There were no statistically significant differences between HCMV and EBV-
specific CD8+ T cells with regard to any of the measured markers. However, EBV-
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specific CD8+ T cells showed a trend towards higher levels of expressing for both CD27 
and CD28 compared cells specific to HCMV (CD27: 60.05% ± 4.3% EBV vs. 46.4% ± 
5.2% HCMV; P> 0.05) (CD28: 20.01% ± 6.09% EBV vs. 10.4% ± 3.8% HCMV; P> 
0.05). Additionally, HCMV and EBV specific CD8+ T cells were analyzed in the 
context of patients with inflammation and without inflammation and in this regard, none 
of the comparisons between inflammatory and non-inflammatory patients reached 
statistical significance.  
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Figure 5-12: Representative FACS plots of CD45 (RO and RA) expressing CD8+ (NLV+) T cells from 
an inflammatory CVID patient. 
For the expression of CD45 RA and RO, cells were gated on both total CD8+ T cells (Panels A and B) 
and NLV-specific CD8+ T cells (Panels C and D). Gates were adjusted according to the appropriate 
isotype controls. 
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Figure 5-13: Mean percentage of CD8 (A) and NLV- specific CD8+ T cells (B) expressing CD45RO and 
CD45RA in CVID patients with (stars) and without inflammation (open circles).  
Horizontal bars represent the median values. Each point represents a single subject. 
A) 
B) 
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Figure 5-14: Representative FACS plots of CD27 and CD28 expressing CD8+ (NLV+) T cells from an 
inflammatory CVID patient. 
For the expression of CD27 and CD28, cells were gated on both total CD8+ T cells (Panels A and B) and 
NLV-specific CD8+ T cells (Panels C and D). Gates were adjusted according to the appropriate isotype 
controls. 
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Figure 5-15: Mean percentage of total CD8 and NLV-specific CD8+ T cells expressing CD27 and CD28.  
Mean percentage of total CD8 (A) and NLV specific CD8+ T cells (B) expressing CD27 and 28 in CVID 
patients with (stars) and without inflammation (open circles). Horizontal bars represent the mean values. 
Each point represents a single subject. 
A) 
B) 
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Marker Pentamer % Frequency (Mean ± SD) P value 
CD45RO 
HCMV 29.35 ± 4.52 
P> 0.05 
EBV 26.62 ± 3.79 
CD45RA 
HCMV 25.96 ± 4.89 
P> 0.05 
EBV 34.14 ± 8.01 
CD27 
HCMV 46.46 ± 5.26 
P> 0.05 
EBV 60.05 ± 4.30 
CD28 
HCMV 10.48 ± 3.81 
P> 0.05 
EBV 20.01 ± 6.09 
 
Table 5-2: Evaluation of functional phenotypic markers on antigen-specific CD8+ T cells in CVID 
patients.  
The table below shows the mean percentage frequency of each marker (CD45RO, CD45RA, CD27, and 
CD28) on HCMV and EBV-specific CD8+ T cells from CVID patients (with and without inflammation).  
. 
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5.6 T cell phenotyping of CVID patients with and without 
inflammation 
Samples from all patients were routinely subjected to extensive immunological 
phenotyping by staff in the diagnostic immunology laboratory as part of standard 
clinical management. As the data were available, I included them in my analysis. 
For most of the parameters measured, there was no significant difference between the 
inflammatory and non-inflammatory groups; however, as shown in Figure 5-16 the 
overall percentage of CD8+ CD27- CD28- cells was significantly higher in patients with 
inflammatory diseases compared to those without inflammation (P< 0.01).  
Analysis of these total cell population phenotyping data in the context of my own 
functional observations on HCMV-specific responses revealed a statistically significant 
inverse correlation between the proportion of NLV+ CD8+ T cells expressing PD-1 or  
granzyme B and the percentage of CD8+ CD27- CD28- cells (PD-1: r2= 0.83, P< 
0.0001; Granzyme B: r2= 0.36, P= 0.009) (Figure 5-17). No correlation was seen with 
either the EBV-specific cells or between the percentages of CD8+ CD27- CD28- cells 
and the proportion of total CD8+ cells expressing PD-1 or granzyme B. 
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Figure 5-16: Phenotypic analysis of T cell markers in CVID patients with (black bars) and without 
inflammation (white bars). 
Data were analyzed using 2-way ANOVA and significant values are shown with asterisks (** indicates P< 
0.01). 
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Figure 5-17: Reverse correlation between the expression of functional markers (PD-1 and granzyme B) 
on HCMV-specific CD8+ T cells and the proportion of CD8+CD27-CD28- cells of CVID patients with 
(red dots) and without inflammation (black dots).  
Linear regression, r2, and P values were determined in Graphpad Prism.  
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5.7 Discussion  
The aim of this chapter was to further investigate the phenotypic characteristics of 
HCMV and EBV-specific CD8+ T cells in CVID patients with and without 
inflammation. On this basis, CD8 cells were described using a broad panel of surface 
(CD57, PD1, CD45RO, CD45RA, CD27, and CD28) and intracellular (granzyme B) 
markers. This is the first example of the phenotypic signature of virus-specific T cells 
being investigated in inflammatory CVID patients compared to non-inflammatory CVID 
patients.  
CVID patients with inflammatory disease, but not those without inflammatory disease, 
had significantly elevated frequencies of CD57+ HCMV-specific CD8+ T cells (P= 
0.007). In the non-inflammatory group there was a wide range of CD57+ frequencies. In 
contrast to CD57 expression on HCMV-specific CD8+ T cells, the frequency of CD57 
expression on EBV-specific CD8+ T cells in CVID patients (with and without 
inflammation) were comparable with healthy subjects (P> 0.05). 
Although, the exact role of CD57+ cells is not fully understood; it has been shown that 
there is a correlation between HCMV seropositivity and the number of CD8+CD57+ 
cells in transplant patients and healthy elderly subjects, suggesting the involvement of 
persistent viral antigen stimulation behind the expansion of CD8+ CD57+ T cells. For 
example, a dose dependent rise in the number of CD57+ cells has been observed 
following the addition of both IL-2 and HCMV supernatant to allogenic fibroblasts. 
Interestingly, after day 13 this increase in the frequency of CD57+ CD8+ T cells has 
been found only in the presence of HCMV (Rowbottom et al., 2000).  
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Although the molecular mechanisms and signaling pathways of CD57 are not yet fully 
understood, follow up studies will determine whether a high frequency of CD57+ CD8+ 
T cells in patients without inflammatory disease is predictive of developing 
inflammatory disease. Moreover, higher frequencies of CD8+ T cells expressing CD57 
in these patients may have occurred as a direct consequence of repeated episodes of past 
virus replication, resulting perhaps from the lack of specific antibodies. Although 
asymptomatic, this may have led to an expansion of mature antigen-specific populations 
which may be necessary for control of the infection. It may also be possible that in this 
impaired immune setting, the inflammation as a direct or indirect consequence of 
repeated antigen exposure leads to a marked elevation of CD8+ T cells expressing CD57 
in CVID patients with inflammation. 
Analysis of intracellular levels of granzyme B which is an indicator of cytolytic capacity 
of T cells also yielded similar results. A significant elevation was observed in the levels 
of granzyme B on both total CD8+ T cells and HCMV-specific CD8+ T cells of CVID 
patients compared to healthy individuals (P= 0.002). No such difference was found with 
CD8+ T cells specific to EBV (P> 0.05). High level expression of granzyme B is 
indicative of the cytotoxic capacity of CD8+ T cells specific to HCMV in these patients. 
It is yet not clear why HCMV and EBV-specific CD8+ T cell populations followed 
different patterns of CD57 and granzyme B expression. It may reflect the differing 
nature of latency associated with these pathogens or reflect persistent presence of 
HCMV antigen (this will be discussed in Chapter 6).   
Unlike CD57 and Granzyme B in which expression in inflammatory CVID patients was 
significantly higher than non-inflammatory patients as well as healthy controls, the 
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levels of PD-1 expression (on both total CD8+ T cells and Ag-specific CD8+ T cells) in 
these patients although marginally higher than healthy controls, was generally very low.  
This is the first study looking at the PD-1 expression of CD8+ T cells in CVID patients. 
Together, these results indicate that compared to non-inflammatory patients, CD8+ T 
cells in CVID patients with inflammation not only display a distinctive phenotype that is 
characterized by a high frequency of CD57 expression and low levels of PD-1 
expression and this phenotype also was specific to HCMV. It appears that HCMV-
specific CD8+ T cells seen in this particular group of patients are functionally competent 
as they are characterized by high expression of CD57 and low PD-1 expression. In 
addition, as described in Chapter 3, HCMV stimulated CD8+ T cells of this group of 
CVID patients produce high levels of IFN-γ and TNF-α after overnight peptide 
stimulation.  
Both groups of CVID patients had high frequencies of granzyme B-expressing HCMV-
specific CD8+ T cells but expressed very low levels of PD-1. High levels of PD-1 
expression have been associated with poor proliferative capacity of T cells in a number 
of chronic viral infections (Trautmann et al., 2006;Golden-Mason et al., 2007) and  in 
the case of HCMV, high PD-1 expression on CD8+ T cells has been observed in liver 
transplant patients during periods of HCMV replication and disease and also in renal 
transplant patients experiencing high level HCMV replication (Sester et al., 2008;La 
Rosa et al., 2008). So this implys that HCMV CD8+ T cell in inflammatory patients are 
destined to have high proliferative potential.  
The association found between the proportion of NLV+ CD8+ T cells expressing PD-1 
(or granzyme B) and the overall percentage of CD8+ CD27- CD28- cells was 
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interesting. PD-1 is considered as a negative regulator of T cell function, yet, by all 
measures, the HCMV specific response in both subsets of CVID patients is functional. 
The association of this marker with lack of CD27 and CD28 expression is perhaps more 
consistent with direct role in the control of T cell differentiation. 
 The statistically significant elevation in the frequency of CD8+CD27-CD28- cells in the 
inflammatory CVID patients was of interest in the context of a possible role for HCMV 
in the causation or potentiation of the inflammatory disease. This late-differentiated 
effector cell type is typically enriched in HCMV+ individuals (Waller et al., 2008) and is 
a key contributor to the functional deficit associated with immunosenescence (Akbar and 
Vukmanovic-Stejic, 2007), thought to be a consequence of multiple re-exposures to 
antigen via repeated episodes of virus reactivation (Cantisan et al., 2009). 
HCMV infection has been known to increase the magnitude of circulating CD27-CD28- 
T cells and it has been suggested that these cells may play a role in the 
immunosuppression associated with HCMV infection (Tovar-Salazar et al., 2010) or 
might be a reflection of continuous stimulation of HCMV-specific CD8+ T cells over 
long period of times (Sacre et al., 2005). Regarding CVID, it is not yet clear whether this 
HCMV associated phenomenon has any role in attenuating immune response against 
other pathogens such as EBV.      
Various other cell surface markers including CD45RA (and CD45RO), CD27, and 
CD28 were also used to further characterize the heterogeneity and functional signature 
of HCMV and EBV-specific CD8+ T cells in the CVID patients with and without 
inflammation. Phenotypic analysis of T cells in CVID samples showed a marked inter-
individual variability of effector/memory cell population that expressed varying levels of 
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CD45RO, CD45 RA, and CD27. This was seen with both HCMV and EBV specific 
cells in inflammatory as well as non-inflammatory patients. CD28 expression which was 
low (or negative) on both total and Ag-specific CD8+ T cells was the only exception. 
Although based on the combined expression of various effector (or memory) markers 
expressed by CD8+ T cells, anatomical origins, and the state of infection (acute or 
latent), different differentiation models for memory CD8+ T cells have been proposed 
(Appay et al., 2002;van Lier et al., 2003;van Leeuwen et al., 2006), it seems that there is 
considerable inter-individual variability indicating the complexity of direct extrapolation 
of memory state of Ag-specific immune responses. However, low PD-1 expression 
combined with the CD27+CD28- phenotype suggests that HCMV-specific CD8+ T cells 
in CVID patients are not late memory cells and are not in a stunned or memory inflated 
state, rather, they resemble intermediate memory T cells. However, it is worth noting 
that further analysis will be needed to give us a better understanding of the role of these 
specific T cell subsets in these patients. 
Taken together, the data presented in this chapter showed that in CVID patients with 
inflammatory disease CD8+ T cells specific to HCMV (but not EBV) exhibit a distinct 
phenotypic functional signature as determined by high expression of CD57 and 
granzyme B, but low PD-1 expression with no sign of exhaustion. These cells tend to 
consist of an effector-memory phenotype. In line with the distinct cytokine profile of 
HCMV - specific CD8+ T cell responses seen in inflammatory CVID patients (Chapters 
3 and 4) these data support the hypothesis that persistent activation of CD8+ T cells 
caused by reactivation of virus may act as a trigger of the inflammatory process in this 
particular subset of patients.   
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6.1 Introduction 
In the presence of growth factors, T lymphocytes naturally proliferate upon being 
exposed to mitogen or antigens. What is not yet clear is the nature of the factors 
controlling T cell proliferation and whether these can be regulated differentially in T cell 
subsets (Migliaccio et al., 2006). The relative composition and size of the memory 
CD8+ T cell population has been shown to be influenced by various factors including 
the interaction of T cell receptor (TCR) with peptide–MHC complexes (signal 1), co-
stimulatory molecules (signal 2), and inflammatory cytokines (signal 3) (Mescher et al., 
2006a;Wiesel et al., 2009) as shown in Figure 6-1.  
The level of antigen available in vivo seems to be an important element in governing the 
extent of T cell proliferation. For example, by infecting mice with recombinant vaccinia 
strains producing either high or low quantities of an ovalbumin (OVA) epitope, it has 
been shown that the size of the responding CTL population was proportional to epitope 
abundance (Wherry et al., 1999;Kaech et al., 2002c). Moreover, it has been suggested 
that the inflammatory environment associated with infection can contribute to high 
levels of proliferation of Ag-specific CD8+ T cells. In addition to the crucial role of 
proinflammatory cytokines in stimulating antimicrobial defenses, the importance of 
proinflammatory cytokines such as IFN-γ for optimal CD8+ T cell proliferation during 
virus infection has also been studied (Masopust et al., 2004;Whitmire et al., 2005;Haring 
et al., 2006;Jameson and Masopust, 2009). Extensive CD8+ T cell proliferation has been 
observed during viral and intracellular bacterial infections although this response is quite 
heterogeneous depending on different factors such as type of antigen, cytokines and co-
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stimulator molecules (Callan, 1996;Wills et al., 1996;Kaech and Ahmed, 
2001;Migliaccio et al., 2006). Understanding the mechanisms behind this expansion as 
well as its regulation could provide important therapeutic opportunities to enhance or 
abrogate immune responses. 
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Figure 6-1: Schematic representation of signals (black circles) involved in T cell activation. 
Interaction of T-cell receptor with antigen presented in the context of MHC class I is the key stage (also 
termed signal 1) in T cell activation. Co-stimulatory molecules and proinflammatory cytokines form 
signals 2 and 3, respectively.  
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The initial aim of this chapter was to investigate the proliferative capacity of Ag-specific 
CD8+ T cells to ask whether these cells in CVID patients with and without inflammation 
could proliferate following specific peptide stimulation in the absence of cytokines and 
co-stimulators. In a conventional assay using 5 days stimulation of CFSE labeled 
PBMCs with the pp65 peptide pool in the presence of exogenous IL-15, the expansion of 
HCMV specific CD8+ T cells from CVID patients has been demonstrated (Raeiszadeh 
et al, personal communication). In the case of proliferation, the chapter further aimed to 
study expression levels of Ki-67, as a marker of in vivo cycling, and activation marker 
HLA-DR to assess the specificity of proliferation phenomenon.  
Ki-67, a nuclear protein which is widely accepted as an intracellular marker associated 
with cellular proliferation, was first described by Gerdes et al (1991). The name of Ki-67 
is derived from both Kiel (the city of origin) and the number of the original clone in the 
96-well plate (Gerdes et al., 1991;Shedlock et al., 2010). Using immunohistochemistry 
or flow cytometry staining techniques, Ki-67 has been frequently measured as a marker 
of the proliferative capacity and for determining the growth fraction of a given cell 
population (Brown and Gatter, 2002;Shedlock et al., 2010). 
A number of factors such as the level of T cell response, the number of targeted 
epitopes, functionality of the responses, and the longevity of the response have been 
suggested to be important in determining the outcome of disease in viral infections. In 
both murine models and human infections, CD8+ T cells capable of recognizing very 
low amounts of antigen have been shown to be more efficient in keeping viruses in 
check (Alexander-Miller et al., 1996;Almeida et al., 2007;Walker et al., 2010). Recent 
developments in tetramer technology have made it possible to assess the avidity of T cell 
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receptors (TCRs) on a T cell via modifications in the binding interaction of the peptide-
MHC: CD8. This approach, which allow an immediate ex vivo analysis of CD8 binding, 
utilizes T cell binding tetramers where CD8 interaction is abrogated (termed CD8-null 
tetramers) to identifying CD8+ T cells of high avidity (Walker et al., 2010).  
There is no data available regarding functional (HCMV specific-) CD8+ T cell avidity in 
CVID patients. Therefore, this chapter aimed to study the binding avidity of CD8+ T 
cells in a subset of CVID patients with and without inflammation. Additionally, this 
chapter further aimed to investigate the association between activated cycling HCMV-
specific CD8+ T cells and inflammatory CVID by measuring the expression of CD73 
(an ecto-5-nucleotidase which is known to have anti-inflammatory function) on both 
total CD8+ and HCMV-specific CD8+ T cells. CD73 is abundantly expressed on 
endothelial cells and leukocytes. As a component of an ectoenzyme cascade on 
lymphocytes, CD73 converts extracellular nucleoside-5'-monophosphates (AMP and 
IMP) into nucleosides such as adenosine and inosine. By acting on G protein-coupled 
receptors, adenosine can induce anti-inflammatory cellular responses (Zimmermann, 
1992;Niemela et al., 2004;Grunewald and Ridley, 2010). It has been suggested that 
adenosine not only has anti-inflammatory properties in many physiological and 
pathological events (Cronstein, 1994;Ohta and Sitkovsky, 2001;McPherson et al., 
2001;Grunewald and Ridley, 2010) but also acts, through adenosine receptors on T cells, 
to stimulate the production of T-regulatory cells and mediate immune suppression 
(Kobie et al., 2006;Deaglio et al., 2007). An ischematic representation of CD73 
expression and its anti-inflammatory activities is illustrated in Figure 6-2.   
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Figure 6-2: Schematic representation of CD73 expression and its anti-inflammatory potential. 
CD73 is a 70-kDa cell surface enzyme expressed on many cell types including subsets of lymphocytes, 
endothelial cells and epithelial cells. During inflammation and the initiation of primary immune responses, 
ATP is released from damaged target cells into the extracellular environment and is converted to AMP by 
CD39. This AMP is converted to extracellular adenosine by the catalytic action of CD73. Why adenosine 
is important? Extracellular adenosine has potent immunosuppressive and anti-inflammatory effects, 
mediated through its four G protein-coupled receptors: A1, A2A, A2B, and A3. The image is redrown from 
Nat Rev Immunol; 2005 (5): 760 – 71.  
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The final aim of this chapter was to investigate the telomere length of CD8+ T cells in a 
FACS based Flow Fish as described in Chapter 2 (section 2.9). Telomeres are gene-poor 
regions that are located at the end of chromosomes and contain long repeats of 
TTAGGG sequences protecting chromosomes from inappropriate DNA damage and 
recombination. Telomeres shorten after each cell division because DNA polymerase 
cannot duplicate the 3' end of linear DNA. After a critical length is reached, telomeres 
cannot function properly, and cells will either become senescent or apoptotic (Verdun 
and Karlseder, 2007;van de Berg et al., 2010b). Although large inter-individual 
variations are seen among people of the same age it has been shown that telomere length 
steadily decreases in somatic cells with aging. The exact origins of this variation have 
not been elucidated, but the role of genetic factors, oxidative stress, and chronic 
inflammatory challenges have been implicated (Epel et al., 2004;van de Berg et al., 
2010b). In this context, it has also been shown that short telomere length in leukocytes 
can be a risk factor for age-related diseases such as cardiovascular disease and 
Alzheimer’s disease (Samani et al., 2001;Brouilette et al., 2003;Cawthon et al., 2003). 
Spontaneous hyperactivity of the immune system such as autoantibody production, 
inflammation, and oxidative stress are a characteristic of many autoimmune and 
inflammatory diseases. Although the mechanisms behind these processes are not yet 
fully understood, interestingly, inflammation as well as increased leukocyte renewal 
have been associated with telomere shortening suggesting a link between the telomere 
(or telomerase) system and these diseases (Georgin-Lavialle et al., 2010). Telomere 
length erosion of the circulating T cell pool has also been found to be exacerbated 
following cytomegalovirus infection suggesting that immune response to HCMV can be 
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a major cause in variation of telomere length in healthy subjects (van de Berg et al., 
2010b). 
Overally, this chapter aimed to assess the functional aspects of CD8+ T cells, with 
respect to proliferative capacity following single virus-specific peptide stimulation, CD8 
binding avidity and anti-inflammatory potential of CD8+ T cells in CVID patients (with 
and without inflammation). 
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6.2 Ex vivo Proliferative potential of CD8+ T cells in CVID 
patients 
PBMCs from a subset of samples from CVID patients (with and without inflammation; n 
= 6 and n = 8, respectively), and healthy individuals (n = 4) were CFSE labeled before 
being stimulated with PHA (positive control), HCMV A*0201 restricted NLV peptide, a 
HCMV pp65 peptide pool, and EBV A*0201 restricted GLC peptide in the absence of 
any exogenous cytokines or co-stimulators. To determine background levels of 
proliferation, cells were CFSE stained and incubated without stimulation. After 5 days, 
cells were examined by FACS for a decrease in CFSE fluorescence indicating 
proliferation.  
No expansion was observed in PBMC from non-inflammatory patients or healthy 
controls (Figure 6-3A). Interestingly, CD8+ T cell proliferation was found in all six 
PBMCs from inflammatory CVID patients following HCMV peptide stimulation but not 
following stimulation with the EBV GLC peptide (Figure 6-3B). Figure 6-4 illustrates an 
example of representative FACS plots showing CFSE-labeled cells from a representative 
non-inflammatory CVID patient (A) and an inflammatory CVID patient (B) after 5 days 
stimulation with and without antigens. 
Two inflammatory and two non-inflammatory patients had subsequent samples (2-3 
samples per patient) and these were re-tested over several months to determine whether 
these observations were consistent over time. The proliferation seen not only was 
consistent between inflammatory CVID patients but it also was consistent over time 
(Figure 6-5A). In addition, the frequency of HCMV-specific CD8+ T cells from same 
inflammatory patient was monitored over a long period of time to test whether this 
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heterogeneity seen in proliferation is associated with the levels of CD8+ T cells specific 
to HCMV. As shown in Figure 6-5B (bar chart), the frequency of HCMV-specific CD8+ 
T cells remained relatively stable and consistent over long period of time.  
Moreover, using ModFit software the extent of CD8+ T cell proliferation was equivalent 
to 5 divisions consistent with a doubling time of approximately 24 hours (Figure 6-6). 
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Figure 6-3: The proliferation response of CD8+ T cells to 5 days stimulation (shown as stim) with and 
without specific antigens.  
Bars indicate the proportion of CD8+ T cells that had expanded (judged by low CFSE staining) 5 days 
after stimulation. Each bar on the graphs shows the results from a single patient. Except for PHA 
stimulation, in non-inflammatory CVID patients (n = 8) there was no proliferation of CD8+ T cells in 
response to both HCMV (NLV) and EBV (GLC) peptide stimulation (A). In contrast, all CFSE-labeled 
CD8+ T cells from inflammatory patients (n = 6) proliferated in response to NLV peptide stimulation (B). 
A) 
B) 
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Figure 6-4: Representative FACS scatter plots demonstrating the response of CFSE labelled CD8+ T cells 
to 5 days stimulation with and without specific antigens. 
Gates were set on the live T lymphocyte population and CD8+ T cells. Numbers in the top left quadrant 
indicate the proportion of proliferating cells expressed as the percentage of total CD8+ T cells. Panel A 
illustrates the CFSE labeled T cells of a representative non-inflammatory CVID patient compared to an 
inflammatory CVID patient shown in panel B. 
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Figure 6-5: Proliferation of CD8+ T cells at different time points from an inflammatory CVID patient. 
Proliferation of CFSE labeled CD8+ T cells of inflammatory CVID patient in four different time points 
(A). Gates were set on the live T lymphocyte population and CD8+ T cells. The proliferation was 
consistent although the extent of proliferation was heterogeneous. The frequency of HCMV (NLV)-
specific CD8+ T cells from same inflammatory CVID patient is shown over different time points (B). Red 
bars indicate the frequency of NLV-specific CD8+ T cells related to the indicated FACS plots.   
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Figure 6-6: Generational analysis of proliferation of a representative NLV peptide stimulated 
inflammatory sample. 
A) Using ModFit software the expanded cells were analyzed to assess how many generation they went 
through. B) The same expanded CD8+ T cell population is ploted (as histogram) against control samples: 
unstimulated cells and unlabeled cells which are shown as green and red lines, respectively.  
A) 
B) 
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6.3 Investigation of soluble factors mediating proliferation of 
antigen-specific CD8+ T cells in CVID patients with 
inflammation 
The proliferation described above was only seen in HCMV-specific CD8+ T cells of 
inflammatory CVID patients. This phenomenon presented a potential model system for 
investigating the control of T cell proliferation in these patients. As a first step to assess 
whether soluble factors were involved in the proliferation process two approaches were 
adopted. In the first, PBMCs from inflammatory patients were stimulated with a 
mixture, containing different ratios, of the HCMV and EBV peptides to determine 
whether HCMV proliferating cells produced a soluble factor capable of rendering the 
proliferation of EBV-specific CD8+ T cells. 
The results shown in Figure 6-7A show that when cells were stimulated with mixtures of 
NLV and GLC peptides, the majority of the proliferated cells were NLV specific. Thus, 
GLC specific cells did not proliferate after cognate peptide stimulation even in an 
environment favouring proliferation of NLV specific cells. To address whether these 
expansions were antigen specific in the mixed population stimulated cells, the expanded 
cells were surface stained with class I HLA pentamers for the HCMV and EBV A*0201 
restricted epitopes. The majority (>90%) of the proliferated cells were HCMV specific 
in all cases indicating that the EBV-specific CD8+ T cells did not proliferate even in an 
environment favouring proliferation (Figures 6-7B). Figure 6-8 illustrates representative 
FACS plots demonstrating the response of CFSE labelled CD8+ T cells from 
inflammatory CVID patient in response to mixed peptide stimulation (NLV+GLC).  
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The second approach involved the transfer of supernatants from the proliferating cells of 
inflammatory CVID cultures (n = 4) at 2 days post stimulation into cell cultures taken 
from non inflammatory (n = 1) as well as healthy controls (n = 3). The results indicated 
that supernatant transfer from NLV stimulated PBMCs from inflammatory CVID 
patients enhanced NLV-peptide driven proliferation of HCMV-specific CD8+ T cells of 
both healthy and non-inflammatory patients in a dose dependent fashion (Figure 6-9). 
Although the expansion was not as substantial as that observed in the T cell cultures 
derived from the CVID inflammatory disease patients, it was clearly HCMV specific as 
no expansion was found in EBV (GLC) stimulated CD8+ T cells following supernatant 
transfer (Figure 6-10A). To determine whether these expanded CD8+ T cells were 
HCMV specific, labeled cells were surface stained with NLV class I HLA pentamers 
and anti-CD8 antibodies. More than 80% of expanded CD8 cells were found to be 
HCMV (NLV) specific. Stimulation with a pp65 peptide pool produced similar results to 
those observed with NLV peptide stimulation (Figure 6-10B). 
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Figure 6-7: CD8+ T cell proliferation measured 5 days post-stimulation with HCMV (NLV) and EBV 
(GLC) peptides mixed in the indicated ratios (µg/ml).  
The percentage of total CD8+ T cells assayed 5 days after stimulation that had proliferated is given in 
each case (A). Panel B shows the antigen specificity of expanded CD8+ T cells from the experiment 
shown in panel A. The proportion of expanded CD8+ T cells that stained with the HCMV NLV (black 
bars) or EBV GLC (white bar) pentamers is indicated (B).  
 
 
 
 
 
 
 
 
 
 
A) B) 
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Figure 6-8: Representative FACS scatter plots of CFSE labeled CD8+ T cells in response to mixed 
peptide stimulation. 
The response of CFSE labelled CD8+ T cells from an inflammatory CVID patient to 5 days post-
stimulation with (GLC, NLV/GLC, and NLV) and without antigen (A). Gates were set on the live T 
lymphocyte population and CD8+ T cells. (B) Antigen specificity of expanded CD8+ T cells from the 
experiment shown in panel A. 
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Figure 6-9: Dose-dependent proliferation of NLV-stimulated cells. 
To determine the optimal volume of cell cultured supernatant for supernatant transfer assay, PBMCs from 
an inflammatory CVID patient were labeled with CFSE and cultured in the absence and presence of NLV 
peptide stimulation. On day 2, supernatants were collected, centrifuged, and filtered as explained in 
chapter 2. Two different volumes (50µl and 100µl) of supernatant were transferred to the pre-labeled 
NLV-stimulated PBMCs of a non-inflammatory CVID patient and incubated for 5 days. A dose-dependent 
enhancement was found in the proliferation of NLV-stimulated CD8+ T cells from non-inflammatory 
patient following transfer of increased volume of supernatant. 
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Figure 6-10: Supernatant transfer to illustrate the role of soluble factors in proliferation. 
A) Proliferation of antigen stimulated (GLC, NLV or pp65) CD8+ T cells from non-inflammatory and 
healthy subjects in the presence or absence of supernatant (SNT) from HCMV stimulated inflammatory 
CVID patient cells. B) Representative FACS plots showing specificity of expanded CD8+ T cells. HCMV 
NLV peptide or pp65 peptide pool stimulated PBMCs (from a healthy control subject) were analyzed 5 
days after supernatant transfer. CD8+ T cells were stained with HCMV NLV pentamer. The gated values 
show: proliferated CD8+ T cells (as a % of total CD8+) and % of the proliferated CD8+ T cell population 
defined in that was HCMV NLV pentamer positive. 
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6.4 Use of anti-cytokine antibodies to Block proliferation  
Since the cytokine profile of the stimulated NLV-specific CD8+ T-cells in CVID 
patients with inflammation showed a high frequency of TNF-α and IFN-γ double 
producing cells (see Chapter 3) I reasoned that these cytokines may be important as 
drivers of expansion in the proliferation assays described in previous sections. 
Therefore, the proliferation assay was repeated in the presence of increasing 
concentrations of antibodies against TNF-α (0-02µg/ml) and IFN-γ (0-0.26µg/ml) 
either alone or in combination. Anti-IFN-γ (Figure 6-11) and anti-TNF-α (Figure 6-13) 
inhibited proliferation by 50% and 80% respectively and a combination of the two 
antibodies inhibited proliferation by 85% (Figure 6-15). As shown in Figure 6-12, anti-
IFN-γ antibody reduced both the proportion of expanded NLV specific-CD8+ T cells 
(91.7% to 50.6%) and total expanded cells (3.55% to 0.33%). Similarly, following 
addition of anti-TNF-α antibody the proportion of total expanded cells reduced from 
4.93% to 0.72% with a commensurate reduction of NLV specific-CD8+ T cells from 
77.6% to 22.3% (Figure 6-14).  
Although these results indicated that IFN-γ and TNF-α were both major contributing 
cytokines to the proliferation and it remains possible that other cytokines are involved 
either at the initial stages of proliferation or during the ongoing proliferation stages.   
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Figure 6-11: Dose-dependent reduction of CD8+ T cell proliferation following addition of soluble anti-
IFN-γ.  
The dose-dependent reduction of total expanded CD8+ T cells as well as expanded NLV-specific CD8+ T 
cells (inset) in the absence or presence of different concentrations of anti-IFN-γ (0 - 0.26µg/ml).  
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Figure 6-12: Representative FACS plots of dose-dependent reduction of CD8+ T cell proliferation 
following addition of soluble anti-IFN-γ antibody. 
Dose-dependent reduction of A): expanding CD8+ T cells and B): expanded NLV-specific CD8+ T cells 
in the absence and presence of different concentration of anti- IFN-γ antibody (0 - 0.26µg/ml). 
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Figure 6-13: Dose-dependent reduction of CD8+ T cell proliferation following addition of soluble anti-
TNF-α antibody. 
The dose-dependent reduction of total expanded CD8+ T cells as well as expanded NLV-specific CD8+ T 
cells (inset) in the absence or presence of different concentrations of anti-TNF-α antibody (0 - 0.2µg/ml).  
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Figure 6-14: Representative FACS plots of dose-dependent reduction of CD8+ T cell proliferation 
following addition of soluble anti-TNF-α antibody. 
Dose-dependent reduction of A): expanding CD8+ T cells and B): expanded NLV-specific CD8+ T cells 
in the absence and presence of different concentration of anti-TNF-α antibody (0 - 0.2µg/ml). 
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Figure 6-15: Representative FACS plots of dose-dependent reduction of CD8+ T cell proliferation 
following addition of soluble anti-TNF-α and anti-IFN-γ antibodies (0.05µg/ml and 0.4µg/ml). 
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6.5 Activation profile of HCMV specific CD8+ T cells in CVID 
patients 
Since CD8+ T cells of inflammatory CVID patients were found to proliferate following 
HCMV NLV peptide stimulation but not with EBV stimulation and had a low levels of 
PD-1, the activation status of HCMV specific CD8+ T cells further assessed in CVID 
patients with and without inflammation using Ki-67 and HLA-DR expression. 
As mentioned in previous sections, high proliferative capacity was observed on HCMV-
specific CD8+ T cells of CVID patients with inflammation compared to non-
inflammatory patients (Figures 6-3 and 6-4). Interestingly, consistent with the 
proliferation results, CD8+ T cells of CVID patients with inflammation expressed 
significantly higher levels of Ki-67, when compared to non-inflammatory CVID patients 
and healthy controls (Mean ± SD; 2.4% ± 0.37% inflammatory vs. 0.75% ± 0.15% non-
inflammatory; P= 0.0002) (2.4% ± 0.37% inflammatory vs. 0.32% ± 0.03% healthy; P= 
0.002) (Figure 6-16). This distinction was greatly enhanced when Ki-67 expression in 
HCMV (NLV)-specific CD8+ T cells was analyzed, with cells from inflammatory CVID 
patients expressing significantly higher levels of ki-67 compared to non-inflammatory 
patients and healthy controls (36.8% ± 7.4% inflammatory vs. 1.86% ± 0.7% non-
inflammatory; P< 0.0001) (36.8% ± 7.4% inflammatory vs. 0.68% ± 0.4% healthy; P= 
0.003) (Figures 6-17 and 6-18). 
A similar result was found when the frequency of HLA-DR expression by CD8+ T cells 
was investigated (Mean ± SD; 34.5% ± 8.03% inflammatory vs. 11.3% ± 3.05% non-
inflammatory: P= 0.005; 34.5% ± 8.03% inflammatory vs. 3.8% ± 2.2% healthy: P= 
0.01). Consistent with total CD8+ T cells, HCMV-specific CD8+ T cells from 
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inflammatory CVID patients expressed significantly higher frequencies of HLA-DR 
compared with non-inflammatory patients and healthy controls (61.1% ± 7.03% 
inflammatory vs. 36.4% ± 6.3% non-inflammatory: P= 0.03; 61.1% ± 7.03% 
inflammatory vs. 21.4% ± 3.2% healthy: P= 0.002) (Figures 6-19 and 6-20). 
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Figure 6-16: Frequency of total CD8+ T cells expressing Ki-67. 
CD8+ T cells from inflammatory CVID patients (n = 6) expressed significantly higher levels of Ki-67 
compared to non-inflammatory patients (n = 11) as well as healthy controls (n = 4).  Bars indicated mean 
values. Each point represents a single subject. 
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Figure 6-17: Representative FACS plots showing Ki-67 expression on HCMV (NLV)-specific CD8+ T 
cells. 
HCMV-specific CD8+ T cells expressing Ki-67 is shown for an inflammatory CVID patient (upper 
panels), a non-inflammatory patient (middle panels), and a healthy subject (lower panels). Gates were 
adjusted based on appropriate isotype control.  
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Figure 6-18: Frequency of HCMV (NLV)-specific CD8+ T cells expressing Ki-67. 
HCMV-specific CD8+ T cells from inflammatory CVID patients (n = 5) expressed significantly higher 
levels of ki-67 compared to non-inflammatory patients (n = 10) as well as healthy controls (n = 4).  Bars 
indicated mean values. Each point represents a single subject. 
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Figure 6-19: Frequency of total CD8+ T cells expressing HLA-DR. 
A) CD8+ T cells from inflammatory CVID patients (n = 5) expressed significantly higher levels of HLA-
DR compared to both non-inflammatory patients (n = 10) and healthy controls (n = 4). Bars indicated 
mean values. Each point represents a single subject. Representative FACS plots of HLA-DR expression on 
total CD8+ T cells from CVID patient with inflammation (B). 
Isotype FITC 
C
D
8 
Pe
rC
p 
C
y5
.5
 
HLA-DR FITC 
C
D
8 
Pe
rC
p 
C
y5
.5
 
A) 
B) 
Chapter 6: Proliferative capacity of CD8+ T cells in CVID [2010] 
222 
 
 
Non-inflammatory Inflammatory Healthy
0
20
40
60
80
100
CVID
P= 0.03 P= 0.002
P> 0.05
HL
A-
DR
+ 
ce
lls
 (p
er
ce
nt
 o
f N
LV
+ 
CD
8+
 T
 c
ell
s)
 
 
Figure 6-20: Frequency of HCMV (NLV) - specific CD8+ T cells expressing HLA-DR. 
A) HCMV-specific CD8+ T cells from inflammatory CVID patients (n = 10) expressed significantly 
higher levels of HLA-DR compared to non-inflammatory patients (n = 5) as well as healthy controls (n = 
4). Bars indicated mean values. Each point represents a single subject. Representative FACS plots of 
HLA-DR expression on NLV specific CD8+ T cells from a CVID patient with inflammation (B). 
A) 
B) 
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6.6 Avidity of HCMV specific CD8+ T cells in CVID patients 
The capacity of HCMV (NLV) - specific CD8+ T cells from inflammatory patients to 
undergo autonomous proliferation in response to peptide stimulation may indicate an 
enhanced functional sensitivity (Walker et al., 2010). Therefore, using point-mutated 
soluble tetrameric class I HLA complexes refolded with the pp65 A*0201 epitope, the 
avidity of HCMV-specific CD8+ T cells in a subset of CVID patients with (n = 5) and 
without inflammation (n = 5) was assessed. 
As shown in Figure 6-21, in 4 of 5 inflammatory CVID patients studied, the normal and 
CD8-null HCMV tetramers identified similar numbers of cognate CD8+ T cells, 
indicating that in these patients, CD8+ T cell responses specific to HCMV exhibit a high 
degree of avidity for this peptide antigen. In contrast, in all five noninflammatory CVID 
patients tested there was a dominant population of low avidity CD8+ T cells. The 
frequency of HCMV-specific CD8+ T cells identified by CD8 null tetramers was 
remarkably low when compared with normal tetramers (3.05% vs. 0.8%; 0.58% vs. 
0.3%; 4.82% vs. 0.14%; 1.25% vs. 0.28%; 0.37% vs. 0.081%), indicating the low 
avidity of HCMV-specific CD8 cells in this group of patients (Figure 6-22).  
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Figure 6-21: The avidity binding of HCMV (NLV)-specific CD8+ T cells from inflammatory CVID 
patients (n = 5). 
 A) Bar graphs depicts the frequency of HCMV-specific CD8+ T cells stained with the normal (red bars) 
and null (white bars) class I HLA tetramers. B) A representative FACS plot of tetramer (normal and null) 
staining patterns for an inflammatory CVID patient. 
A) 
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Figure 6-22: The avidity binding of HCMV (NLV)-specific CD8+ T cells from non-inflammatory CVID 
patients (n = 5). 
 A) Bar graphs depicts the frequency of HCMV-specific CD8+ T cells stained with the normal (red bars) 
and null (white bars) class I HLA tetramers. B) A representative FACS plot of tetramer (normal and null) 
staining patterns for a non- inflammatory CVID patient. 
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6.7 Frequency of CD73 expressing CD8+ T cells in CVID 
patients 
The role of CD73 as a potent anti-inflammatory molecule has been described in many 
studies as mentioned in section 6.1. The ex vivo expression of CD73 on both total- and 
HCMV-specific CD8+ T cells in inflammatory (n = 6) and non-inflammatory CVID 
patients (n = 12) was investigated. There was no significant difference in the frequency 
of CD73 expression on total CD8+ T cell population between the two groups of CVID 
patients and healthy controls although the expression level in the inflammatory patients 
was slightly higher (Mean ± SD: 3.8% ± 1.6% non-inflammatory vs. 5.07% ± 1.06% 
inflammatory vs. 6.7% ± 1.18% healthy; P> 0.05) (Figure 6-23). However, when CD73 
expression on CD8+ T cells specific to HCMV was analyzed, a significant difference 
was found between inflammatory CVID patients and non-inflammatory patients. Indeed, 
the frequency of CD73 expressing HCMV-specific CD8+ T cells from inflammatory 
CVID patients was significantly lower compared to non-inflammatory patients and 
healthy controls (1.67% ± 0.8% inflammatory vs. 42.01% ± 8.05% non-inflammatory: 
P= 0.004) (1.67% ± 0.8% inflammatory vs. 19.8% ± 7.9% healthy: P= 0.03) (Figure 6-
24).  
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Figure 6-23: The frequency of CD73 expression on total CD8+ T cells. 
CD73 expressing CD8+ T cells from inflammatory CVID patients (n = 6) compared to non-inflammatory 
patients (n = 11) as well as healthy controls (n = 5). Bars indicated mean values. Each point represents a 
single subject. 
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 Figure 6-24: The frequency of CD73 expression on HCMV (NLV)-specific CD8+ T cells. 
 A) CD73 expression on CD8+ NLV+ T cells in inflammatory CVID patients (n = 6) compared to non-
inflammatory patients (n = 11) and healthy controls (n = 5). Bars indicated mean values. Each point 
represents a single subject. Representative histograms of isotype control antibody (dash line) and anti-
CD73 antibody (bold blue line) binding to NLV+ CD8+ T cells in an inflammatory and a non-
inflammatory CVID patient (B). 
A) 
B) 
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6.8 Measurement of telomere length of CD8+ T cells in CVID 
patients 
It has been shown that the immune response to HCMV can be a major cause in variation 
of telomere length of T cells in healthy subjects (van de Berg et al., 2010b). Because the 
CVID patients with inflammation showed elevated levels of HCMV-specific CD8+ T 
cells producing proinflammatory cytokines, the telomere lengths of CD8+ T cells in this 
group of patients was investigated. 
CD8+ T cells from ten CVID patients with (n = 5) and without inflammation (n = 5) 
were subjected to a FACS based FlowFish assay as described in Chapter 2 (section 2.9). 
Table 6-1 shows telomere length values for CVID patients with and without 
inflammation determined using FlowFish. The table compares these experimental values 
with predicted telomere length values based on previously published values for healthy 
individuals of the same age. Consistent with previous studies (van de Berg et al., 2010b), 
there was an inverse correlation between increase of age and telomere length in the 
CVID patients (r2= 0.85; P= 0.0001) (Figure 6-25). Shorter telomere length values were 
found in CVID patients (with and without inflammation) when compared to the 
predicted telomere length values of healthy subjects at the same age (Table 6-1).  
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Figure 6-25: Correlation of telomere length reduction with age. 
A strong inverse correlation was found between telomere length on CD8+ T cells of ten CVID patients 
(with and without inflammation) and age. Linear regression, r2, and P values were determined in Graphpad 
Prism. 
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Patients No Age 
(years) 
Actual values 
- CVID (bp) 
Predicted values 
- Healthy (bp)* 
Summary 
 
 
Inflammatory  
1 58 4.6 6.5 Shorter 
2 64 4.8 5.9 Shorter 
3 61 4.6 6.2 Shorter 
4 36 11.3 8.5 Longer 
5 61 4.6 6.2 Shorter 
 
 
Non-inflammatory  
6 66 4.3 5.7 Shorter 
7 41 11.4 8.1 Longer 
8 51 6.9 7.1 Shorter 
9 66 3.9 5.7 Shorter 
10 49 11.4 7.3 Longer 
Table 6-1: Summary of actual and predicted telomere length (TRL) on CD8+ T cells. 
 Actual values of TRL were determined in 5 inflammatory CVID patients (1-5) and 5 noninflammatory 
ones (6-10). Predicted TRL values (column labeled with asterisk*) for healthy individuals of the same age 
were extracted based on previously published data (van de Berg et al., 2010b). The summary column 
indicates the telomere length of CVID patients compared to Healthy subjects. 
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6.9 Discussion  
The work presented in this chapter demonstrated for the first time that HCMV-specific 
CD8+ T cells from inflammatory CVID patients show evidence of proliferation in vivo 
and respond rapidly to antigen in vitro. In CVID patients with inflammatory disease, 
HCMV-specific CD8+ T cells proliferative in vitro following stimulation with HCMV 
antigens alone whereas this phenomenon was not observed in non-inflammatory patients 
or in healthy individuals. HCMV-specific CD8+ T cells in inflammatory patients 
showed no evidence of exhaustion, with low levels of PD-1 (as presented in Chapter 5) 
and high TCR avidity. Rather, they showed features consistent with high in vivo 
functionality and proliferative activity. 
T cell exhaustion, especially of high avidity cell populations, has been described in HIV, 
HCV and LCMV infections (Alexander-Miller et al., 1996;Derby et al., 2001;Anderton, 
2001). However, in inflammatory CVID patients the majority of HCMV-specific CD8+ 
T cells were found to be high avidity (Figure 6-21) for cognate antigen as assessed using 
the modified tetramers (Walker et al., 2010) whereas this property was not observed for 
non-inflammatory patients (Figure 6-22) where a substantial proportions of cells were 
CD8 dependent, indicating lower avidity.  
Interestingly, in inflammatory CVID patients, the majority of HCMV-specific CD8+ T 
cells expressed HLA-DR and were able to proliferate and maintain full functionality. To 
investigate this further, Ki-67 expression which is indicative of in vivo proliferation was 
analyzed and its expression was much more frequent in CD8+ T cells from 
inflammatory patients. These suggest that 20-30% of the circulating CD8+ T cells were 
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in cycle, indicating a very high degree of turnover in these particular patients, compared 
to non-inflammatory patients or healthy controls (1-2%). The increased peripheral 
proliferation of T cells may also be indicative of compensatory adaptation for the 
ineffective thymic output in adults. Although I did not evaluate the thymic output in 
these patients, others have shown reduced expression of CD31, a marker of thymic 
output, in a large proportion of CVID patients (Giovannetti et al., 2007). The levels of 
proliferation of EBV (GLC)-specific CD8+ T cells were also low in the CVID patients. 
Consistent with the Ki-67 expression pattern observed in vivo, T cells from 
inflammatory patients showed substantial proliferative capacity in vitro after NLV 
peptide stimulation. Unlike healthy individuals where minimal cell proliferation is seen 
in the absence of exogenous cytokines or co-stimulation, in inflammatory CVID 
patients, a remarkable expansion of CD8+ T cells was found in response to HCMV 
peptide stimulation alone. In this setting, it appears that both the inflammation milieu 
and particular antigen stimulation are important because the proliferation of CD8+ T 
cells only occurred in patients suffering from inflammation. Under these assay 
conditions, addition of exogenous peptide did not lead to the proliferation of HCMV 
specific CD8+ T cells in either healthy donors or CVID patients without inflammatory 
disease. 
 Additionally, CD8+ T cells only proliferated in response to HCMV (NLV/pp65) peptide 
stimulation but not with EBV (GLC) peptide stimulation in parallel experiments, 
indicating the antigen specificity of proliferated CD8+ T cells observed in inflammatory 
CVID patients with the majority of (~90-95%) of T cells being HCMV specific using 
HCMV-specific pentamers. These data confirm the substantial proliferative capacity of 
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the CD8+ T cells in CVID patients and underline the fact that the cellular response is not 
exhausted. Although the mechanism behind the enhanced proliferative capacity in these 
experiments is not clear, it could include differences in avidity, cytokine production 
(which could have an autocrine effect in vitro) and response to endogenous co-
stimulation. 
Since proliferation of HCMV specific CD8+ T cells, but not EBV specific cells, was 
only observed in CVID patients with inflammation, the possibility that soluble factors 
produced either by specific CD8+ T cell subsets or bystander cells such as CD4+ T cells 
and B cells was investigated using two approaches. In the first, combined stimulation 
using different ratios of the HCMV and EBV peptides showed that the majority (> 90%) 
of the proliferating cells were HCMV specific i.e. the EBV-specific CD8+ T cells did 
not proliferate even in an environment of HCMV proliferating cells. Secondly, when 
supernatants from the proliferating cells of inflammatory CVID cultures were 
transferred to cultures of cells from non-inflammatory patients as well as healthy 
controls, HCMV specific cells were driven to proliferate although it was not as 
substantial as that observed in the T cell cultures derived from the CVID inflammatory 
disease patients. This suggests that soluble factors are mediating the proliferation 
enhancement of HCMV-specific CD8+ T cells of both healthy and non-inflammatory 
patients. Interestingly, transfer of supernatants from the proliferating cultures was only 
able to enhance expansion of HCMV-specific CD8+ T cells in non-inflammatory 
patients and healthy controls but had no effect on EBV-specific CD8+ T cells indicating 
that the cytokine receptors available on HCMV-specific CD8+ T cells may be 
particularly geared towards a specific cytokine profile. 
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Since the cytokine profile of the HCMV-specific CD8+ T cells in CVID patients with 
inflammation showed a high frequency of TNF-α and IFN-γ producing cells it seemed 
reasonable to suggest that these cytokines rather than IL-2 may be the primary driver of 
expansion. This hypothesis was tested using anti-TNF-α and IFN-γ antibodies, alone or 
in combination. Adding anti-TNF-α and anti-IFN-γ inhibited proliferation by 80% and 
50% respectively and a combination of the two antibodies inhibited proliferation by 85% 
showing that the major cytokines mediating this expansion were IFN-γ and in particular 
TNF-α. Proinflammatory cytokines have been shown to play an important role not only 
in the control of viral infections (by influencing the antigen level) but also contribute in 
CD8+ T cells priming, resulting in survival, modulation of proliferation, and effector 
function acquisition (Steinman and Hemmi, 2006;Mescher et al., 2006b;Wiesel et al., 
2009).  
As mentioned in section 6-1, in an optimal CD8 stimulation three signals initiate a 
complex course of proliferation; however, it appears in CVID patients with 
inflammation the quality of both the original signal provided by HCMV antigen 
exposure and inflammatory cytokines may have a critical impact on subsequent CD8+ T 
cell proliferation. It is not yet clear whether sequential stimulation or a relatively short 
encounter with virus antigens could launch the CD8+ T cells into successive rounds of 
proliferation. Perhaps the most striking distinctions between the two CVID groups was 
seen when the frequencies of CD8+ T cells expressing the potent anti-inflammatory 
molecule CD73 was measured. Interestingly, when looking at CD73 expressing HCMV-
specific CD8+ T cells, a significant increase was found in the levels of CD73 expression 
in non-inflammatory CVID patients compared to inflammatory patients (Figure 6-24). 
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Since this difference was not observed when comparing total CD8+ T cells expressing 
CD73, it suggests a connection between HCMV infection or HCMV antigen stimulation 
and CD73 expression. Beside anti-inflammatory properties (Ohta and Sitkovsky, 2001) 
and mediating immune suppression (Deaglio et al., 2007), adenosines generated by 
CD73 suppress T cell proliferation (Erdmann et al., 2005). A recent study documented 
joint swelling after Borrelia garinii infection of CD73-/- mice and suggested that low 
levels of adenosine may favour local inflammatory responses and persistent infection 
(Yegutkin et al., 2010). There is very little data on CD73 expression on antigen-specific 
CD8+ T cells in other infections, but intuitively it seems likely that the enzyme is 
downregulated during antigen driven proliferation to allow adequate T cell expansion for 
control of the infection.    
Since telomeric erosion of PBMC has been already shown in several diseases such as 
systemic lupus erythematosus, rheumatoid arthritis, sarcoidosis, and type I diabetes 
(Schonland et al., 2003;Guan et al., 2007;Fyhrquist et al., 2010;Georgin-Lavialle et al., 
2010), in this chapter, telomere length values were also measured on CD8+ T cells taken 
from a subset of CVID patients with and without inflammation. Telomere lengths where 
shown to be shorter in CVID patients compared to age matched controls. Whether this 
telomeric shortening is connected to CVID disease is not clear. It has been suggested 
that accumulative oxidative damage during aging or repeated activation of specific T 
cells could be potentially underlie telomere attrition (von Zglinicki, 2002;Akbar and 
Vukmanovic-Stejic, 2007). However, in addition to aging several other factors including 
inflammation, oxidative stress, and increased leukocyte renewal have been suggested to 
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be main environmental factors associated with accelerated telomere shortening (von 
Zglinicki, 2002;Georgin-Lavialle et al., 2010).  
Taken together, data from this chapter showed: firstly, HCMV (NLV) specific CD8+ T 
cells from inflammatory CVID patients showed evidence of substantial proliferation in 
vivo and respond rapidly to antigen in vitro. Second, in this subset of patients HCMV 
specific CD8+ T cells were characterized by high levels of avidity for cognate antigens 
whereas the equivalent cells from non-inflammatory patients included substantial 
proportions where binding was CD8 dependent, indicating lower avidity. Third, while 
there was no significant difference in CD73 expressing CD8+ T cells in both groups of 
patients, HCMV-specific CD8+ T cells of inflammatory CVID patients expressed 
significantly lower levels of CD73 compared to non-inflammatory patients. Fourth, 
compared to telomere length values available for age matched healthy controls, CVID 
patients generally had a reduced telomere length. Additionally a strong correlation was 
found between telomere length reduction and age. 
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This study, as a PhD project, aimed to investigate various aspects of the functional 
capacity of CD8+ T cells against human cytomegalovirus infection in CVID patients 
with a focus on the subset of patients who experienced inflammatory diseases within a 
variety of organs. The study comprised four experimental chapters based on the 
hypothesis that HCMV is a major factor driving CD8+ T cell expansion and is 
associated with an aberrant HCMV specific CD8+ T cell response in CVID patients with 
inflammation.  
CVID is the most common primary antibody immunodeficiency and is characterized by 
defective antibody production and consequent increased susceptibility to some infections 
(Park et al., 2008). Although monogenic defects have been described in a minority of 
CVID cases (Yong et al., 2008), for the remaining population the etiology is unknown. 
Importantly, a significant proportion of these patients suffer from inflammatory 
complications that are expressed either as organ specific involvement that may lead to 
fibrosis and granuloma formation or, less frequently, as multisystem granulomatous 
disease. The organs most commonly affected are the lung, liver, spleen, skin, and 
gastrointestinal tract. Persistent as yet undefined viral infection(s) has been suggested as 
a potential cause of granulomatous disease in CVID (Chapel and Cunningham-Rundles, 
2009). Historically, CVID patients have not been considered at risk of serious viral 
infections. However, a small number of patients develop persistent entroviral infection 
of the central nervous system with significant morbidity and mortality (Halliday et al., 
2003). In addition, some CVID patients infected with HCV by contaminated 
immunoglobulin batches have an aggressive clinical course of their hepatitis (Yap et al., 
1994).  
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The present PhD project investigated the functional capacity of HCMV-specific CD8+ T 
cells in CVID patients in more detail. There are several important lines of evidence 
supporting the rationale for investigating the role of this virus in these patients: 
1- Although HCMV rarely causes disease in immunocompetent individuals, it exerts its 
full pathogenic potential when the immune system is not functioning properly. The two 
most common settings are in HIV infected individuals and transplant recipients where 
there is a pathogenic and therapeutic immunosuppression, respectively (Emery, 2001). 
By triggring chronic inflammation even subclinical active HCMV infection may have 
critical pathophysiological consequences as shown for cronic allograft injury (Reinke et 
al., 1994).  
 2- The role of HCMV infection in inflammatory diseases and some of the long term 
complications of solid organ transplantation such as atherosclerosis is supported by data 
from epidemiological, interventional and mechanistic studies (Soderberg-Naucler, 
2006). For example, HCMV infection has been shown to differentially modulate the 
levels of matrix metalloproteinases and leukotrienes (Bolovan-Fritts et al., 
2007;Bolovan-Fritts and Spector, 2008). Additionally, HCMV is detected frequently in 
the gut of patients with inflammatory bowel disease and systemic lupus erythematosus 
(Soderberg-Naucler, 2006) as well as in tumors of the colon (Harkins et al., 2002) and 
the virus has been implicated in contributing to the net state of immunosuppression seen 
in cancer patients (Miller, 2009). 
3- The ability to elicit a remarkable antiviral immune response (Sylwester et al., 2005) in 
addition to the great capability of this virus in modulating the immune system 
particularly in immunocompromised settings. 
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Until fairly recently it was not recognised how common HCMV was in CVID patients. 
However, since antibody measurement is uninformative due to underlying B cell 
deficiencies as previously reported, prior exposure to HCMV and EBV in the CVID 
patients can be documented by using CD4+ T cell assays (Raeiszadeh et al., 2006). 
Previous work leading up to this work showed a highly significant association between 
HCMV exposure and inflammatory complications. Thirty one of 43 (72%) HCMV 
exposed CVID patients had one or more features of chronic inflammation as compared 
to 8 of 31 (26%) HCMV naïve patients (Raeiszadeh M, personal communication). 
Although CVID manifests as an antibody deficiency, CD20+ EBV-associated 
lymphoma has been described in the context of CVID (Le et al., 2003) validating the use 
of this virus as a control for my studies of HCMV. Until the work in this thesis, HCMV-
specific CD8+ T cell responses in the context of inflammatory CVID disease had not 
been investigated. Cytotoxic CD8+ T cells are a fundamental component of the immune 
response to viral infections and play an important role in immunosurveillance. 
Therefore, this study first aimed to investigate the functional capasity of CD8+ T cell 
responses specific to HCMV and EBV in CVID patients (with and without inflammatory 
disease) and healthy controls. This functional assessment of antigen-specific T cells was 
mainly performed on the basis of cytokine production (IFN-γ, TNF-α, and IL-2) 
(Chapter 3) and the pattern of cytokines secreted as described in Chapter 4. 
HCMV-specific CD8+ T cell frequencies were significantly elevated in CVID patients 
compared to healthy controls whereas EBV-specific CD8+ T cell frequencies were 
similar in these two groups. However, when the CVID patients were sub-divided 
according to the presence of inflammatory diseases, the elevated HCMV responses 
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predominantly segregated with the patients with inflammatory diseases. These 
elevations were observed for both HCMV pentamer+ CD8+ T cells and for HCMV-
specific CD8+ T cells producing IFN-γ and TNF-α after NLV peptide stimulation but 
were not seen in the subset of CD8+ T cells producing IL-2. Thus, in CVID patients 
with inflammatory disease the IFN-γ and TNF-α producing HCMV-specific CD8+ T 
cell populations are expanded without a commensurate increase in IL-2 producing cells. 
In contrast, no difference was observed in the cytokine expression profiles for EBV-
specific CD8+ T cells after peptide stimulation between CVID patients with or without 
inflammatory disease or when compared to healthy controls. In these analyses, the 
frequencies of HCMV NLV-specific CD8+ T cells measured by the pentamer reagent 
and by intracellular cytokine staining after peptide stimulation (as described in Chapter 
2) were comparable indicating that these T cells are functionally competent at least in 
cytokine production. Although these data describe the response to a single epitope in 
HCMV ppUL83, the same elevation was observed in IFN-γ production from CD8+ T 
cells in CVID patients with inflammatory diseases after stimulation with peptide pools 
for ppUL83 and also for the HCMV major immediate-early antigen suggesting that 
CD8+ T cells targeted against multiple HCMV epitopes have a similar phenotype. 
Recently it has been shown that latent HCMV infection in healthy individuals can 
induce a sustained systemic inflammatory response with a type 1 cytokine signature (van 
de Berg et al., 2010a) which is in agreement of the data presented here where a 
significantly elevated inflammatory response was found in CVID patients with 
inflammation. However, these data contrast with what have been shown in renal 
transplant recipients where risk of high level HCMV replication and disease after 
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transplantation is associated with a HCMV-specific CD8+ T cell population with a 
reduced ability to produce IFN-γ after peptide stimulation (Crough et al., 2007;Mattes 
et al., 2008).  
In addition to analysing typical effector functions such as single cytokine production, 
results can be integrated in polyfunctional analysis and the term "polyfunctional" has 
been used to define T cell immune responses (Pantaleo and Harari, 2006;Seder et al., 
2008;Cellerai et al., 2010). It has been shown in some cases, at least, that cells producing 
two or three cytokines are functionally superior to single cytokine producers 
(Kannanganat et al., 2007). In Chapter 4, the co-expression of IFN-γ, TNF-α and IL-2 by 
HCMV- and EBV-specific CD8+ T cells was investigated in the target populations to 
produce a polyfunctional CD8+ T cell signature associated with these infections in the 
different clinical settings. Within the subset of CVID patients with inflammatory 
disease, the CD8+ T cell response to the HCMV (NLV) peptide showed a remarkable 
focus on IFN-γ producing cells, either as single producers or as IFN-γ / TNF-α double 
producers (notably both subsets also failed to produce significant levels of IL-2), these 
two subsets comprising an avarage 79.8 percent of the total population of HCMV NLV-
specific CD8+ T cells. This distribution was reflected in the iMFI analysis, which 
combines frequency and MFI providing an estimate of the total amount of cytokine in 
the system (Darrah et al., 2007), emphasizing the prominence of IFN-γ in this 
response. In contrast, the frequency distribution in the non-inflammatory patients was 
essentially the same as that seen in healthy controls. Analysis of the response to the EBV 
peptide showed no differences between the two CVID patient groups emphasizing that 
the focus seen in the HCMV-specific response in the CVID patients with inflammatory 
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disease does not reflect a general elevation in IFNγ producing CD8+ T cell populations 
in these patients. In fact, the EBV specific responses in both CVID patient groups 
mirrored those of the healthy controls. Importantly, the polyfunctional signatures 
obtained after HCMV and EBV peptide stimulation in the healthy donors were 
essentially the same. 
HCMV-specific CD8+ T cells in CVID patients with inflammatory disease displayed a 
distinctive intracellular cytokine expression profile (TNF-α high, IFN-γ high, IL-2 low), 
with the majority of cells producing IFN-γ only (47%) or IFN-γ and TNF-α (33%), a 
feature indicating good functional capacity (Casazza et al., 2006;Kannanganat et al., 
2007). These results might indicate active antigen stimulation in CVID patients with 
inflammation. It has already been shown that T cell responses can be influenced 
substantially by the antigen load (Pantaleo and Harari, 2006). Additionally, higher IFN-γ 
production was shown to be directed by recent and stronger in vivo T cell activation 
(Schlingmann et al., 2009). It has been also suggested that IFN-γ and TNF-α play an 
important role in HCMV reactivation (Soderberg-Naucler et al., 1997a). For example, it 
has been shown that TNF-α can stimulate the immediate early enhancer/ promoter of 
HCMV in the tranfected granulocyte/monocyte progenitor-like cell line HL-60 (Prosch 
et al., 1995) and immature monocytic cells (Stein et al., 1993). Thus, the T cell response 
to HCMV in inflammatory CVID patients may paradoxically enhance HCMV 
replication. Such antigen-induced immune activation by triggering proinflammatory 
cytokines as found in inflammatory CVID patients may be of crucial pathophysiological 
importance in these particular patients by contributing to the immunophatogenesis of 
inflammatory injuries.   
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Since the HCMV CD8+ T cells in the CVID patients with inflammatory disease 
expressed pro-inflammatory cytokines after stimulation, this thesis then aimed to further 
define the phenotype of these CD8+ T cells ex vivo (as presented in Chapter 5) and 
identify functional profiles that may correlate with protective CD8+ T cell responses as 
has already been characterized in other settings (Cellerai et al., 2010).  
It has been already shown that during HCMV latency, a pool of highly differentiated 
HCMV-specific CD4+ and CD8+ T cells is maintained after resolution of the primary 
infection and this late-differentiated effector cell type is typically enriched in elderly 
HCMV seropositive individuals and is a key contributor to the functional deficit 
associated with immunosenescence, thought to be a consequence of multiple re-
exposures to antigen via repeated virus reactivations (Appay et al., 2002;Waller et al., 
2008). However, CVID patients with inflammatory disease, but not those without 
inflammatory disease, had significantly elevated frequencies of CD57+ HCMV-specific 
CD8+ T cells. The range of CD57+ frequencies in the latter group encompasses almost 
all the frequency values seen in the CVID with inflammation group. Moreover, CVID 
patients had high frequencies of granzyme B-expressing HCMV-specific CD8+ T cells. 
Follow up studies will be needed to determine whether a high frequency of CD57+ cells 
in patients without inflammatory disease is predictive of development of inflammatory 
disease.  
Studies in healthy HCMV-seropositive individuals have shown that HCMV-specific 
CD8+ T cells express high levels of CD57 (Chong et al., 2008) that are oligoclonally 
derived (Wang et al., 1995) and as effector memory T cells capable of immediate 
functional activity with limited proliferative capacity and shortened telomere length 
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(Appay et al., 2002). However, recently it has been shown in healthy donors that 
CD8+CD57+ T cells are capable of rapid expansion (Chong et al., 2008) and induction 
of IFN-γ and TNF-α synthesis in response to HCMV peptides (Kern et al., 1999), 
thereby challenging the use of CD57 molecule as a marker of terminal differentiation or 
replicative senescence (Petrovas et al., 2009). Studies looking at the differential 
association of CD57 and PD-1, a molecule found in association with “exhausted” 
populations in LCMV and HIV infection (Barber et al., 2006;Day et al., 2006), have 
shown that the majority of CD8+ T cells specific to HIV exhibit a characteristic 
phonotype of PD-1hiCD57hi (Petrovas et al., 2009). High level PD-1 expression has been 
associated with poor proliferative capacity of T-cells in a number of chronic viral 
infections (Trautmann et al., 2006;Golden-Mason et al., 2007) and in the case of 
HCMV, high PD-1 expression on CD8+ T cells has been observed in liver transplant 
patients during periods of HCMV replication and disease and also in renal transplant 
patients experiencing high level HCMV replication (Sester et al., 2008;La Rosa et al., 
2008). 
In CVID patients with inflammatory disease, HCMV-specific CD8+ T cells expressed 
low levels of PD-1 and, indeed, the expression levels or expression frequencies of PD-1 
observed on HCMV or EBV- specific CD8+ T cells were not significantly different 
between any of the groups, with, in general, all CD8+ T cells expressing low levels of 
PD-1. The striking correlation observed between the proportion of NLV pentamer+ cells 
expressing granzyme B, or PD-1, and the overall percentage of CD8+, CD27-, and 
CD28- cells was surprising (refer to the Figure 5-17). PD-1 is considered as a negative 
regulator of T cell function, yet, by all measures, the HCMV specific response in both 
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groups of CVID patients is functional. The inverse association of this marker with lack 
of CD27 and CD28 expression is perhaps more consistent with a direct role in the 
control of T cell differentiation. The statistically significant elevation in frequency of 
CD8+ CD27-, CD28- cells in the inflammatory group was of interest in the context of a 
possible role for HCMV in causation or potentiating of the inflammatory disease. 
Studies have shown that following resolution of HCMV viremia, a certain percentage of 
effector memory CD8+ T cells re-express CD45RA (Waller et al., 2008;Cantisan et al., 
2010), and are therefore named EMRA (Romero et al., 2007). Additionally, it has been 
found that the majority of EMRA CD8+ T cells hardly express CD27 and CD28, and are 
specific to HCMV (Appay et al., 2002;van Lier et al., 2003;Waller et al., 2008). Until 
recently, these cells were considered by some groups as fully differentiated with defect 
in proliferation (Rufer et al., 2003;Cantisan et al., 2010). However, this notion has been 
challenged by other studies where these revertant memory CD8+ T cells were shown to 
proliferate perfectly well in response to HCMV peptide (Wills et al., 2002;van Leeuwen 
et al., 2002;Carrasco et al., 2006;Waller et al., 2008).   
The data presented in Chapters 3-5 defined a distinct polyfunctional phenotype of 
HCMV specific CD8+ T cells that accumulate in CVID with inflammatory disease that 
is characterized by the CD57hi, PD-1lo, granzyme Bhi phenotype able to produce both 
high levels of IFN-γ and IFN-γ +TNF-α after peptide stimulation. Since persistent 
HCMV replication in inflamed tissues could lead to an environment in which HCMV 
specific CD8+ T cells are driven to immune exhaustion, in Chapter 6, the thesis then 
sought to investigate the proliferative capacity of the CD8+ T cells from CVID patients 
with inflammation compared to non-inflammatory patients. T cell exhaustion, especially 
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of high avidity cell populations, has been described in HIV, HCV and LCMV and in 
other settings (Alexander-Miller et al., 1996;Derby et al., 2001;Anderton, 2001). In spite 
of significantly elevated frequency of HCMV pp65-NLV specific CD8+ T cells in 
inflammatory patients, these cells showed no evidence of exhaustion, with low levels of 
PD-1 and high levels of TCR avidity, indicating that these cells are functionally 
competent in this subset of patients. These data are consistent with the data obtained 
from healthy individuals although it has been noted that CD8+ T cells with high avidity 
are more prone to cell death in an environment of excess antigen load (Alexander-Miller 
et al., 1996;Price et al., 2005). Although avidity in healthy individuals may be variable 
(Price et al., 2005) these may suggest that chronic HCMV replication in the CVID 
patients with inflammatory disease is not associated with loss of high avidity 
populations. 
Not only did HCMV-specific CD8+ T cells in inflammatory patients not show any 
evidence of an exhaustion phenotype, rather, they showed features consistent with high 
in vivo functionality and proliferative activity. Indeed, the majority of HCMV specific 
CD8+ T cells also expressed HLA-DR, considered as an activation marker. In addition, 
Ki-67 expression on CD8+ T cells was very high in inflammatory patients compared to 
both non-inflammatory patients and healthy controls. Interestingly, this distinction was 
greatly enhanced when Ki-67 expression in HCMV-specific CD8+ T cells was analyzed, 
with healthy controls and non-inflammatory patients showing less than 2% and 
inflammatory patients around 40% Ki-67 positive implying a high proportion of the 
HCMV T cells were actively cycling. To support this, when PBMC were cultured with 
HCMV peptides in the absence of exogenous cytokines such as IL-15, HCMV-specific 
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CD8+ T cells from CVID patients with inflammation proliferated with a doubling time 
of approximately 1 day whereas cells from the other groups showed no proliferation 
under these conditions. Interestingly, there was no proliferation in response to EBV 
peptides in parallel experiments indicating that this was a HCMV specific effect. 
Additionally, transfer of supernatants from the proliferating cultures enhanced 
proliferation of CD8+ T cells specific to HCMV from non-inflammatory and healthy 
controls but had no effect on EBV specific- CD8+ T cells. This may indicate that the 
cytokine receptors available on HCMV specific CD8+ T cells are particularly geared 
towards a specific cytokine profile or that these cells are intrinsically better able to 
respond to the relevant cytokines such as IFN-γ and TNF-α. The ex vivo proliferation 
required both IFN-γ and TNF-α since adding anti-TNF-α and anti-IFN-γ inhibited 
proliferation to 80% and 50%, respectively. Although these results indicated that IFN-γ 
and TNF-α were both major contributing cytokines to the proliferation it was still 
possible that other cytokines such as IL-15 and IL-2 could be involved. The role of IL-
15 as a growth factor for T cell proliferation has been documented by both in vitro and 
in vivo studies (Li et al., 2001;Judge et al., 2002;Schluns and Lefrancois, 2003).  
Whether IFN-γ and TNF-α induce T cell proliferation in these inflammatory patients by 
causing the release of other cytokines, such as IL-15, that then act directly on T cells is 
not clear. However, it is tempting to speculate that these proinflammatory cytokines, at 
least in part, may stimulate other cell types, either directly or indirectly, to produce 
secondary cytokines that then act directly on T cells. To support this, studies have shown 
that like IFN type I, IFNγ and IL-12 can induce IL-15 production by antigen-presenting 
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cells and that IL-15 causes selective stimulation of purified CD44hi CD8+ T cells in vitro 
(Zhang et al., 1998;Judge et al., 2002). 
 Consistent with this observation, recent data suggests a role for proinflammatory 
cytokines including IFN-γ and TNF-α in the pathogenesis of inflammatory bowel 
diseases as well as autoimmune arthritis (Neurath and Finotto, 2006b;Kim and Moudgil, 
2008b). Additionally, treatment of CVID patients with the anti-TNF antibody Infliximab 
has been shown to reduce the inflammatory symptoms (Chua et al., 2007a). 
Interestingly, a similar effect has been found with the antiviral drug ganciclovir that 
inhibits HCMV replication (Raeiszadeh et al., 2006). Indeed, although preliminary, a 
marked reduction in HCMV (NLV) pentamer+ CD8+ T cell frequencies (4% of CD8+ T 
cells pre-therapy to 0.3% post-therapy) was observed that parallels clinical improvement 
in an inflammatory CVID patient undergoing antiviral therapy (Figure 7-1).  
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Figure 7-1: Frequency of HCMV (NLV)-specific CD8+ T cells in one inflammatory CVID patient before 
and after gancyclovier (GCV) treatment. 
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These data confirm the substantial proliferative capacity of the CD8+ T cells in CVID 
patients and underline the fact that the CD8+ T cell response is not exhausted. Although 
the mechanism behind the enhanced proliferative capacity in these experiments is 
unknown, it could include differences in avidity, cytokine production (which could have 
an autocrine effect in vitro), cytokine responsiveness and response to endogenous co-
stimulation or protection against cell death. 
Further supporting a role of HCMV-specific CD8+ T cells in the inflammatory disease 
seen in CVID patients was the observation that the frequency of CD73 expression on 
HCMV-specific CD8+ T cells was significantly reduced in inflammatory patients. CD73 
is an ecto-5-nucleotidase which acts in the purine salvage pathway to generate 
nucleosides such as adenosine, which has anti-inflammatory properties (Colgan et al., 
2006;Grunewald and Ridley, 2010). Indeed, in a recent study, Borrelia garinii infection 
of CD73 -/- mice was shown to be associated with joint swelling and the authors 
suggested that low levels of adenosine may favour local inflammatory responses and 
persistent infection (Yegutkin et al., 2010). Interestingly, infection of endothelial cells 
with CMV has been shown to increase the expression and activity of CD39 (ecto-ATP) 
and CD73 (Kas-Deelen et al., 2001). 
Data presented in Chapter 6 indicated: first, HCMV (NLV) specific CD8+ T cells in 
inflammatory CVID patients were characterized by high levels of avidity for cognate 
antigens whereas the equivalent cells from non-inflammatory patients included 
substantial proportions where binding was CD8 dependent, indicating lower avidity. 
Second, while there was no significant difference in CD73 expressing CD8+ T cells in 
both groups of patients, HCMV-specific CD8+ T cells of inflammatory CVID patients 
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expressed significantly lower CD73 compared to non-inflammatory patients. Third, 
compared to telomere length values available for age matched healthy controls, CVID 
patients tested were shown to have reduced telomere values. Additionally a strong 
correlation was found between telomere length reduction and age. 
It appears that HCMV can induce a chronic proinflammatory state not only in 
immunosuppressed patients but also in healthy individuals as a correlation was found 
between serum C-reactive protein (CRP) and IFN-γ levels during latent HCMV infection 
in healthy individuals, suggesting the involvement of both acute phase response proteins 
and type 1 cytokines in generating a proinflammatory state following HCMV infection 
(van de Berg et al., 2010a). There is increasing evidence indicating the potential role of 
HCMV in inflammation either directly or indirectly (Soderberg-Naucler, 2008). 
None of the CVID patients in this study had HCMV DNAemia in whole blood implying 
that T-cell responses were sufficient to control replication even in the absence of 
antibody production and ruling out any assessment of the relationship of persistent 
antigen expression to PD-1 expression. Although more data are needed to investigate the 
presence of HCMV in the sites of inflammatory disease, it has been previously shown by 
our group that in a CVID patient with chronic gut inflammation HCMV DNA was 
present in lesions at moderate levels (~10,000 genomes/150,000 cell equivalents) in 
association with a high frequency of HCMV epitope-specific CD8+ T cells (~5%) 
among cells eluted from the biopsy (Raeiszadeh et al., 2006). The presence of viral DNA 
may indicate persistent low level replication that would be consistent with the elevated 
HCMV-specific responses observed in these patients. 
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Until now there has been no rational explanation for the frequent occurrence of many of 
the inflammatory complications associated with CVID (Fasano et al., 1996;Webster 
ADB, 1999;Malamut et al., 2008), or the persistent lymphocyte activation or oligoclonal 
expansions of activated CD8+ T cells described in a subset of CVID patients (Wright et 
al., 1990;Jaffe et al., 1993;Serrano et al., 2000;Carbone et al., 2006). This has been 
compounded by the inability to provide evidence of pathogens in inflamed organs using 
conventional histology/immunohistochemistry despite gene array analysis of PBMCs 
suggesting that the T-cells in these CVID patients are responding to a persistent stimulus 
(Holm et al., 2004). However, by utilising an enhanced immunohistochemistry approach 
(Samanta et al., 2003;Soderberg-Naucler, 2008), further support for the involvement of 
HCMV in driving the inflammatory pathology came from the collaborative work in 
which HCMV antigens were detected at the sites of inflammation (Figure 7-2), 
providing the first direct evidence of actively replicating virus in the inflamed tissues 
and supporting the conclusion that CMV infection is a major factor accounting for the 
aforementioned observations. Further investigations are needed to reveal the extent of 
HCMV infection and HCMV specific CD8+ T cell infiltration at sites of inflammation 
and whether this HCMV CD8+ T cell phenotypic signature is the same as that found in 
peripheral T cell population. 
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Figure 7-2: Immunohistochemical detection of CMV antigens in colon biopsy from inflammatory CVID 
patient.  
In collaborative work with Karolinska institute, sections were stained for CMV IE-1 (Panels A and D) or 
L (Panels B and E) antigen; a-actin (Panel C); or as processed without a primary antibody (Panel F). 
Panels D and E are enlargements of the sections of the sections highlighted in panels A and B. Bars are 
50mM. The image is provided with the permission of Professor Vincent Emery. 
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Taken together, the data presented above show that the HCMV-specific CD8+ T cells 
that accumulate in CVID with inflammatory disease display a distinctive polyfunctional 
phenotype that is characterized by a high frequency of CD57 expression and low level 
PD-1 expression. The cells are granzyme B+ and produce high levels of IFN-γ or of 
IFN-γ and TNF-α after peptide stimulation. Further investigations are needed to reveal 
the extent of HCMV infection and HCMV-specific CD8+ T cell infiltration at sites of 
inflammation and whether this HCMV-specific CD8+ T cell signature is associated with 
increased proliferative capacity and is an early marker of patients destined to develop 
inflammatory disease.  
In conclusion, this PhD thesis provide compelling evidence base that HCMV infection is 
the stimulus for persistent T cell activation in many CVID patients and a specific 
HCMV CD8+ T cell phenotype is likely to be directly, or indirectly responsible for most 
of the chronic inflammatory complications in CVID patients suffering from 
inflammation. As the marked increase of proinflammatory cytokines was only found in 
these subset of patients, it is more likely that these cytokines are involved in changing 
the cytokine microenvironment to trigger ubiquitous inflammatory processes of local 
tissues in this group of patients, as there are some recently published data emphasizing 
the role of proinflammatory cytokines including IFN-γ and TNF-α in the pathogenesis of 
inflammatory bowel diseases as well as autoimmune arthritis (Neurath and Finotto, 
2006b;Kim and Moudgil, 2008b). Thus, removal of the antigen or suppression of the 
inflammatory T-cell response can be effective in controlling inflammatory disease in this 
setting. The on-going longitudinal follow-up of CVID patients without inflammatory 
disease but with the characteristic CD8+ T cell signature of patients with inflammatory 
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disease will determine the temporal relationship between expression of immune markers 
and the onset of symptoms. In addition, the data presented in this PhD thesis suggest that 
the CD8+ T cell response to HCMV in CVID, and in particular the differences observed 
between the two CVID patient groups in the response to HCMV, but not EBV, provides 
a powerful and tractable model of immune regulation. 
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Antibody  Conjugate   Cat. No  Company  
CD8 PerCP Cy5.5 341050 BD Biosciences 
CD4 PerCP Cy5.5 332772 BD Biosciences 
IFN-γ APC 554702 BD Biosciences 
TNF-α PE 559321 BD Biosciences 
IL-2 FITC 340448 BD Biosciences 
CD57 FITC 333169 BD Biosciences 
Geranzyme B APC GRB05 Invitrogen  
CD45RO FITC 555492 BD Biosciences 
CD45RA APC 550855 BD Biosciences 
CD27 FITC 555440 BD Biosciences 
CD28 APC 559770 BD Biosciences 
PD-1 FITC 557860 BD Biosciences 
Ki-67 FITC 556026 BD Biosciences 
HLA-DR APC FAB4869A R&D 
CD73 APC 17-0739-42 e-Biosciences  
Isotype IgG1k FITC 555909 BD Biosciences 
Isotype IgG1k APC IC002A R&D 
Isotype IgG2ak FITC IC003F R&D 
CD28 Pure  348040 BD Biosciences 
Caltag medium A Fixation  GA50015-100 Invitrogen 
Caltag medium B/ Perm. Permeabilisation  GA50025-100 Invitrogen 
Appendix 1: The list of antibodies and reagents used in this thesis for ex vivo or intracellular staining. 
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Item and sequences  Cat. No Company  
NLV pentamer/ A0201/ NLVPMVATV/ R-PE F2B-008 Proimmune 
GLC pentamer/ A0201/ GLCTLVAML/ R-PE F2A00 Proimmune 
NLV peptide/ A0201/ NLVPMVATV P008-0B-G Proimmune 
GLC peptide/ A0201/ GLCTLVAML P0A001 Proimmune 
PepMix HCMVA (pp65)/ UL83/ 561 aa 
MESRGRRCPE………CIASTPKKHR G 
P06725 JPT 
PepMix HCMVA (IE-1)/ UL123/ 491aa 
MESSAKRKMD……..HPMVTRSKAD Q 
P13202 JPT 
HCMV Lysate 10-144-000 Autogen bioclear 
Appendix 2: The list of pentamers and peptides used in this thesis. 
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Appendix 3: Setting up the cut-off for T cell response positivity and prior exposure to HCMV (this graph 
originally was made by Mohammad Raeiszadeh).  
Serological confirmation of HCMV infection in CVID patients is not practical. Therefore, the presence of 
CD4+ T cells expressing IFN-γ was measured following stimulation with HCMV infected cell lysates as a 
marker of prior exposure to HCMV infection. To set the appropriate cut-off for this analysis, 27 healthy 
donors (17 HCMV IgG positive, 10 HCMV IgG negative) were tested and found that in the HCMV IgG 
negative individuals, the mean frequency of CD4+ T-cells responding to HCMV lysate was 0.013% (SD = 
0.021%). CD4+ T cell frequencies greater than 2 standard deviations above this value was used to 
distinguish HCMV exposed and HCMV naïve CVID patients. In this thesis only HLA-A2 subjects (25 
patients and 14 healthy controls) were included.  
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Appendix 4: Setting up the cut-off for prior exposure to EBV in CVID patients with and without 
inflammation. 
CD8+ T cells were stained ex vivo with EBV (GLC) pentamer and CD8+ T cell frequencies greater than 2 
standard deviations above the mean frequency of EBV-specific CD8+ T cells in EBV naïve patients were 
considered as a cutoff (blue dashed line) to distinguish EBV exposed and EBV naïve CVID patients. 
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No CVID patients 
HLA types 
HLA-A HLA-B 
1 √ 0201/01L/07/09/11/15N – 0101/04N 0801/02/08N 
2 √ 0201/01L/02/07/09/14/15N – 0205/06 5101/03/09 
3 √ 0201/01L/04/07/15N/18/20 – 0301/39 1501/01N 
4 √ 0201/04/07/09/12/43N – 2601/02/08 1501/12/14 
5 √ 0201/07/09/18/20 – 3201/05 1501/12/14 
6 √ 0201/04/07/09/20 – 0202/04/15 1501/12/14/51 
7 √ 0201/07/09/20/24 – 1101/02/03 2703/05/09/17 
8 √ 0201/01L/07/09/15N – 0101/04N/06 0801/04/08N 
9 √ 0201/07/09/25 – 0301/03N/04 0702/10 
10 √ 0201/02/04/07/32N 4402/05/14/17 
11 √ 0201/01L/04/07/09 – 2402/02L/03 0801/04/08N/81 
12 √ 0201/04/12/13/31 – 2402/11N/13 - 
13 √ 0201/07/09/21 – 0101/04N/02/06 4001/14/22N 
14 √ 0201/01L/04/07/09/20/24/42 4501 
15 √ 0201/04/13/27 – 0301/02/03N/04 0702/10 
16 √ 0201/1L/07/15N/49 – 0101/04N 4402/23/33 
17 √ 0201/01L/04/07 – 2402/02L/03/08 1501/01N 
18 √ 0201/01L/07/09/20/24 5101/03/09 
19 √ 0201/04/07/09/12/16 – 0301/02/03N 1501/12/14/19 
20 √ 0201/01L/07/09/15N – 0101/04N/06 0702/04/05 
21 √ 0201/04/07/09/17/18/20/24 4402/03/07 
22 √ 0201/02/07 – 0205/06 - 
23 √ 0201/07/09/18/20/22 1501/12/14/19 
24 √ 0201/04/12/13 – 2402/03/06 2703/05/09 
25 √ 0201/01L/07/09/15N 5801/04 
Appendix 5: HLA-phenotyping of CVID patients with and without inflammatory patients. 
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No Healthy controls 
HLA types 
HLA-A HLA-B 
1 √ 0201 0801 
2 √ 0201 - 0101 1501 
3 √ 0201 - 2301 4901 
4 √ 0201/02/04/07 – 2301/03 0702 
5 √ 0201/07/09 – 1101/02/03 3501/07 
6 √ 0201 - 2402 0801 
7 √ 0201/04/07/09 – 2601/02 1501/12 
8 √ 0201 - 
9 √ 0201/01L/07 – 0301/01N 4402 
10 √ 0201 - 0101 0702 
11 √ 0201/02/04 – 3101/05 1501 
12 √ 0201 - 2402 2703 
13 √ 0201 - 
14 √ 0201 - 
Appendix 6: HLA-pehontyping of healthy controls.  
